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Abstract	  
	  	   X-­‐linked	  Lymphoproliferative	  type	  1	  (XLP1)	  disease	  is	  a	  rare	  inherited	  syndrome	  characterized	  by	  generalized	  immunodeficiency,	  an	  extreme	  sensitivity	  to	  viral	  infections	  and	  a	  predisposition	  to	  the	  development	  of	  lymphoma.	  The	  disease	  is	  caused	  by	  loss-­‐of-­‐function	  mutations	  in	  the	  gene	  encoding	  the	  SLAM-­‐associated	  protein	  (SAP).	  SAP	  is	  a	  SH2-­‐domain-­‐containing	  protein	  that	  interacts	  with	  the	  cytoplasmic	  tail	  of	  signaling	  receptors	  and	  protein	  tyrosine	  kinases	  to	  promote	  T	  cell	  activation	  following	  stimulation	  of	  the	  T	  cell	  receptor	  (TCR).	  T	  cell	  signaling	  regulates	  the	  balance	  between	  cell	  activation	  and	  death,	  and	  defects	  contribute	  to	  the	  lymphoproliferative	  nature	  of	  the	  disease.	  Previous	  studies	  have	  examined	  the	  various	  roles	  of	  SAP	  in	  modulating	  T	  cell	  responses,	  but	  these	  influences	  require	  further	  investigation,	  and	  are	  the	  focus	  of	  this	  study.	  To	  clarify	  the	  role	  of	  SAP	  in	  T	  cell	  signaling,	  we	  took	  a	  gene	  editing	  approach	  to	  disrupt	  the	  SAP	  gene	  and	  created	  a	  
SAP-­‐null	  T	  cell	  line.	  Through	  this	  approach	  we	  identified	  SAP-­‐specific	  effects,	  which	  included	  cytokine	  production,	  transcription	  factor	  activity,	  and	  calcium	  mobilization.	  Interestingly,	  SAP-­‐null	  cells	  exhibited	  a	  decrease	  in	  IL-­‐2	  expression,	  attributable	  to	  defective	  nuclear	  factor	  of	  activated	  T	  cells	  (NFAT)	  activation,	  and	  increased	  IFN-­‐γ	  production	  following	  TCR	  stimulation.	  Moreover,	  cells	  with	  SAP	  deficiencies	  have	  a	  heightened	  sensitivity	  to	  apoptotic	  stimuli.	  These	  results	  suggest	  that	  SAP	  defects	  drastically	  alter	  T	  cell	  activation	  and	  the	  cytokine	  environment,	  
	   x	  
making	  T	  cells	  more	  sensitive	  to	  apoptotic	  stimuli,	  potentially	  impeding	  their	  ability	  to	  respond	  to	  immune	  challenges.	  Together,	  these	  results	  identify	  specific	  SAP-­‐dependent	  defects	  in	  T	  cell	  signaling	  that	  could	  contribute	  to	  the	  characteristic	  phenotypes	  of	  patients	  with	  XLP1	  disease.	  
 
	   1	  
Chapter	  1	  X-­‐Linked	  Lymphoproliferative	  (XLP)	  Disease	  
	  
1.1	  Introduction	  	  	   X-­‐linked	  Lymphoproliferative	  (XLP)	  disease	  is	  a	  rare	  inherited	  immune	  disorder	  resulting	  from	  respective	  mutations	  or	  loss-­‐of-­‐function	  in	  the	  SLAM-­‐associated	  protein	  (SAP)1–3	  or	  X-­‐linked	  inhibitor	  of	  apoptosis	  protein	  (XIAP)4.	  While	  these	  two	  genes	  co-­‐occupy	  the	  Xq25	  locus5,	  they	  share	  no	  sequence	  homology,	  nor	  do	  their	  proteins	  appear	  to	  interact6.	  Affected	  children	  exhibit	  a	  spectrum	  of	  hematological	  defects,	  and	  these	  defects	  are	  often	  triggered	  by	  exposure	  to	  the	  Epstein-­‐Barr	  Virus	  (EBV)7.The	  lymphoproliferative	  nature	  of	  the	  disease	  suggests	  that	  the	  delicate	  balance	  between	  immune	  cell	  activation	  and	  death	  is	  disturbed8.	  While	  previous	  work	  has	  advanced	  the	  understanding	  of	  SAP’s	  role	  as	  an	  adaptor	  protein,	  which	  modulates	  T	  cell	  signaling,	  the	  precise	  role	  of	  SAP	  in	  T	  cell	  signaling	  is	  not	  fully	  understood.	  The	  goal	  of	  this	  thesis	  is	  to	  investigate	  how	  SAP	  modulates	  T	  cell	  signaling	  and	  death	  to	  generate	  the	  phenotypes	  of	  XLP.	  	   In	  this	  thesis	  a	  gene	  editing	  approach	  was	  taken	  to	  disrupt	  the	  human	  SAP	  gene	  in	  an	  established	  cell	  line	  to	  model	  the	  effects	  of	  SAP	  deficiencies	  (chapter	  2).	  These	  SAP-­‐deficient	  cells	  allowed	  the	  functional	  characterization	  of	  defects	  following	  T	  cell	  receptor	  (TCR)	  stimulation.	  Through	  this	  approach	  we	  identified	  
SAP-­‐specific	  effects,	  which	  included	  cytokine	  production,	  transcription	  factor	  activity,	  and	  calcium	  mobilization,	  and	  these	  results	  are	  presented	  in	  chapter	  3.	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Moreover,	  cells	  with	  SAP	  deficiencies	  have	  a	  heightened	  sensitivity	  to	  apoptotic	  stimuli,	  as	  discussed	  in	  chapter	  4.	  Together,	  these	  results	  identify	  specific	  SAP-­‐dependent	  defects	  in	  T	  cell	  signaling	  in	  a	  gene-­‐edited	  model	  cell	  line,	  which	  could	  contribute	  to	  the	  characteristic	  clinical	  picture	  of	  patients	  with	  XLP1	  disease.	  
1.2	  Primary	  Immunodeficiencies	  and	  XLP	  	  	  	   X-­‐linked	  lymphoproliferative	  disease	  (XLP)	  is	  one	  of	  many	  rare	  primary	  immunodeficiencies	  (PIDs)	  where	  patients	  have	  genetic	  defects	  that	  predispose	  them	  to	  develop	  abnormal	  numbers	  or	  improperly	  functioning	  immune	  cells9.	  Although	  the	  diseases	  may	  differ,	  symptoms	  often	  manifest	  after	  exposure	  to	  viruses10.	  Advances	  in	  molecular	  genetics	  have	  led	  to	  the	  identification	  of	  many	  new	  PIDs	  and	  facilitated	  their	  diagnosis11.	  Table	  1.1	  identifies	  select	  primary	  immunodeficiencies	  along	  with	  their	  most	  commonly	  mutated	  genes	  within	  their	  respective	  disorder.	  Perhaps	  the	  most	  recognized	  PID	  is	  severe	  combined	  immunodeficiency	  (SCID)	  where	  patients	  exhibit	  severe	  reactions	  to	  infections	  due	  to	  low	  or	  absent	  numbers	  of	  T,	  NK,	  and	  B	  cells12,13,	  immune	  cells	  described	  later.	  There	  are	  also	  primary	  conditions	  where	  inherited	  mutations	  cause	  cytotoxic	  defects	  such	  as	  autoimmune	  lymphoproliferative	  syndrome	  (ALPS)	  that	  stems	  from	  mutations	  in	  the	  FAS	  gene14.	  Mutations	  within	  the	  cytoplasmic	  tail	  of	  the	  receptor	  Fas	  impair	  the	  formation	  and	  activation	  of	  apoptotic	  signaling	  complexes	  and	  results	  in	  excessive	  proliferation	  of	  lymphocytes14,15.	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Disease	   	   	   	   	   	   	   Defective	  Gene	  	  Severe	  combined	  immunodeficiency	  (SCID)	   	   IL-­‐2RG,	  RAG,	  CD3,	  etc13	  Autoimmune	  lymphoproliferative	  syndrome	  (ALPS)	   FAS16	  Hemophagocytic	  lymphohistiocytosis	  (HLH)	   	   PRF1,	  UNC13D17	  Wiskott-­‐Aldrich	  syndrome	  (WAS)	   	   	   	   WASP18	  X-­‐linked	  lymphoproliferative	  disease	  (XLP)	   	   SAP/XIAP	  
	  
Table	  1.1	  Select	  primary	  immunodeficiencies.	  Primary	  immunodeficiencies	  result	  in	  aberrant	  numbers	  or	  impaired	  function	  of	  immune	  cells	  due	  to	  inherited	  genetic	  defects.	  While	  these	  diseases	  can	  results	  from	  defects	  in	  several	  different	  genes,	  the	  most	  commonly	  mutated	  genes	  are	  listed	  with	  their	  respective	  disease.	  	  	   Patients	  with	  hemophagocytic	  lymphohistiocytosis	  (HLH)	  inherit	  defects	  where	  cytotoxic	  lymphocytes	  are	  unable	  to	  kill	  virally	  infected	  cells.	  The	  cytotoxic	  capability	  is	  limited	  by	  defects	  that	  impair	  the	  ability	  to	  produce	  or	  transfer	  apoptotic	  inducing	  enzymes	  into	  virally	  infected	  cells19.	  The	  virally	  infected	  cells	  survive	  and	  produce	  elevated	  amounts	  of	  cytokines	  that	  activate	  macrophages	  which	  accumulate	  in	  the	  liver	  and	  spleen	  causing	  organ	  enlargement17.	  Another	  primary	  immunodeficiency,	  Wiskott-­‐Aldrich	  syndrome	  (WAS),	  is	  associated	  with	  excessive	  immune	  cell	  proliferation	  due	  to	  abnormally	  low	  levels	  of	  regulatory	  T	  cells20,21.	  Lymphoma	  is	  identified	  in	  a	  portion	  of	  WAS	  patients	  with	  excessive	  T	  cell	  proliferation22,23.	  Other	  WAS	  patients	  exhibit	  defects	  in	  the	  ability	  of	  actin	  to	  mobilize	  during	  the	  formation	  of	  the	  immune	  synapsis,	  impairing	  activation24.	  Thus,	  WAS	  patients	  can	  exhibit	  either	  lymphoproliferation	  or	  impaired	  T	  cell	  activation.	  Similarly,	  a	  fraction	  of	  patients	  with	  XLP	  also	  develop	  lymphomas25	  and	  have	  impaired	  immune	  cell	  development	  and	  persistent	  infections	  due	  to	  defects	  in	  cytotoxic	  immune	  effector	  cells26.	  	   XLP1	  also	  known	  as	  Duncan’s	  disease27,	  is	  caused	  by	  mutations	  in	  SAP	  (SLAM-­‐associated	  protein)5.	  	  As	  shown	  in	  figure	  1.2,	  these	  mutations	  are	  randomly	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distributed	  and	  are	  a	  combination	  of	  missense	  and	  nonsense	  mutations5,28,29.	  SAP	  is	  a	  small	  128	  amino	  acid	  protein,	  largely	  comprised	  of	  a	  phosphotyrosine-­‐binding	  SH2	  domain30	  that	  is	  only	  expressed	  in	  T	  and	  natural	  killer	  (NK)	  cells1,31,32.	  Point	  mutations	  observed	  in	  XLP1	  patients	  have	  been	  shown	  to	  affect	  the	  phospho-­‐tyrosine	  binding	  pocket,	  the	  hydrophobic	  cleft,	  or	  the	  stability	  of	  the	  SAP	  protein33.	  	  
	  
Figure	   1.1	   Structure	   and	  mutations	   of	   SAP.	   SAP	   is	   a	   small	   SH2	  domain	   containing	  protein	  with	  mutations	   spanning	   the	   entire	   region	   of	   the	   gene34.	   	   Each	   line	   indicates	   an	   annotated	   patient	  mutation	  and	  the	  star	  denotes	  nonsense	  mutations.	  (Adapted	  from	  Blood	  (2010)	  116:18.)	  	  
SAP	  defects	  manifests	  with	  a	  range	  of	  clinical	  presentations,	  outlined	  in	  table	  1.2,	  and	  there	  is	  a	  general	  gap	  in	  the	  scientific	  evidence	  to	  why	  XLP1	  patients	  develop	  these	  symptoms.	  	   	   	   	   	   	   	   	  	  	  	  	  	   	  %	  of	  patients	   (n=33)	   	   	   	   	   	   	  	   55	   Hemophagocytic	  Lymphohistiocytosis	  (HLH)	   	  	  	  	  	  	  	  	  	  	   92	   EBV	  triggered	  HLH	   	   	   	   	   	  	  	  	  	  	  	  	  	  	   61	   HLH	  associated	  lethality	  (HLH	  patients)	   	   	  	  	  	  	  	  	  	  	  	   67	   Hypogammaglobulinemia	   	   	   	   	  	  	  	  	  	  	  	  	   	  	  7	   Splenomegaly	  (w/o	  HLH)	   	   	   	   	  	  	  	  	  	  	  	  	  	   30	   Lymphoma	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  
Table	  1.2	  The	  clinical	  picture	  of	  XLP1.	  XLP1	  patients	  have	  a	  range	  of	  phenotypes	  including	  lymphoma34.	  (Adapted	  from	  Blood	  (2011)	  117(5).)	  	   	  
HLH	  is	  the	  most	  common	  XLP	  morbidity	  and	  is	  characterized	  by	  excessive	  proliferation	  of	  lymphocytes	  and	  macrophages	  in	  response	  to	  infection35,	  most	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commonly	  triggered	  during	  the	  infection	  of	  B	  cells	  by	  EBV36–38.	  Moreover,	  HLH	  is	  associated	  with	  the	  abnormal	  production	  of	  cytokines29	  such	  as	  interferon-­‐γ	  (IFN-­‐γ)	  and	  interleukin-­‐6	  (IL-­‐6),	  which	  stimulates	  the	  activation	  of	  many	  accessory	  cell	  types39.	  To	  counter	  the	  overproduction	  of	  cytokines	  and	  macrophage	  activation,	  the	  curative	  treatment	  for	  HLH	  and	  XLP	  is	  an	  allogeneic	  bone	  marrow	  transplant40.	  As	  previously	  mentioned,	  XLP	  is	  a	  rare	  disease41,	  but	  the	  clinical	  burden	  may	  be	  under-­‐diagnosed	  since	  SAP	  is	  not	  routinely	  screened	  in	  a	  pediatric	  setting.	  	  Notably,	  one-­‐third	  of	  XLP1	  patients	  develop	  lymphoma	  due	  to	  SAP-­‐deficiencies42.	  
1.3	  	  XLP1	  and	  B-­‐cell	  lymphoma	  	  	   The	  majority	  of	  SAP-­‐mutated	  lymphomas	  are	  of	  B	  cell	  origin43,44	  and	  are	  classified	  as	  Burkitt’s	  lymphoma33.	  Previous	  associations	  of	  EBV	  with	  cancer	  demonstrated	  that	  endemic	  EBV	  infection	  in	  African	  children	  contributes	  to	  the	  development	  of	  Burkitt’s	  lymphoma,	  resulting	  from	  irregular	  B	  cell	  proliferation45.	  The	  comparison	  of	  endemic	  to	  sporadic	  Burkitt’s	  lymphoma,	  shown	  in	  table	  1.3,	  illustrates	  that	  there	  are	  worldwide	  differences	  in	  this	  disease.	  Both	  endemic	  and	  sporadic	  Burkitt’s	  lymphoma	  are	  characterized	  by	  chromosomal	  translocations	  involving	  the	  c-­‐MYC	  oncogene	  with	  over	  80%	  of	  patients	  harboring	  t(8;14)	  involving	  the	  Ig	  heavy	  chain	  that	  results	  in	  rapidly	  proliferating	  B	  cells	  by	  over-­‐activation	  of	  the	  cell	  cycle	  cell46.	  Orem,	  et	  al.	  (2007)	  proposed	  the	  model	  of	  the	  EBV-­‐dependent	  development	  of	  B	  cell	  lymphoma	  where	  EBV	  infects	  African	  infants	  and	  T	  cells	  normally	  prevent	  the	  expansion	  of	  infected	  B	  cells.	  Exposure	  to	  other	  infections,	  such	  as	  malaria47,	  suppress	  T	  cell	  activity	  and	  allow	  for	  the	  rapid	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proliferation	  of	  B	  cells	  where	  chromosomal	  translocations	  can	  occur	  leading	  to	  the	  development	  of	  lymphoma.	  	  
	  	  	  	  	  	  	  	  	  	  	  Burkitt’s	  Lymphoma	  	   	   	   Endemic	  (African)	   	   Sporadic	  (Worldwide)	   	  Onset	   	   	   Childhood	  	   	   	   Child	  (30%);	  Adult	  (70%)	  	  Median	  age	   	   7	   	   	   	   30	   	   	   	  Co-­‐morbidity	  	   Malaria	   	   	   ?;	  HIV	   	   	   	  Tumor	  site	   	   Face	  &	  jaw	   	   	   Gastrointestinal	  EBV	  status	   	   100%	  +	   	   	   30%	  +	  	   	   	  	  
Table	  1.3	  Comparison	  of	  endemic	  and	  sporadic	  Burkitt’s	  lymphoma.	  While	  endemic	  African	  and	  sporadic	  Burkitt’s	  lymphoma	  share	  similarities,	  they	  appear	  to	  be	  very	  different	  based	  on	  the	  age	  of	  onset	  and	  location	  of	  tumor	  development.	  The	  influence	  of	  additional	  co-­‐morbidities	  and	  the	  correlation	  with	  EBV	  infection	  is	  unclear	  in	  sporadic	  lymphoma.	  XLP1-­‐associated	  lymphoma	  patients	  have	  childhood	  onset	  but	  the	  contributions	  of	  additional	  co-­‐morbidities	  are	  unclear.	  [Table	  is	  adapted	  from	  African	  Health	  Sciences	  (2007)	  7(3):	  166-­‐175.]	  	  
	   XLP1-­‐associated	  lymphoma	  shares	  similarities	  with	  both	  endemic	  and	  sporadic	  Burkitt’s	  lymphoma	  patients.	  	  The	  age	  of	  onset	  is	  during	  childhood	  and	  is	  largely	  associated	  with	  EBV	  infection48,	  similar	  to	  endemic	  cases,	  but	  the	  tumor	  sites	  are	  similar	  to	  sporadic	  cases	  involving	  the	  GI	  tract	  and	  kidneys49.	  It	  is	  possible	  that	  different	  strains	  of	  the	  virus	  exist	  and	  the	  interactions	  with	  unique	  co-­‐morbidities	  contribute	  to	  the	  variation	  in	  endemic,	  sporadic,	  and	  XLP1	  lymphoma	  patients.	  Although	  there	  have	  been	  studies50	  where	  SAP	  expression	  was	  measurable	  in	  B	  cells	  from	  EBV+	  lymphoma	  patients,	  it	  is	  generally	  accepted	  that	  B	  cells	  do	  not	  express	  SAP1,31,32.	  This	  suggests	  that	  the	  development	  of	  lymphoma	  in	  XLP1	  patients	  is	  due	  to	  non-­‐cell	  autonomous	  roles	  of	  SAP	  in	  the	  cancer	  cell.	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   Lymphoma	  in	  XLP1	  patients	  is	  thought	  to	  result	  from	  impaired	  immune	  surveillance	  of	  EBV	  infected	  B	  cells	  due	  to	  the	  absence	  of	  NKT	  (natural	  killer	  T)	  cells	  or	  impaired	  cytotoxic	  activity	  of	  CTLs	  (cytotoxic	  T	  lymphocytes)	  and	  NK	  (natural	  killer)	  cells51.	  NKT	  cells,	  a	  subpopulation	  of	  immune	  cells	  with	  NK	  like	  characteristics,	  express	  T	  cells	  receptors	  (TCRs).	  NKT	  cells	  contain	  an	  invariant	  TCR	  that	  recognizes	  the	  ligand	  α-­‐galactosyl	  ceramide	  (α-­‐GC)52.	  	  Upon	  binding	  α-­‐GC,	  NKT	  cells	  release	  cytokines	  such	  as	  IFN-­‐γ	  (interferon-­‐γ)52	  that	  stimulate	  other	  lymphocytes	  during	  the	  adaptive	  immune	  response.	  	  In	  addition	  to	  a	  lack	  of	  NKT	  cells,	  XLP1	  patients	  have	  defective	  NK	  cells5.	  NK	  cells	  are	  specialized	  innate	  immune	  cells	  that	  directly	  kill	  foreign	  pathogens	  by	  cytotoxic	  activity,	  similar	  to	  CD8+	  T	  cells.	  However,	  NK	  cells	  do	  not	  have	  TCRs,	  and	  their	  effects	  are	  executed	  when	  virally	  infected	  cells	  are	  not	  recognized	  as	  self	  by	  MHC-­‐I	  (major	  histocompatibility	  class	  I)53,54.	  The	  persistence	  of	  virally	  infected	  cells	  within	  patients	  facilitates	  the	  transformation	  of	  infected	  B	  cells	  by	  the	  EBV	  genome2,55,56	  and	  the	  unopposed	  expansion	  of	  this	  population	  supports	  the	  neoplastic	  characteristics	  observed	  during	  the	  formation	  of	  XLP1-­‐associated	  B	  cell	  lymphoma49.	  	  
	   Relevant	  to	  XLP1	  are	  two	  hallmarks	  of	  cancer	  that	  might	  be	  deregulated	  in	  the	  disease:	  genetic	  mutations	  contributing	  to	  genome	  instability,	  and	  the	  avoidance	  of	  immune	  surveillance57.	  As	  depicted	  in	  figure	  1.2,	  immune	  cells	  identify	  mutant	  or	  precancerous	  cells	  and	  target	  them	  for	  destruction	  during	  immune	  surveillance.	  Pre-­‐cancerous	  cells	  can	  acquire	  somatic	  mutations	  that	  facilitate	  their	  survival	  and	  neoplastic	  expansion.	  In	  the	  case	  of	  XLP1,	  the	  patients	  have	  an	  inherited	  genetic	  defect	  that	  increases	  the	  likelihood	  of	  cancer	  development.	  While	  EBV	  is	  primarily	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asymptomatic	  in	  the	  normal	  healthy	  population,	  XLP1	  patients	  have	  defects	  in	  their	  immune	  cells	  that	  contribute	  to	  the	  persistence	  of	  virally	  infected	  B	  cells.	  In	  this	  case,	  rather	  than	  a	  pre-­‐cancerous	  cell	  acquiring	  capabilities	  to	  avoid	  immune	  surveillance	  the	  immune	  cells	  with	  SAP	  defects	  are	  ineffective	  at	  either	  the	  recognition	  of	  or	  the	  killing	  of	  infected	  B	  cells.	  	  
	  
Figure	  1.2.	  Immune	  surveillance	  defects	  contribute	  to	  cancer.	  The	  immune	  surveillance	  system	  identifies	  mutant	  or	  precancerous	  cells	  and	  targets	  them	  for	  destruction.	  When	  the	  immune	  system	  is	  defective,	  this	  permits	  the	  outgrowth	  and	  clonal	  expansion	  of	  cells	  to	  generate	  the	  formation	  of	  various	  neoplasms.	  	  
	   It	  is	  not	  well	  understood	  how	  cancer	  cells	  evade	  a	  fully	  functional	  immune	  system,	  but	  previous	  work	  has	  identified	  several	  possibilities.	  Studies	  have	  shown	  that	  tumors	  are	  able	  to	  downregulate	  major	  histocompatibility	  class	  I	  (MHC-­‐I)	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expression	  to	  escape	  T	  cell-­‐mediated	  immune	  surveillance58.	  Anywhere	  from	  40-­‐90%	  of	  human	  tumors	  are	  deficient	  for	  MHC-­‐I	  expression	  due	  to	  the	  partial	  or	  complete	  loss	  of	  the	  allele	  or	  by	  locus	  downregulation58.	  Virally	  infected	  cells	  that	  have	  lower	  levels	  of	  MHC-­‐I	  expression	  are	  targeted	  by	  NK	  cells	  while	  cells	  with	  higher	  levels	  of	  MHC-­‐I	  are	  recognized	  by	  TCR	  expressing	  CTLs59.	  Viral	  proteins	  are	  also	  capable	  inhibiting	  the	  production,	  movement,	  or	  formation	  of	  MHC-­‐I	  and	  thus	  impair	  the	  ability	  for	  CTLs	  to	  recognize	  virally	  infected	  cells60.	  Following	  infection,	  viral	  proteins	  are	  encapsulated	  in	  endosomes	  and	  undergo	  proteasomal	  processing	  allowing	  the	  peptides	  to	  move	  to	  the	  ER,	  where	  they	  are	  loaded	  onto	  MHC-­‐I	  components	  for	  movement	  through	  the	  Golgi	  forming	  secretory	  vesicles	  that	  migrate	  to	  the	  cell	  surface60.	  At	  the	  surface,	  the	  peptide	  within	  the	  MHC-­‐I	  pocket	  is	  presented	  to	  cytotoxic	  T	  cells.	  	  For	  example,	  the	  HIV	  viral	  protein	  Nef	  down-­‐regulates	  MHC-­‐I	  on	  the	  cell	  surface	  by	  binding	  to	  the	  cytoplasmic	  tail	  of	  MHC-­‐I	  causing	  it	  to	  migrate	  to	  the	  endosome	  for	  degradation61	  while	  Tat	  inhibits	  MHC-­‐I	  promoter	  activity62.	  Similarly,	  the	  EBV	  latent	  member	  protein	  2A	  (LMP2A)	  has	  been	  shown	  to	  impair	  the	  expression	  of	  MHC-­‐II	  by	  impairing	  the	  class	  II	  transactivator	  (CIITA)	  protein63.	  In	  both	  cases,	  altered	  MHC	  expression	  restricts	  the	  types	  of	  immune	  cells	  that	  can	  respond	  to	  infected	  cells	  increasing	  oncogenic	  potential64.	  	  It	  is	  possible	  that	  XLP1	  patients	  have	  downregulated	  MHC-­‐I	  and,	  in	  particular	  following	  EBV	  infection,	  MHC-­‐II.	  This	  would	  result	  in	  the	  inability	  of	  CTLs	  to	  target	  infected	  cells	  and	  impair	  the	  recognition	  of	  infected	  B	  cells	  and	  recruitment	  of	  the	  appropriate	  T	  cell	  help.	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   While	  tumor	  cells	  are	  capable	  of	  avoiding	  immune	  surveillance,	  it	  is	  plausible	  that	  cancer	  develops	  due	  to	  defects	  inherent	  in	  the	  immune	  cells	  themselves,	  maintaining	  a	  tumor	  permissive	  environment.	  This	  is	  supported	  by	  findings	  that	  the	  majority	  of	  viral	  induced	  cancers	  are	  within	  immunocompromised	  individuals65	  suggesting	  that	  the	  mechanisms	  that	  control	  viral	  infections	  must	  become	  deregulated	  in	  order	  for	  cancer	  to	  develop.	  Notably,	  the	  pathological	  examination	  of	  tumors	  have	  shown	  that	  immune	  cells	  are	  present	  within	  the	  tumors,	  sometimes	  at	  high	  numbers66.	  Innate	  immune	  cells,	  in	  particular,	  are	  thought	  to	  secrete	  tumor	  promoting	  growth	  factors67,68	  or	  secrete	  reactive	  oxygen	  species	  (ROS)	  that	  promote	  genetic	  mutations69.	  Lymphocyte	  activation	  signals	  would	  results	  in	  additional	  immune	  cell	  proliferation	  while	  additional	  mutations	  from	  exposure	  to	  ROS	  could	  convey	  a	  survival	  advantage	  within	  the	  pre-­‐neoplastic	  or	  cancer	  cells	  in	  an	  inflammatory	  tumor	  microenvironment.	  Several	  studies	  using	  mouse	  models	  with	  defective	  CD8+	  cytotoxic	  T	  cells,	  CD4+	  T	  helper	  1	  cells,	  or	  natural	  killer	  cells	  demonstrated	  that	  animals	  with	  deficient	  immune	  cells	  have	  increased	  formation	  of	  tumors70,71.	  In	  the	  context	  of	  XLP1-­‐associated	  lymphoma,	  it	  is	  possible	  that	  SAP	  mutations	  impair	  the	  ability	  of	  immune	  cells	  to	  effectively	  kill	  EBV	  infected	  B	  cells	  and	  the	  transformed	  B	  cells	  avoid	  destruction	  by	  altered	  expression	  of	  MHC	  on	  their	  surface.	  Therefore,	  non-­‐autonomous	  influences	  of	  SAP	  contribute	  to	  the	  development	  of	  lymphoma.	  In	  this	  case,	  it	  is	  particularly	  important	  to	  understand	  how	  SAP	  defects	  impair	  immune	  cell	  activation	  as	  this	  could	  elucidate	  how	  XLP1	  patients	  generate	  a	  permissive	  environment	  for	  the	  clonal	  expansion	  of	  EBV	  transformed	  B	  cells	  resulting	  in	  the	  development	  of	  lymphoma.	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   The	  burden	  of	  XLP1-­‐associated	  B	  cell	  lymphoma	  may	  be	  under-­‐represented	  in	  the	  population.	  A	  previous	  study72	  retrospectively	  analyzed	  the	  records	  of	  158	  males	  diagnosed	  with	  B	  cell-­‐lymphomas	  and	  focused	  on	  patients	  with	  recurrent	  lymphoma,	  of	  which	  five	  were	  found	  to	  have	  undiagnosed	  SAP	  mutations.	  Thus,	  XLP1	  may	  have	  a	  higher	  clinical	  burden	  and	  this	  disease,	  characterized	  by	  several	  phenotypes	  such	  as	  HLH	  and	  lymphoma,	  disrupts	  the	  normal	  immune	  response	  to	  infection34.	  	  As	  described	  in	  more	  detail	  below,	  T	  cells	  play	  a	  major	  role	  in	  the	  immune	  responses	  that	  are	  altered	  within	  XLP	  patients.	  
1.4	  T	  cells	  and	  signaling	  
	  	  	   T	  cell	  activation	  involves	  the	  combination	  of	  stimulation	  of	  the	  T	  cell	  receptor	  (TCR)	  and	  modulation	  of	  the	  strength	  of	  the	  response	  by	  co-­‐stimulatory	  receptors.	  The	  TCR	  is	  a	  complex	  of	  multiple	  CD3+	  subunits:	  the	  extracellular	  variant	  α and	  β	  chains,	  the	  transmembrane	  invariant	  γ,	  δ,	  and	  ε chains,	  and	  the	  intracellular	  
ζ signaling	  chains73.	  The	  extracellular	  α	  and	  β	  chains	  recognize	  antigen	  peptides,	  while	  the	  invariant	  γ , δ, and ε chains	  assemble	  the	  rest	  of	  the	  TCR	  complex	  and	  the	  
ζ	  chain,	  in	  conjunction	  with	  other	  signaling	  molecules,	  activates	  the	  T	  cell	  signaling	  cascade.	  Antigen-­‐primed	  major	  histocompatibility	  (MHC)	  binds	  the	  TCR74	  and	  the	  ligation	  of	  additional	  co-­‐stimulatory	  receptors,	  for	  example	  the	  well	  described	  CD28	  receptor,	  induces	  T	  cell	  proliferation,	  differentiation,	  and	  cytokine	  production75.	  CD28	  is	  expressed	  on	  T	  cells	  and	  interacts	  with	  the	  B7.1	  (CD80)	  and	  B7.2	  (CD86)	  receptor	  on	  antigen	  presenting	  cells	  during	  T	  cell	  activation75.	  Prior	  to	  activation,	  B7	  binds	  with	  high	  affinity	  to	  the	  structurally	  similar	  inhibitory	  cytotoxic	  T-­‐
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lymphocyte-­‐associated	  protein	  4	  (CTLA-­‐4)	  expressed	  on	  inactive	  T	  cells75.	  	  Ligation	  of	  CD28	  increases	  the	  expression	  of	  CTLA-­‐4	  to	  maintain	  homeostasis	  and	  prevent	  excessive	  T	  cell	  activation76.	  In	  cooperation	  with	  CD3,	  CD28	  also	  has	  roles	  in	  the	  production	  of	  IL-­‐277,78,	  discussed	  in	  detail	  below.	  	   The	  two	  primary	  categories	  of	  T	  cells	  are	  classified	  by	  the	  presence	  of	  surface	  receptors	  CD4	  or	  CD879.	  	  CD4	  expressing	  cells	  include	  the	  T	  helper	  (Th)	  and	  T	  regulatory	  (Treg)	  lineages,	  while	  CD8	  expressing	  cells	  are	  cytotoxic	  T	  cells.	  Initially,	  the	  thymic	  progenitors	  rearrange	  their	  α	  and	  β variable	  chains80,	  in	  a	  process	  similar	  to	  VDJ	  recombination	  used	  in	  B	  cells	  to	  produce	  immunoglobulins81,	  to	  recognize	  a	  large	  number	  of	  antigens80.	  Cells	  that	  successfully	  generate	  variant	  α	  and	  β	  subunits	  become	  double	  positive	  for	  CD4	  and	  CD8	  and	  proceed	  through	  self-­‐recognition	  and	  selection	  before	  peripheral	  dispersal82,83.	  	  The	  differentiation	  of	  T	  cells	  into	  cytotoxic	  or	  T	  helper	  cells	  is	  guided	  by	  whether	  thymocytes	  bind	  MHC	  Class	  I	  or	  Class	  II	  ligands,	  respectively80.	  	  These	  single	  positive	  CD4	  or	  CD8	  T	  cells	  migrate	  to	  the	  periphery	  where	  they	  await	  activation	  based	  on	  cytokines	  and	  microenvironmental	  cues.	   	  	  	  	   SAP	  was	  originally	  thought	  to	  bind	  to	  the	  intracellular	  domain	  of	  the	  signaling	  lymphocyte	  activation	  molecule	  (SLAM)	  family	  of	  receptors84	  to	  function	  as	  a	  termination	  signal.	  	  SLAM	  receptors	  contain	  an	  extracellular	  immunoglobulin-­‐like	  domain,	  a	  transmembrane	  portion,	  and	  a	  cytoplasmic	  tail	  region84,85	  with	  variable	  numbers	  of	  immunoreceptor	  tyrosine-­‐based	  switch	  motifs	  (ITSMs)	  that	  control	  the	  cell	  activation	  programs33,86.	  SAP	  recognizes	  the	  threonine/isoleucine-­‐tyrosine-­‐x-­‐x-­‐valine/isoleucine	  (T-­‐I/Y-­‐x-­‐x-­‐V/I)	  motif	  in	  the	  cytoplasmic	  tail	  of	  SLAM	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receptor86,	  and	  this	  binding	  can	  occur	  in	  the	  presence87	  or	  absence	  of	  phosphorylation88.	  However,	  further	  studies	  have	  ascribed	  SAP’s	  role	  as	  an	  adaptor	  protein	  which	  not	  only	  binds	  the	  ITSMs	  but	  also	  recruits	  proteins	  such	  as	  protein	  tyrosine	  kinases	  (PTKs)	  to	  interact	  with	  the	  SLAM	  receptor	  family53,54,89	  linking	  SAP	  as	  a	  facilitator	  in	  T	  cell	  signaling.	  	  	   T	  cells	  rely	  on	  various	  kinases	  to	  initiate	  multiple	  signaling	  cascades90,91	  and	  activate	  transcription	  factors	  that	  lead	  to	  cytokine	  production	  and	  T	  cell	  activation92.	  SAP	  binding	  to	  SLAM	  recruits	  PTKs	  that	  phosphorylate	  the	  cytoplasmic	  immunoreceptor	  tyrosine-­‐based	  activation	  motifs	  (ITAMs)	  of	  the	  T	  cell	  receptor	  subunits93.	  During	  TCR	  stimulation	  two	  PTKs,	  lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  (LCK)	  and	  FYN,	  are	  recruited	  to	  the	  TCR	  complex	  94,95,	  as	  shown	  in	  figure	  1.3.	  	  Co-­‐stimulation	  by	  CD28	  has	  been	  shown	  to	  recruit	  LCK	  to	  the	  lipid	  raft96,	  regions	  on	  the	  plasma	  membrane	  where	  signaling	  proteins	  are	  colocalized	  to	  facilitate	  their	  interactions97.	  LCK	  is	  associated	  with	  CD4	  in	  T	  cells98	  whereas	  FYN	  is	  able	  to	  associate	  with	  multiple	  proteins,	  including	  SAP94.	  Structurally,	  LCK	  and	  FYN	  both	  contain	  SH3,	  SH2,	  and	  carboxy-­‐terminal	  kinase	  domains99.	  	  The	  SH3	  domains	  mediate	  binding	  to	  proline	  rich	  regions,	  while	  SH2	  domains	  mediate	  interactions	  at	  phosphotyrosine	  residues100.	  As	  mentioned,	  disruption	  of	  the	  SAP/FYN	  interaction	  is	  shown	  to	  impair	  the	  development	  of	  NKT	  cells	  in	  mice101	  and	  this	  is	  thought	  to	  be	  why	  XLP1	  patients	  do	  not	  develop	  NKT	  cells5.	  SAP	  has	  been	  shown	  to	  interact	  with	  FYN95	  to	  augment	  the	  phosphorylation	  of	  the	  SLAM	  receptor	  at	  tyrosine	  307	  and	  tyrosine	  32795.	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   The	  kinase	  domains	  of	  FYN	  and	  LCK	  are	  able	  to	  phosphorylate	  the	  ITAMs	  of	  the	  TCR	  and	  other	  target	  proteins	  during	  T	  cell	  signaling.	  One	  of	  the	  main	  functions	  of	  LCK	  is	  the	  phosphorylation	  of	  ζ-­‐chain	  associated	  protein	  kinase	  of	  70	  kDa	  (ZAP-­‐70)	  after	  TCR	  stimulation.	  	  ZAP-­‐70	  is	  normally	  bound	  in	  an	  inactive	  state	  to	  the	  ζ	  chain	  of	  the	  TCR	  at	  two	  phosphorylated	  residues.	  	  Following	  stimulation	  with	  CD3,	  CD28	  recruits	  LCK	  to	  the	  TCR96	  where	  LCK	  phosphorylates	  and	  activates	  ZAP-­‐70102.	  In	  turn,	  ZAP-­‐70	  phosphorylates	  other	  adaptors,	  such	  as	  the	  linker	  activator	  for	  T	  cells	  (LAT)103,104.	  LAT,	  in	  turn,	  activates	  several	  additional	  components	  including	  factors	  in	  the	  MAPK	  (mitogen	  activated	  protein	  kinase)	  and	  extracellular	  signal	  regulated	  kinase	  (ERK)	  pathways,	  as	  well	  as	  phospholipase	  C	  γ-­‐1	  (PLCγ−1)105.	  Studies	  examining	  the	  influence	  of	  co-­‐stimulatory	  molecules	  have	  shown	  that	  CD28	  also	  modulates	  the	  levels	  of	  PLCγ−1	  in	  the	  presence	  of	  CD3	  stimulation106.	  PLCγ−1 initiates	  calcium	  dependent	  and	  independent	  effects,	  discussed	  later.	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Figure	  1.3	  T	  cell	  activation	  and	  signaling	  cascades.	  	  The	  PTK	  LCK	  is	  associated	  with	  the	  CD4	  receptor	  and,	  upon	  CD3	  and	  CD28	  stimulation,	  moves	  to	  the	  vicinity	  of	  the	  T	  cell	  receptor.	  	  LCK	  phosphorylates	  ZAP-­‐70,	  which	  is	  bound	  to	  doubly	  phosphorylated	  ITAMs.	  	  This	  activates	  other	  proteins	  such	  as	  LAT	  and	  PLCγ−1	  to	  stimulate	  T	  cell	  activation.	  	  SAP	  is	  bound	  to	  the	  co-­‐stimulatory	  SLAM	  receptor	  and	  recruits	  the	  PTK	  FYN	  to	  the	  TCR.	  FYN	  activates	  several	  proteins,	  including	  ZAP-­‐70,	  which	  can	  similarly	  activate	  PLCγ−1 and	  PKC−θ.	  Blue	  lines	  denote	  initial	  phosphorylation	  events	  upon	  TCR	  activation	  and	  co-­‐stimulation.	  	  (PTK-­‐protein	  tyrosine	  kinase;	  TCR-­‐T	  cell	  receptor;	  LCK-­‐lymphocyte-­‐specific	  protein	  tyrosine	  kinase;	  ZAP-­‐70-­‐ζ	  chain	  associated	  protein	  of	  70kD;	  LAT-­‐linker	  activator	  for	  T	  cells;	  PLCγ1-­‐	  phospholipase	  C	  γ-­‐1;	  PKC−θ− protein	  kinase	  C-­‐θ;	  SLAM-­‐	  signaling	  lymphocytic	  activation	  molecule;	  SAP-­‐SLAM-­‐associated	  protein;	  ITSM-­‐	  immunoreceptor	  tyrosine-­‐based	  switch	  motif)107.	  	  	  	   T	  cell	  activation	  stimulates	  PLCγ−1	  to	  affect	  the	  downstream	  activation	  of	  the	  transcription	  factor	  families	  nuclear	  factor-­‐κΒ	  (NF-­‐κB)	  and	  nuclear	  factor	  of	  activated	  T	  cells	  (NFAT).	  In	  turn,	  PLCγ−1	  stimulates	  the	  hydrolysis	  of	  phosphatidylinositol-­‐4,5-­‐bisphosphate	  (PIP2)	  into	  diacylglycerol	  (DAG)	  and	  inositol	  triphosphate	  (IP3)98.	  Previous	  work	  in	  human	  primary	  CD4+	  cells	  has	  suggested	  that	  CD28	  signaling	  regulates	  PIP2	  conversion106.	  The	  product	  of	  PIP2,	  DAG,	  indirectly	  activates	  NF-­‐κB	  by	  activating	  protein	  kinase	  C-­‐θ	  (PKC-­‐θ)92,108	  (figure	  1.4).	  Sap-­‐deficient	  mice	  exhibit	  impaired	  PKC-­‐θ	  expression	  and	  NF-­‐κB	  activation	  following	  TCR	  stimulation109	  and	  this	  has	  been	  attributed	  to	  decreased	  DAG	  production110,111.	  This	  suggests	  that	  CD3/CD28	  stimulation	  requires	  T	  cells	  to	  express	  SAP	  in	  order	  for	  DAG	  to	  be	  produced.	  In	  the	  presence	  of	  SAP,	  activated	  PKC-­‐θ	  phosphorylates	  CARMA-­‐1	  (CARD11	  or	  caspase	  recruitment	  domain-­‐and	  membrane-­‐associated	  guanylate	  kinase-­‐like	  domain-­‐containing	  protein	  1)112,	  recruiting	  the	  constitutively-­‐associated	  BCL10	  (B-­‐cell	  lymphoma/leukemia	  10)	  and	  MALT1113	  (mucosa-­‐associated	  lymphoid	  tissue	  lymphoma	  translocation	  protein	  1)	  proteins	  to	  form	  the	  CARMA1/BCL10/MALT1	  (CBM)	  complex113.	  The	  CBM	  complex	  phosphorylates	  the	  IκBα	  subunit	  causing	  its	  dissociation	  and	  proteasomal	  degradation114	  thus	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liberating	  the	  nuclear	  localization	  signal	  of	  the	  remaining	  NF-­‐κB	  subunits	  (p65	  and	  p50)115,	  allowing	  nuclear	  translocation.	  	  
	  
Figure	  1.4	  T	  cell	  activation	  leading	  to	  IL-­‐2	  transcription.	  	  T-­‐cell	  receptor	  (TCR)	  signaling	  relies	  on	  primary	  and	  co-­‐stimulation	  events	  that	  activate	  T	  cell	  responses	  through	  signaling	  cascades.	  	  Initial	  T	  cell	  activation,	  following	  TCR	  recognition	  of	  antigen,	  and	  co-­‐stimulatory	  events,	  such	  as	  recognition	  by	  the	  SLAM-­‐family	  of	  receptors,	  trigger	  a	  series	  of	  phosphorylation	  events	  that	  activate	  phospholipase	  C	  γ-­‐1	  (PLCγ-­‐1).	  	  Once	  PLCγ-­‐1	  is	  activated,	  both	  the	  nuclear	  factor	  of	  activated	  T	  cells	  (NFAT)	  and	  nuclear	  factor	  kappa	  β	  (NF-­‐κB)	  families	  of	  transcription	  factors	  are	  localized	  to	  the	  nucleus	  where	  they	  bind	  with	  the	  IL-­‐2	  promoter	  during	  T	  cell	  activation.	  In	  addition,	  TCR	  stimulation	  activates	  the	  MAPK	  (mitogen-­‐activated	  protein	  kinase)	  pathway	  resulting	  in	  the	  formation	  of	  the	  AP-­‐1	  transcription	  factor,	  which	  also	  converges	  on	  the	  IL-­‐2	  promoter	  with	  the	  constitutively	  active	  Oct1.	  	  	   For	  effective	  T	  cell	  activation,	  a	  sustained	  elevation	  of	  intracellular	  calcium	  is	  required,	  through	  a	  combination	  of	  receptor	  activation	  and	  ion	  channels,	  to	  activate	  the	  NFAT	  transcription	  factor	  family,	  as	  shown	  above.	  IP3,	  generated	  by	  PIP2	  cleavage	  following	  CD28	  co-­‐stimulation106,	  binds	  to	  the	  IP3-­‐receptor	  on	  the	  endoplasmic	  reticulum	  (ER),	  stimulating	  the	  release	  of	  calcium	  ions	  from	  intracellular	  stores116.	  The	  CRAC	  (Ca2+	  Release-­‐Activated-­‐	  Ca2+)	  channels	  at	  the	  cell	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membrane	  are	  then	  opened	  to	  replenish	  calcium	  within	  the	  ER117.	  Within	  the	  cell,	  the	  free	  Ca2+	  binds	  to	  four	  motifs	  within	  the	  calcium-­‐modulated	  protein	  (calmodulin)118,	  which	  interacts	  with	  the	  phosphatase	  calcineurin	  through	  a	  calmodulin	  binding	  domain119.	  	  	  Calcineurin	  dephosphorylates	  NFAT,	  allowing	  for	  its	  nuclear	  translocation120,	  and	  modulates	  the	  formation	  of	  the	  CBM	  complex	  by	  dephosphorylating	  BCL10,	  which	  allows	  it	  to	  bind	  CARMA1121.	  	  Notably,	  there	  have	  been	  reports	  of	  excess	  intracellular	  calcium	  levels	  in	  vitro	  from	  TCR	  stimulated	  T	  cells	  from	  XLP1	  patients122.	  Although	  this	  finding	  has	  not	  been	  thoroughly	  explored,	  calcium	  imbalances	  can	  be	  detrimental	  to	  T	  cells	  as	  it	  can	  lead	  to	  PLCγ−1	  and	  PKC-­‐θ	  degradation123	  or	  apoptosis124.	  	  	  
	   TCR	  stimulation	  activates	  NFAT	  and	  NF-­‐κB	  and	  these	  transcription	  factors	  converge	  on	  the	  IL-­‐2	  promoter	  (figure	  1.3).	  IL-­‐2	  is	  of	  particular	  importance	  in	  T	  cell	  signaling,	  as	  it	  influences	  T	  cell	  proliferation.	  In	  addition	  to	  NFAT	  and	  NF-­‐κB,	  TCR	  activation	  allows	  CD28	  to	  bind	  growth	  factor	  receptor-­‐bound	  protein	  2	  (GRB2)125	  which	  facilitates	  the	  stimulation	  of	  Ras	  and	  the	  serine/threonine	  mitogen-­‐activated	  protein	  kinases	  (MAPK)78	  to	  activate	  c-­‐Fos	  and	  c-­‐Jun126.	  The	  transcription	  factor	  subunits	  c-­‐Fos	  and	  c-­‐Jun	  dimerize	  to	  form	  the	  AP1	  transcription	  factor	  and	  bind	  to	  the	  IL-­‐2	  promoter127	  along	  with	  the	  constitutively	  active	  Oct1128.	  Studies	  have	  shown	  that	  T	  cells	  from	  XLP1	  patients	  have	  decreased	  IL-­‐2	  production,	  suggesting	  impaired	  proliferation122,129.	  Taken	  together,	  the	  T	  cell	  signaling	  cascades	  involve	  the	  production	  of	  cytokines	  and	  the	  interaction	  of	  various	  proteins	  and	  these	  insights	  identified	  avenues	  to	  examine	  for	  specific	  SAP-­‐dependent	  defects	  following	  TCR	  stimulation.	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1.5	  Models	  to	  study	  XLP1	  	   	  	   Much	  of	  the	  understanding	  on	  how	  SAP	  influences	  the	  immune	  system	  is	  from	  previous	  work	  examining	  Sap-­‐deficient	  mice	  and	  table	  1.3	  summarizes	  these	  findings	  in	  comparison	  to	  XLP1	  patients.	  A	  striking	  similarity	  between	  the	  Sap-­‐deficient	  mice	  and	  XLP1	  patients	  is	  the	  lack	  of	  NKT	  development130,	  a	  feature	  that	  has	  been	  previously	  attributed	  to	  the	  interaction	  of	  SAP	  and	  FYN	  during	  development131.	  	  Similarly,	  Sap	  defects	  are	  associated	  with	  impaired	  germinal	  center	  formation132–135.	  	  	   Germinal	  centers	  form	  in	  B	  cell	  follicles	  and	  is	  the	  location	  where	  long-­‐term	  antibody	  memory	  is	  established136.	  B	  cell	  memory	  occurs	  following	  class	  switching	  of	  IgA,	  IgG,	  or	  IgE	  and	  hypermutation	  of	  the	  antigen	  binding	  variable	  chains137.	  	  CD4+	  T	  cells	  are	  required	  for	  the	  formation	  of	  germinal	  centers138	  and	  B	  cell	  function139.	  Specifically,	  follicular	  dendritic	  cells	  present	  antigen	  to	  follicular	  T	  helper	  cells	  (TFH)140,141	  which,	  in	  turn,	  signals	  the	  establishment	  of	  germinal	  centers	  and	  interactions	  with	  B	  cells142.	  It	  is	  this	  T:B	  interaction	  that	  stimulates	  class	  switching	  and	  B	  cells	  expansion	  and	  disruption	  is	  associated	  with	  hypergammaglobulinemia,	  impaired	  antibody	  production	  during	  the	  humoral	  response142.	  	  	   Exposure	  to	  various	  infections	  normally	  increases	  the	  production	  of	  specific	  antibodies	  but	  in	  the	  absence	  of	  Sap,	  mice	  have	  impaired	  antibody	  production.	  Sap-­‐deficient	  mice	  have	  defects	  in	  TFH	  cell	  production	  and	  secretion	  of	  IL-­‐4,	  components	  required	  for	  B	  cell	  differentiation143.	  	  Similarly,	  following	  influenza	  infection,	  Sap-­‐deficient	  mice	  have	  impaired	  expansion	  of	  B	  cells	  due	  to	  faulty	  CD4+	  T	  helper	  cell	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activity144,145	  and	  restoration	  of	  Sap	  expression	  was	  able	  to	  rescue	  antibody	  production	  and	  germinal	  center	  formation32.	  	  	   Importantly,	  impairments	  to	  CD4+	  T	  cells	  from	  XLP1	  patients	  have	  also	  been	  shown	  to	  affect	  T:B	  interactions,	  resulting	  in	  decreased	  antibody	  production32	  due	  to	  impaired	  GC	  formation133–135	  .	  Defective	  germinal	  center	  formation	  has	  been	  associated	  with	  immunodeficiency	  and	  the	  development	  of	  lymphoma,	  attributable	  to	  mutations	  or	  translocations	  involving	  the	  immunoglobulins	  and	  various	  oncogenes146,147.	  These	  mutations	  may	  confer	  proliferative	  advantages	  to	  infected	  cells	  or	  impair	  the	  release	  of	  antibodies	  in	  response	  to	  pathogens	  leading	  to	  persistent	  inflammation.	  	  	   While	  some	  studies	  have	  shown	  that	  SAP	  is	  expressed	  in	  B	  cells	  148–150	  it	  is	  generally	  thought	  that	  SAP	  is	  restricted	  to	  T	  and	  NK	  lineages	  implying	  that	  GC	  formation	  and	  B	  cell	  induced	  antibody	  production	  depends	  on	  cues	  from	  SAP	  expressing	  T	  helper	  cells.	  CD4+	  T	  cells	  from	  Sap-­‐deficient	  mice,	  in	  vitro,	  have	  decreased	  production	  of	  IL-­‐4	  which	  is	  required	  for	  Th2	  development32,151.	  Together,	  these	  data	  suggest	  that	  SAP	  potentially	  regulates	  T:B	  cell	  interactions	  by	  the	  production	  of	  surface	  proteins	  or	  modulates	  the	  secretion	  of	  cytokines	  necessary	  for	  B	  cell	  development32.	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Sap-­‐deficient	  mice	   	   	   	   	   	   	   XLP1	  patients	  
Cellular	  defects	  Impaired130	   	   	   NKT	  cell	   	   	   	   Not	  formed130	  Impaired132	   	   	  	  	  	  	  	  	  	  	  	  	  	  	   Germinal	  center	  formation	   	   Impaired133–135	  Impaired32	   	   	   TFH:B	  cell	  interactions	   	   Impaired32	  Impaired32,143	  	   	   Th2	  differentiation	  (IL-­‐4)	   	   Impaired152	  Decreased153,154	   	   Antibody	  (Ig)	  production	   	   Decreased155	  Increased153,156	  	   	  	  	  	  	  	  	  	  	  	  	  	  	   CD8+	  T	  cells	  (after	  infection)	   Increased152	  Impaired157,158	   	   CTL/NK	  activity	   	   	   Impaired159	  Decreased160	   	   	   Apoptosis	  (CD8+)	   	   	   Decreased159	  Increased	  (+MHV-­‐68)153,154	   Histiocytosis	   	   	   	   HLH	  (+EBV)161	  Increased	  (+LCMV)152	   IFN-­‐γ	  production	   	   	   Variable	  	  
Table	   1.4.	   Comparison	   of	   SAP	   defects	   in	  mice	   and	   humans.	   Studies	   in	  Sap-­‐deficient	  mice	  have	  identified	  many	  similarities	  to	  defects	  observed	  in	  XLP1	  patients.	   	  NKT-­‐natural	  killer	  T	  cells;	  Th2-­‐T	  helper	   2	   cells;	   CTL-­‐cytotoxic	   T	   cells;	   NK-­‐natural	   killer	   cell;	   TFH-­‐T	   follicular	   helper	   cells;	   and	   EBV-­‐Epstein-­‐Barr	   virus.	   *Mice	   cannot	   be	   infected	   by	   EBV	   and	   are	   infected	   by	   either	   lymphocytic	  choriomeningitis	  virus	  (LCMV)	  or	  murine	  gammaherpesvirus	  (MHV-­‐68).	  	  	  	  	   Both	  Sap-­‐deficient	  mice	  and	  XLP1	  patients	  have	  exhibited	  increased	  CD8+	  cells	  following	  viral	  infection	  and	  impaired	  cytotoxic	  killing	  abilities6,84,91,133,152.	  Infections	  increase	  the	  quantity	  of	  CD8+	  cells	  but	  studies	  have	  attributed	  defects	  in	  the	  killing	  of	  infected	  target	  cells	  to	  impaired	  interactions	  of	  SAP	  with	  the	  2B4	  receptor157	  	  and	  Ly-­‐108	  receptor158.	  The	  elevated	  quantities	  of	  CD8+	  cells	  exhibit	  increased	  resistance	  to	  apoptosis160	  suggesting	  that	  the	  accumulation	  of	  lymphocytes	  is	  SAP	  specific.	  	  	   Previous	  studies	  infecting	  Sap-­‐deficient	  mice	  with	  murine	  gammaherpesvirus-­‐68	  (MHV-­‐68),	  used	  to	  mimic	  EBV	  infection,	  have	  shown	  that	  more	  CD8+	  T	  cells	  are	  produced	  compared	  to	  their	  Sap	  expressing	  controls153.	  The	  excessive	  quantities	  of	  CTLs	  generate	  a	  phenotype	  similar	  to	  HLH	  with	  evidence	  of	  tissue	  infiltration	  that	  is	  not	  observed	  in	  their	  control	  counterparts154.	  Studies	  have	  also	  shown	  that	  these	  expanded	  T	  cell	  populations	  produce	  excessive	  levels	  of	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cytokines.	  Sap-­‐deficient	  mice	  infected	  with	  lymphocyte	  choriomeningitis	  virus	  (LCMV)	  exhibit	  elevated	  levels	  of	  IFN-­‐γ	  production	  by	  T	  cells152.	  Additionally,	  splenocytes	  from	  mice	  lacking	  Sap	  expression	  were	  shown	  to	  have	  increased	  IFN-­‐γ	  production,	  independent	  of	  infection152.	  Correlations	  between	  Sap-­‐deficient	  mice	  and	  XLP1	  patients	  have	  enhanced	  the	  appreciation	  for	  the	  myriad	  of	  influences	  that	  SAP	  have	  on	  immune	  cell	  development	  and	  function.	  However,	  much	  remains	  to	  be	  understood	  as	  to	  how	  these	  defects	  contribute	  to	  the	  multiple	  phenotypes	  observed	  in	  XLP1	  patients.	  
1.6	  Summary	  and	  Dissertation	  Goals	  	  	   XLP	  disease	  is	  a	  rare	  inherited	  immunodeficiency	  characterized	  by	  several	  phenotypes	  and	  an	  extreme	  sensitivity	  to	  infections,	  which	  results	  from	  mutations	  in	  either	  SAP	  or	  XIAP34.	  It	  is	  unclear	  why	  there	  is	  a	  range	  of	  phenotypes	  and	  how	  SAP	  and	  XIAP	  influence	  them.	  SAP	  defects	  result	  in	  the	  lack	  of	  NKT	  cell	  development5,101	  and	  disrupt	  T	  cell	  signaling122,129,	  but	  there	  are	  many	  unanswered	  questions	  as	  to	  how	  these	  defects	  occur.	  The	  goal	  of	  this	  dissertation	  was	  to	  reveal	  insights	  into	  how	  
SAP-­‐deficiencies	  influence	  T	  cell	  signaling,	  using	  a	  cell-­‐based	  model	  approach	  to	  affect	  targeting	  of	  the	  SAP	  gene.	  
	   To	  clarify	  the	  role	  of	  SAP	  in	  T	  cell	  signaling,	  we	  took	  a	  gene	  editing	  approach	  to	  disrupt	  the	  SAP	  gene	  and	  created	  a	  SAP-­‐null	  cell	  line,	  as	  discussed	  in	  chapter	  2.	  This	  SAP-­‐deficient	  cell	  line	  was	  used	  to	  identify	  SAP-­‐specific	  effects,	  which	  included	  cytokine	  production,	  transcription	  factor	  activity,	  and	  calcium	  mobilization,	  with	  results	  presented	  in	  chapter	  3.	  Moreover,	  chapter	  4	  illustrated	  a	  SAP-­‐dependent	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heightened	  sensitivity	  to	  apoptosis.	  These	  results	  suggested	  that	  SAP	  defects	  drastically	  alter	  T	  cell	  activation	  and	  the	  cytokine	  environment,	  making	  T	  cells	  more	  sensitive	  to	  apoptotic	  stimuli,	  potentially	  impeding	  their	  ability	  to	  respond	  to	  immune	  challenges.	  Together,	  these	  results	  identified	  specific	  SAP-­‐dependent	  defects	  in	  T	  cell	  signaling	  that	  could	  contribute	  to	  the	  characteristic	  phenotypes	  of	  patients	  with	  XLP1	  disease.	  	   	  
	   23	  
	  
Chapter	  2	  The	  Generation	  a	  SAP-­‐deficient	  Cell	  Line	  	  
	  
2.1	  Introduction	  	  	   Despite	  efforts	  over	  the	  past	  few	  years	  to	  understand	  how	  SAP	  defects	  impair	  immune	  cell	  responses,	  there	  are	  many	  unanswered	  questions.	  To	  further	  explore	  the	  role	  of	  SAP	  in	  T	  cell	  signaling,	  we	  chose	  to	  exploit	  an	  established	  SAP-­‐expressing	  human	  cell	  line	  for	  analysis.	  The	  Jurkat	  cell	  line	  has	  been	  extensively	  used	  to	  characterize	  cytokine	  production	  and	  T	  cell	  signaling107	  and	  it	  was	  therefore	  selected	  as	  the	  model	  system	  to	  determine	  the	  impacts	  of	  SAP-­‐deficiencies	  following	  stimulation	  of	  the	  T	  cell	  receptor	  (TCR).	  A	  common	  approach	  to	  this	  is	  to	  use	  RNAi	  technology	  to	  suppress	  gene	  expression,	  and	  these	  are	  powerful	  tools	  to	  assess	  the	  influences	  of	  a	  particular	  gene	  in	  a	  biological	  system.	  However,	  there	  are	  disadvantages	  to	  this	  approach	  as	  the	  effects	  are	  transient	  (siRNA)	  and	  stable	  suppression	  (shRNA)	  introduces	  the	  chance	  of	  an	  integration	  event.	  We	  chose	  to	  use	  transcription	  activator-­‐like	  effector	  nucleases	  (TALENs)	  to	  edit	  the	  SAP	  gene	  and	  the	  construction	  and	  validation	  of	  this	  gene	  editing	  technology	  will	  be	  described	  within	  this	  chapter,	  culminating	  in	  the	  generation	  of	  a	  SAP-­‐null	  model	  cell	  line.	  	   The	  development	  of	  transcription	  activator	  like	  effectors	  (TALEs)	  comes	  from	  our	  understanding	  of	  the	  gram-­‐negative	  members	  of	  the	  Xanthomonas	  genus162.	  These	  bacteria	  contain	  TAL	  effector	  (TALE)	  proteins	  that	  bind	  the	  host	  DNA	  and	  transcriptionally	  activate	  genes	  promoting	  bacterial	  survival.	  	  TALEs,	  the	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DNA	  binding	  proteins,	  consist	  of	  repetitive	  sequences	  of	  33-­‐34	  amino	  acids163	  and	  when	  fused	  with	  a	  nuclease	  (FokI)	  form	  a	  TALEN.	  TALENs	  function	  in	  pairs	  and	  each	  member	  of	  the	  pair	  contains	  one-­‐half	  of	  the	  FokI	  nuclease.	  	  When	  bound	  to	  a	  target	  sequence,	  the	  activity	  of	  the	  FokI	  protein	  is	  reconstituted	  generating	  a	  specific	  break	  in	  the	  substrate	  DNA164.	  This	  process	  creates	  a	  DSB	  that	  is	  either	  repaired	  by	  homologous	  recombination	  (HR),	  if	  a	  template	  sequence	  is	  available,	  or	  non-­‐homologous	  end	  joining	  (NHEJ)165.	  Herein,	  I	  describe	  the	  utilization	  of	  a	  TALEN	  gene	  editing	  approach	  to	  generate	  a	  SAP-­‐deficient	  cell	  line	  to	  model	  the	  effects	  of	  SAP	  in	  T	  cells	  signaling.	  
	  
	  	   	  	  
2.2	  TALEN	  cloning	  	  	  	   The	  TALEN-­‐based	  approach	  presented	  here	  used	  a	  non-­‐selection	  based	  plasmid	  that	  is	  transiently	  expressed	  by	  the	  cell	  after	  transfection	  and	  has	  a	  high	  degree	  of	  specificity	  for	  the	  target	  gene.	  Each	  TALEN	  recognizes	  16	  nucleotides	  and	  
Figure	  2.1	  Concept	  of	  gene	  editing.	  A	  DNA	  binding	  protein	  binds	  to	  a	  specific	  nucleotide	  sequence	  and	  the	  corresponding	  nuclease	  activity	  generates	  a	  double	  strand	  break	  in	  the	  DNA	  sequence.	  	  This	  break	  is	  then	  repaired	  by	  either	  homologous	  recombination,	  if	  a	  suitable	  template	  is	  available,	  or	  through	  error-­‐prone	  non-­‐homologous	  end	  joining	  (NHEJ).	  	  NHEJ	  is	  the	  primary	  mechanism	  to	  generate	  insertions	  and	  deletions	  within	  the	  target	  sequence.	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the	  pair	  is	  separated	  by	  a	  15-­‐31	  base	  pair	  spacer	  region166.	  The	  TALEN	  DNA	  binding	  domain	  is	  fused	  to	  the	  FokI	  wildtype	  nuclease,	  which	  is	  necessary	  for	  subsequent	  cleavage	  of	  the	  DNA.	  	  Considering	  the	  TALEN	  binding	  domains	  and	  spacer	  regions,	  it	  is	  estimated	  that	  a	  TALEN	  pair	  binds	  once	  in	  6.2	  billion	  base	  pairs167,	  indicating	  high	  specificity.	  	  In	  the	  TALEN	  protocol	  described	  here,	  the	  TALEs	  were	  constructed	  using	  nested	  PCR	  followed	  by	  ligations	  into	  the	  final	  vector	  that	  contains	  the	  nuclease.	  
	   TALENs	  were	  constructed	  using	  nested	  PCR	  to	  assemble	  unique	  primers	  (TAL	  units),	  which	  specify	  binding	  to	  one	  particular	  target	  nucleotide166,168.	  	  As	  shown	  in	  figure	  2.2,	  four	  TAL	  units	  combined	  to	  generate	  a	  module	  and	  four	  modules	  combined	  to	  form	  a	  TAL	  effector	  (TALE),	  capable	  of	  recognizing	  16	  nucleotides	  of	  a	  target	  sequence.	  
	  	  
Figure	  2.2	  TAL	  Effector	  (TALE)	  composition.	  Each	  TALE	  consists	  of	  TAL	  units,	  a	  primer	  consisting	  of	  ~100	  nucleotides,	  capable	  of	  recognizing	  one	  target	  nucleotide.	  	  Four	  TAL	  units	  were	  combined	  by	  PCR	  to	  generate	  a	  TAL	  module.	  	  The	  TALE	  was	  formed	  by	  the	  ligation	  of	  four	  TAL	  modules	  to	  generate	  a	  ~1600	  nucleotide	  sequence	  that	  can	  recognize	  and	  bind	  16	  nucleotides	  of	  a	  target	  sequence.	  	  Finally,	  the	  TALE	  was	  incorporated	  into	  a	  nuclease	  containing	  plasmid	  to	  generate	  a	  TALEN.	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   2.2.1	  Generation	  of	  the	  TAL	  modules	  
	  	   The	  initial	  step	  for	  designing	  a	  TALEN	  pair	  was	  to	  identify	  the	  specific	  nucleotide	  for	  editing	  within	  the	  gene	  of	  interest.	  A	  nucleotide	  that	  is	  often	  mutated	  in	  XLP1	  patients,	  163	  C	  >T169,	  was	  selected	  to	  target	  by	  gene	  editing.	  	  The	  Zinc	  Finger	  Consortium	  manages	  a	  web-­‐based	  program,	  called	  ZiFiT,	  available	  at	  zifit.partners.org,	  to	  design	  gene	  editing	  systems170,171	  and	  is	  suitable	  for	  designing	  ZFNs,	  TALENs,	  or	  CRISPR/Cas9.	  Based	  on	  the	  specific	  nucleotide	  within	  a	  gene,	  the	  ZiFiT	  program	  recommended	  DNA	  binding	  domains	  for	  the	  TALENs	  to	  target	  within	  the	  flanking	  sequences	  and	  also	  generated	  a	  ZiFiT	  sequence,	  approximately	  1600	  nucleotides,	  which	  are	  the	  basis	  of	  the	  primers	  that	  construct	  the	  TAL	  units.	  Current	  versions	  of	  the	  ZiFiT	  program	  also	  specify	  which	  nuclease	  containing	  backbone	  (e.g.	  JDS	  vector	  for	  TALENs)	  to	  utilize	  for	  final	  assembly.	  	  	  
	   As	  mentioned,	  the	  TAL	  units	  are	  primers	  that	  confer	  binding	  specificity	  to	  one	  target	  nucleotide.	  The	  ZiFiT	  program	  identified	  TAL	  units	  that	  correspond	  to	  the	  target	  sequence,	  depicted	  in	  figure	  2.3.	  	  For	  example,	  TAL	  unit	  7	  recognizes	  a	  cytosine	  and	  TAL	  unit	  11	  recognizes	  an	  adenine.	  	  These	  individual	  primers	  were	  joined	  in	  a	  nested	  PCR	  reaction	  to	  generate	  modules	  1,	  2,	  3,	  and	  4.	  	  An	  initial	  3-­‐part	  ligation	  joined	  modules	  1	  &	  2	  and	  3	  &	  4.	  	  A	  subsequent	  3-­‐part	  ligation	  into	  the	  TALEN	  backbone	  joined	  all	  four	  modules	  to	  complete	  one	  side	  of	  the	  TALEN	  pair.	  	  The	  process	  was	  repeated	  for	  both	  the	  TALEN	  left	  and	  TALEN	  right	  and	  assembly	  of	  the	  modules	  will	  be	  outlined	  with	  more	  detail	  below.	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Figure	  2.3	  TAL	  module	  generation.	  The	  ZiFiT	  assembly	  program	  determines	  the	  order	  of	  specific	  TAL	  units	  to	  assemble	  into	  four	  modules.	  	  These	  modules	  are	  initially	  constructed	  by	  nested	  PCR	  reactions	  followed	  by	  several	  ligations	  to	  generate	  one	  side	  of	  the	  TALEN	  pair,	  capable	  of	  recognizing	  16	  target	  nucleotides.	  This	  process	  was	  repeated	  for	  both	  sides	  of	  the	  TALEN	  pair.	  	  	  	   Each	  of	  the	  four	  TALE	  modules	  was	  generated	  by	  nested	  PCR	  reactions,	  illustrated	  in	  figure	  2.4.	  	  The	  specified	  TAL	  units	  were	  combined	  with	  additional	  scaffolding	  primers	  that	  provided	  the	  ends	  for	  the	  modules	  during	  the	  PCR	  reaction.	  	  These	  scaffold	  primers	  differ	  for	  each	  module	  and	  contained	  specific	  5’-­‐restriction	  enzyme	  sites	  to	  allow	  subsequent	  restriction	  digests	  and	  ligation.	  	  The	  third	  primer	  type	  provided	  connectivity	  among	  the	  growing	  strands.	  
	  
Figure	  2.4	  TAL	  unit	  scaffold.	  The	  nested	  PCR	  reactions	  generate	  TALE	  modules	  1-­‐4	  using	  the	  ZiFiT	  sequence	  as	  a	  guide.	  	  The	  scaffold	  primers	  provides	  the	  framework	  for	  the	  beginning	  and	  end	  of	  the	  module	  while	  the	  connectivity	  primers	  join	  the	  TAL	  unit	  primers	  to	  provide	  continuity	  for	  the	  growing	  fragments.	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   2.2.2	  Construction	  of	  the	  TALEN	  pair	  	  	  	  
	  	   Once	  the	  modules	  1-­‐4	  were	  prepared	  and	  purified,	  the	  first	  3-­‐part	  ligation	  joined	  modules	  1	  &	  2	  and	  modules	  3	  &	  4	  into	  an	  intermediate	  vector	  (T-­‐V0).	  	  To	  prepare	  for	  the	  ligation	  enzymes	  were	  specifically	  selected	  based	  on	  the	  nested	  PCR	  reaction	  primers.	  	  Figure	  2.5	  illustrates	  the	  digest	  of	  the	  module	  PCR	  fragments	  and	  initial	  ligation.	  	  
	  
Figure	  2.5	  Digest	  &	  ligation	  of	  TALE	  modules.	  Modules	  1&3	  were	  digested	  with	  XbaI	  and	  BsaI	  while	  modules	  2&4	  were	  digested	  with	  BbsI	  and	  BamHI.	  The	  digested	  modules	  were	  then	  ligated	  into	  the	  intermediate	  TALEN	  vector	  (T-­‐V0).	  
	   	  	   The	  initial	  3-­‐part	  ligation	  into	  T-­‐V0	  contained	  an	  800	  base	  pair	  insert	  that	  required	  sequencing.	  The	  ligation	  reactions	  were	  transformed	  and	  plated	  in	  preparation	  for	  in-­‐well	  DNA	  preparations	  and	  PCR	  reactions	  prior	  to	  sequencing.	  Approximately	  10-­‐20%	  of	  colonies	  were	  expected	  to	  contain	  the	  correct	  size	  of	  1kb	  band.	  	  	  Selected	  colonies	  were	  then	  prepared	  for	  sequencing.	  Homology	  for	  module	  1/2	  alignment	  began	  at	  5’-­‐GAAC	  and	  stopped	  at	  5’-­‐TTGA	  while	  homology	  for	  module	  3/4	  began	  at	  5’-­‐CTGA	  and	  stopped	  at	  5’-­‐C/TTGA.	  The	  purified	  800	  base	  pair	  modules	  were	  prepared	  for	  the	  final	  ligation	  by	  digest	  with	  BbsI	  and	  BsaI.	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   Figure	  2.6,	  demonstrates	  the	  directional	  cloning	  strategy	  of	  the	  final	  3-­‐part	  ligation	  into	  vector	  (JDS70),	  thereby	  fusing	  the	  TALE	  DNA	  binding	  domain	  to	  the	  
FokI	  nuclease.	  The	  JDS	  vector	  was	  cleaved	  by	  the	  exonuclease	  BsmBI	  at	  two	  sites	  creating	  a	  6kb	  linear	  fragment	  with	  staggered	  overhangs	  that	  were	  complementary	  to	  the	  beginning	  nucleotides	  of	  modules	  1/2	  and	  the	  end	  of	  modules	  3/4.	  	  
	  
	  	  
Figure	  2.6	  The	  final	  3-­‐part	  ligation.	  A)	  The	  final	  three-­‐part	  ligation	  of	  modules	  into	  the	  TALEN	  vector	  was	  facilitated	  by	  digest	  with	  BsmBI.	  The	  JDS	  vector	  backbone	  contains	  two	  BsmBI	  sites,	  where	  the	  enzyme	  cleaved	  at	  the	  indicated	  nucleotides.	  	  B)	  BsmBI	  recognized	  the	  underlined	  nucleotides	  with	  cleavage	  at	  sites	  indicated	  by	  the	  red	  lines.	  	  This	  generated	  ends	  that	  were	  complementary	  to	  the	  alignments	  of	  modules	  1&2	  and	  modules	  3&4	  minimizing	  self-­‐	  or	  inadvertent	  ligation	  of	  a	  single	  module.	  	  
After	  ligation,	  the	  1600	  base	  pair	  fragment	  was	  transformed	  into	  E.coli	  and	  plasmid	  construction	  was	  evaluated	  by	  a	  diagnostic	  restriction	  digest.	  As	  shown	  in	  figure	  2.7,	  
A) 
B) 	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the	  desired	  fragment	  size	  was	  2400	  base	  pairs	  (module	  1/2	  +	  module	  3/4	  	  +	  500	  base	  pairs	  to	  ClaI	  +	  300	  base	  pairs	  to	  BamHI),	  as	  depicted	  below.	  	  The	  plasmid	  preparations	  were	  sequenced	  and,	  at	  this	  point,	  the	  TALENs	  were	  ready	  for	  gene	  editing.	  
	  
	  
2.3	  Results	  	  	  	   The	  SAP	  targeting	  TALEN	  pair	  was	  prepared	  but	  required	  demonstration	  of	  its	  effectiveness	  at	  inducing	  a	  DSB	  at	  the	  target	  nucleotide.	  	  To	  address	  the	  efficacy	  of	  the	  gene	  editing	  plasmids,	  the	  TALEN	  pair	  was	  transfected	  into	  Jurkat	  cells	  followed	  by	  the	  efficiency	  screen	  outlined	  in	  figure	  2.8.	  One	  of	  the	  difficulties	  of	  this	  gene	  editing	  approach	  was	  distinguishing	  cells	  that	  had	  been	  edited	  from	  the	  
Figure	  2.7	  Restriction	  digest	  for	  final	  TALEN	  assembly.	  The	  final	  assembly	  of	  each	  side	  of	  the	   TALEN	   pair	   undergoes	   a	   confirmation	   restriction	   digest	   using	   ClaI	   and	   BamHI.	   The	  desired	   2400	   base	   pair	   fragment	   contained	   the	   JDS	   backbone	   and	   the	   correctly	   inserted	  module	   1/2/3/4	   ligation,	   which	   was	   then	   sequenced	   using	   T7	   and	   NK49	   primers	   for	  comparison	  to	  the	  ZiFiT	  homology.	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unaltered	  population.	  Distinguishing	  the	  altered	  population	  was	  often	  achieved	  through	  DNA	  isolation	  followed	  by	  PCR	  and	  sequencing.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  
Figure	  2.8	  Determining	  TALEN	  efficiency	  and	  clonal	  isolation.	  To	  maximize	  workflow,	  the	  preparation	  of	  single	  cell	  clones	  from	  the	  TALEN	  transfected	  population	  was	  initiated	  while	  concurrently	  assessing	  the	  TALEN	  editing	  efficiency.	  	  Particularly	  for	  cells	  that	  require	  longer	  to	  recover	  from	  single	  cell	  isolation,	  this	  approach	  identified	  whether	  or	  not	  the	  TALENs	  were	  effective	  at	  editing	  the	  target	  cells.	  TALEN	  efficiency	  was	  determined	  by	  extracting	  genomic	  DNA	  from	  the	  transfected	  population	  and	  subcloning	  PCR	  fragments	  specific	  to	  the	  region	  of	  interest	  into	  a	  plasmid.	  	  These	  fragments	  were	  analyzed	  to	  identify	  mutations	  introduced	  within	  the	  targeted	  population.	  	  If	  the	  TALENs	  were	  inefficient,	  the	  transfection	  process	  was	  repeated.	  	  However,	  if	  insertions	  or	  deletions	  were	  identified,	  the	  single	  cell	  clones	  were	  screened	  for	  mutations.	  	  	  
	  	  
To	  determine	  the	  efficacy	  of	  TALEN	  induced	  gene	  edits,	  genomic	  DNA	  from	  the	  transfected	  population	  was	  amplified	  by	  PCR	  using	  SAP	  specific	  primers	  (SAPEX2F/MEL2R)	  that	  surround	  the	  TALEN-­‐binding	  domain	  targeting	  nucleotide	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163	  in	  SAP	  (R55	  in	  SAP	  protein).	  	  These	  286	  base	  pair	  PCR	  fragments	  were	  then	  subcloned	  into	  a	  plasmid	  and	  analyzed	  by	  DNA	  gel	  electrophoresis	  for	  mobility	  changes.	  To	  confirm	  that	  the	  desired	  DNA	  region	  had	  been	  edited,	  sequencing	  was	  performed.	  However,	  the	  sensitivity	  of	  this	  approach	  was	  limited	  by	  resolution,	  which	  is	  based	  on	  fragment	  migration	  during	  gel	  electrophoresis.	  
	  
A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  2%	  Agarose	  Gel	   	   	   	  	  	  B)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8%	  Acrylamide	  Gel	  
	  
	  
Figure	  2.9	  Challenges	  to	  screening	  using	  standard	  DNA	  electrophoresis.	  A)	  PCR	  fragments	  amplified	  for	  SH2DIA	  (SAP)	  exon	  2	  (286	  base	  pair	  fragment)	  were	  analyzed	  on	  a	  2%	  agarose	  gel.	  	  Visualization	  of	  band	  migration	  was	  difficult	  when	  insertions	  or	  deletions	  involved	  few	  nucleotides,	  resulting	  in	  unnecessary	  sequencing	  reactions.	  B)	  Visualization	  of	  PCR	  fragments	  on	  8%	  acrylamide	  gels	  was	  also	  inefficient	  for	  resolving	  small	  changes	  in	  nucleotide	  content.	  	  	  	  
	  
Standard	  agarose	  gel	  electrophoresis,	  figure	  2.9,	  proved	  inefficient	  for	  identifying	  small	  gene	  edits,	  but	  was	  useful	  for	  the	  identification	  of	  select	  larger	  edits,	  as	  shown	  in	  figure	  2.10.	  However,	  poor	  resolution	  by	  DNA	  electrophoresis	  continued	  to	  be	  a	  problem	  when	  screening,	  leading	  to	  the	  incorporation	  of	  capillary	  electrophoresis	  (CE)	  fragment	  size	  analysis.	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Figure	  2.10	  DNA	  electrophoresis	  is	  useful	  for	  resolving	  large	  gene	  edits.	  An	  8%	  acrylamide	  gel	  resolved	  a	  25	  base	  pair	  deletion	  compared	  to	  WT.	  	  This	  deletion	  was	  sequenced	  using	  M13F/R	  primers	  and	  compared	  to	  the	  WT	  reference	  sequence.	  	  Smaller	  insertions	  were	  more	  difficult	  to	  identify	  by	  gel	  mobility.	  	  The	  8	  base	  pair	  insertion,	  confirmed	  by	  sequencing,	  was	  missed	  during	  gel	  electrophoresis.	  	  	   	  
	  	   Capillary	  electrophoresis	  (CE),	  used	  during	  forensic	  Short	  Tandem	  Repeat	  (STR)	  profiling172,173,	  can	  quantify	  the	  size	  of	  a	  PCR	  fragment	  and	  identify	  nucleotide	  insertions	  or	  deletions	  by	  comparison	  to	  wild	  type	  controls,	  thereby	  eliminating	  the	  likelihood	  of	  overlooking	  gene	  alterations	  based	  solely	  on	  gel	  migration	  and,	  at	  the	  same	  time,	  minimize	  sequencing	  reactions.	  The	  PCR	  sample	  was	  loaded	  into	  a	  narrow	  capillary	  tube	  where	  it	  crosses	  electric	  fields,	  separating	  the	  sample	  by	  size,	  where	  a	  detector	  correlated	  the	  fragment	  size	  to	  an	  internal	  size	  standard174.	  The	  CE	  screening	  identified	  two	  mutations	  within	  the	  pooled	  population	  after	  TALEN	  transfection.	  Figure	  2.11A	  illustrates	  the	  fragment	  sizes	  identified	  and	  demonstrated	  that	  the	  population	  contains	  the	  wild	  type	  (286	  base	  pairs),	  and	  an	  insertion	  and	  deletion	  of	  292	  and	  282	  base	  pairs,	  respectively.	  DNA	  from	  the	  corresponding	  E.	  coli	  colonies	  with	  the	  aberrant	  fragment	  sizes	  were	  then	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Figure	  2.11	  Identification	  of	  gene	  edits	  by	  Capillary	  Electrophoresis	  (CE).	  Genomic	  DNA	  was	  extracted	  from	  colonies	  cultured	  in	  a	  96	  well	  plate	  and	  PCR	  reactions	  using	  a	  5’-­‐6-­‐FAM	  primer	  were	  analyzed	  by	  CE.	  	  A)	  The	  majority	  of	  colonies	  contained	  a	  286	  base	  pair	  (bp)	  fragment	  (WT),	  but	  variations	  also	  depicted	  a	  292	  bp	  and	  282	  bp	  fragment,	  indicative	  of	  a	  6	  bp	  insertion	  and	  4	  bp	  deletion,	  respectively.	  B)	  CE	  results	  were	  confirmed	  by	  sequencing,	  as	  shown.	  The	  reference	  sequence	  includes	  the	  TALEN	  binding	  site	  highlighted	  in	  green	  with	  the	  insertion	  and	  deletion	  generating	  stop	  codon	  through	  either	  frameshift	  or	  nonsense	  mutations	  at	  the	  point	  of	  editing,	  respectively.	  	  
	  	   Two	  mutations	  in	  the	  population	  of	  transfected	  Jurkat	  cells	  were	  identified	  during	  TALEN	  efficacy	  screening.	  	  CE	  analysis,	  illustrated	  in	  figure	  2.12A,	  was	  subsequently	  performed	  on	  the	  clonally	  expanded	  Jurkat	  derivatives,	  identifying	  a	  population	  of	  cells	  with	  three	  different	  size	  fragments	  of	  282,	  286,	  and	  292	  base	  pairs.	  	  These	  fragments	  corresponded	  to	  wild	  type,	  the	  insertion,	  and	  the	  deletion	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depicted	  in	  figure	  2.11.	  	  Sequencing	  of	  the	  SAP	  exon	  2	  fragment	  in	  the	  TALEN	  binding	  region	  confirmed	  the	  previously	  identified	  edits.	  	  	  
	  	   A	  potential	  explanation	  for	  three	  peaks	  was	  that	  the	  limiting	  dilution	  generated	  a	  mixed,	  rather	  than	  a	  clonal,	  population.	  Thus,	  additional	  single	  cell	  isolation	  was	  performed	  on	  this	  population.	  	  Two	  fragments,	  282	  and	  292	  base	  pairs,	  were	  identified	  during	  the	  subsequent	  limiting	  dilution,	  figure	  2.13C.	  	  As	  shown	  by	  Western	  blot,	  these	  cells	  no	  longer	  have	  evidence	  of	  SAP	  expression,	  lane	  C	  of	  figure	  2.13D,	  while	  the	  populations	  from	  panels	  A	  and	  B,	  which	  contained	  the	  wild	  type	  peak	  during	  CE	  screening,	  also	  exhibited	  SAP	  expression.	  Two	  additional	  attempts	  of	  clonal	  expansion	  were	  attempted,	  but	  the	  deletion	  alone	  or	  the	  insertion	  alone	  could	  not	  be	  isolated.	  Notably,	  the	  unaltered	  (wild	  type)	  Jurkats	  used	  in	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subsequent	  experiments	  have	  gone	  through	  the	  same	  selective	  influences	  of	  the	  TALEN	  transfection	  and	  clonal	  isolation.	  	  	  
	  
Figure	  2.13	  Generation	  of	  a	  SAP-­‐null	  Jurkat.	  Clonal	  expansions	  of	  Jurkat	  cells	  transfected	  with	  the	  SAP-­‐targeting	  TALEN	  pair	  were	  screened	  by	  capillary	  electrophoresis	  (CE).	  A)	  The	  unaltered	  286	  base	  pair	  fragment	  is	  shown.	  B)	  Analysis	  of	  a	  clonally	  expanded	  population	  demonstrated	  three	  fragments	  with	  sizes	  of	  282,	  286,	  and	  292	  base	  pairs.	  	  This	  population	  was	  further	  isolated	  by	  limiting	  dilutions	  and	  screened	  by	  CE.	  	  C)	  The	  CE	  screen	  of	  the	  newly	  isolated	  clone	  resulted	  in	  two	  fragments	  of	  282	  and	  292	  base	  pairs.	  D)	  Western	  blotting	  demonstrates	  SAP	  expression	  in	  the	  clones,	  corresponding	  to	  the	  CE	  fragments	  shown	  in	  A-­‐C.	  	  The	  282	  and	  292	  size	  fragments	  shown	  in	  C	  show	  no	  evidence	  of	  SAP	  expression	  and	  are	  therefore	  classified	  as	  SAP-­‐null	  Jurkat	  cells.	  	  	  	   To	  further	  identify	  the	  clonal	  SAP-­‐null	  population,	  the	  regions	  surrounding	  the	  TALEN	  binding	  site	  were	  sequenced	  using	  an	  internal	  SAP	  exon	  2	  sequencing	  primer	  (MES1)	  that	  is	  upstream	  of	  the	  TALEN	  left-­‐binding	  site.	  	  The	  TALEN-­‐binding	  site	  is	  indicated	  in	  blue	  on	  the	  chromatogram,	  shown	  in	  figure	  2.14.	  	  The	  FokI	  cleavage	  generated	  a	  double-­‐strand	  break	  within	  the	  spacer	  region,	  at	  nucleotide	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155,	  indicated	  by	  the	  arrow.	  The	  SAP-­‐null	  sequence	  corresponds	  to	  the	  colonies	  previously	  isolated	  and	  sequenced	  containing	  an	  insertion	  and	  deletion,	  both	  leading	  to	  stop	  codons	  within	  the	  SAP	  gene.	  	  	  
	  
	  	  
Figure	  2.14	  Sequencing	  results	  of	  the	  final	  iterations	  of	  clonal	  expansion.	  Genomic	  DNA	  from	  the	  wild	  type	  and	  SAP-­‐null	  Jurkats	  was	  PCR	  amplified	  for	  the	  SAP	  exon	  2	  region	  targeted	  by	  the	  TALEN	  pair.	  The	  WT	  control	  and	  the	  SAP-­‐null	  cells	  were	  sequenced	  using	  the	  MES1F	  primer.	  	  Chromatographs	  show	  that	  the	  SAP-­‐null	  cells	  have	  overlapping	  chromatograms	  at	  the	  point	  of	  the	  double	  strand	  break,	  indicated	  by	  the	  arrow,	  downstream	  of	  the	  TALEN	  left	  binding	  site,	  highlighted	  in	  blue.	  	  
	  	   Gene	  editing	  facilitated	  the	  mutation	  of	  SAP	  to	  generate	  a	  SAP-­‐null	  cell	  line.	  However,	  it	  was	  of	  concern	  whether	  the	  TALENs	  were	  still	  being	  expressed	  in	  the	  cell,	  where	  they	  could	  continually	  induce	  mutations.	  To	  address	  this	  question,	  and	  confirm	  that	  the	  TALENs	  were	  no	  longer	  present	  within	  the	  Jurkat	  cells,	  the	  wild	  type	  and	  SAP-­‐null	  cells	  were	  examined	  for	  FLAG	  expression	  by	  Western	  blot.	  The	  TALEN	  plasmid	  backbone	  (JDS70)	  contains	  a	  FLAG-­‐tag	  sequence,	  which	  would	  be	  detectable	  if	  the	  cells	  were	  still	  expressing	  the	  TALENs.	  For	  this	  experiment,	  the	  wild	  type	  and	  SAP-­‐null	  Jurkats	  were	  transfected	  with	  an	  unrelated	  plasmid,	  while	  separate	  positive	  control	  transfections	  of	  SAP-­‐null	  Jurkats	  with	  a	  FLAG-­‐SAP-­‐expressing	  plasmid	  and	  the	  wild	  type	  cells	  with	  a	  TALEN	  plasmid	  were	  prepared.	  As	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shown	  in	  figure	  2.15,	  there	  was	  no	  evidence	  of	  a	  FLAG-­‐expressing	  protein	  in	  the	  wild	  type	  or	  SAP-­‐null	  populations	  (lane	  1	  and	  lane	  2,	  respectively),	  while	  the	  positive	  controls	  of	  the	  FLAG-­‐SAP	  and	  new	  TALEN	  transfection	  demonstrated	  expression	  of	  FLAG–fusion	  proteins.	  	  This	  suggested	  that	  the	  SAP-­‐deficient	  cell	  line	  had	  no	  residual	  evidence	  of	  TALEN	  expression.	  TALEN	  expression	  in	  the	  SAP-­‐null	  Jurkats	  was	  transient	  and	  that	  there	  was	  no	  evidence	  of	  integration	  within	  the	  genome	  of	  the	  targeted	  cells.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2.15	  Transient	  expression	  of	  the	  TALEN	  pair.	  SAP-­‐null	  Jurkat	  cells	  were	  transfected	  with	  an	  unrelated	  plasmid	  or	  a	  FLAG-­‐SAP	  plasmid.	  	  Wild	  type	  Jurkat	  cells	  were	  transfected	  with	  an	  unrelated	  plasmid	  or	  one	  side	  of	  a	  FLAG-­‐TALEN	  pair	  as	  a	  positive	  control.	  	  The	  TALEN	  generated	  
SAP-­‐null	  Jurkat	  line	  (lane	  2)	  does	  not	  expresses	  FLAG	  protein	  while	  the	  control	  lanes,	  the	  transient	  SAP	  plasmid	  (lane	  3)	  and	  the	  TALEN	  transfected	  into	  the	  WT	  Jurkat	  (lane	  4)	  express	  the	  FLAG	  protein.	  	  
	  	  
	  	   Considering	  that	  multiple	  iterations	  of	  clonal	  isolation	  did	  not	  separate	  the	  cell	  populations	  containing	  insertions	  and	  deletions	  within	  the	  SAP	  locus,	  it	  was	  concerning	  that	  this	  could	  be	  due	  to	  multiple	  X	  chromosomes.	  To	  determine	  if	  there	  was	  more	  than	  one	  copy	  of	  the	  X	  chromosome	  within	  the	  SAP-­‐null	  Jurkats,	  short	  tandem	  repeat	  (STR)	  analysis172,173	  was	  performed.	  	  STR	  analysis	  is	  frequently	  used	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to	  authenticate	  the	  identity	  of	  transformed	  cell	  lines	  in	  culture,	  as	  well	  as	  identify	  cross-­‐contamination	  from	  unrelated	  cell	  lines.	  	  Performing	  STR	  analysis	  served	  two	  functions,	  it	  determined	  the	  number	  of	  X	  chromosomes	  within	  the	  population	  of	  cells,	  and	  confirmed	  the	  identity	  of	  the	  SAP-­‐null	  cells	  compared	  to	  their	  parental	  Jurkat	  lineage.	  Guidelines175	  establish	  that	  in	  order	  to	  confirm	  cell	  line	  identity,	  >80%	  of	  loci	  must	  match	  and	  ranges	  below	  this	  threshold	  require	  further	  analysis,	  as	  they	  suggest	  cell	  line	  contamination.	  	  The	  percent	  match	  of	  alleles	  is	  determined	  by	  multiplying	  the	  number	  of	  shared	  alleles	  by	  two	  and	  dividing	  this	  product	  by	  the	  sum	  of	  the	  total	  alleles	  tested	  and	  the	  number	  of	  reference	  alleles	  compared	  [%	  match	  =	  (shared	  alleles	  x	  2)/(total	  alleles	  tested	  +	  total	  reference	  alleles)].	  Nine	  reference	  STRs	  obtained	  from	  the	  American	  Type	  Culture	  Collection	  (ATCC)	  STR	  database176	  were	  used	  to	  compare	  the	  WT	  and	  SAP-­‐null	  Jurkat	  results.	  Compared	  to	  the	  original	  Jurkat	  cell	  line	  (Jurkat	  E6.1),	  the	  wild-­‐type	  control	  Jurkats	  are	  a	  93.8%	  match	  to	  the	  reference	  file,	  while	  the	  SAP-­‐null	  Jurkats	  are	  an	  89.7%	  match.	  Importantly,	  only	  one	  X	  chromosome	  was	  identified	  during	  this	  analysis.	  Having	  validated	  the	  identity	  of	  the	  SAP-­‐null	  Jurkats,	  the	  final	  concern	  was	  the	  potential	  of	  TALENs	  to	  edit	  at	  unintended	  loci.	  
	   Despite	  the	  specificity	  inherent	  in	  the	  TALEN	  design	  process,	  the	  possibility	  remained	  that	  the	  TALENs	  may	  have	  bound	  at	  other	  regions	  within	  the	  genome.	  Aside	  from	  sequencing	  the	  entire	  genome	  to	  assess	  whether	  the	  TALENs	  disrupted	  at	  other	  loci,	  one	  method	  available	  to	  identify	  other	  regions	  where	  the	  TALENs	  may	  bind	  is	  by	  querying	  the	  NCBI	  BLAST	  nucleotide	  sequence	  program	  for	  the	  human	  genome177.	  The	  50	  nucleotides	  containing	  the	  TALEN	  binding	  domains	  and	  the	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spacer	  region	  were	  entered	  into	  the	  NCBI	  BLASTn	  program	  and	  results	  demonstrated	  that	  SAP	  was	  the	  only	  gene	  to	  contain	  these	  sequences.	  While	  there	  are	  some	  fragments	  where	  one	  of	  the	  TALEN	  pairs	  could	  bind,	  there	  is	  no	  indication	  that	  the	  corresponding	  TALEN	  partner	  could	  bind	  within	  the	  proximity.	  Based	  on	  these	  results,	  it	  is	  unlikely	  that	  this	  particular	  SAP	  targeting	  TALEN	  pair	  will	  effectively	  bind	  and	  induce	  a	  genetic	  edit	  elsewhere	  within	  the	  human	  genome.	  
2.4	  Discussion	  	  	   To	  our	  knowledge,	  this	  is	  the	  first	  study	  in	  which	  gene	  editing	  technology	  was	  employed	  to	  generate	  an	  isogeneic	  cell	  line	  to	  directly	  compare	  the	  effects	  of	  SAP	  on	  T	  cell	  signaling.	  TALENs	  are	  one	  approach	  that	  has	  revolutionized	  the	  field	  of	  gene	  editing	  by	  introducing	  the	  ability	  to	  correct	  mutations	  or	  introduce	  specific	  point	  mutations	  in	  cells	  or	  animal	  models	  with	  relative	  speed.	  Other	  comparable	  gene	  editing	  approaches	  are	  available,	  such	  as	  CRISPR/Cas9	  (clustered	  regularly	  interspaced	  short	  palindromic	  repeats),	  which	  are	  easier	  to	  generate	  and	  are	  guided	  to	  a	  specific	  sequence	  by	  20	  nucleotides178,	  whereas	  TALENs	  are	  more	  difficult	  to	  produce	  but	  they	  have	  higher	  specificity	  by	  recognizing	  32	  target	  nucleotides170.	  CRISPRs	  are	  between	  40-­‐80%	  effective	  for	  targeting	  a	  specific	  region	  while	  TALENs	  range	  from	  20-­‐50%179.	  However,	  recent	  studies	  have	  shown	  that	  the	  CRISPR/Cas9,	  compared	  to	  TALENs,	  have	  higher	  off-­‐target	  effects180.	  Given	  that	  the	  SAP	  TALEN	  pair	  was	  effective	  at	  targeting	  the	  SAP	  locus,	  it	  is	  possible	  that	  theses	  reagents	  could	  be	  used	  to	  repair	  hematopoietic	  stem	  cells	  from	  XLP1	  patients	  with	  mutations	  within	  the	  targeted	  locus.	  	  This	  is	  an	  exciting	  option	  and	  proof-­‐of-­‐principle	  experiments	  have	  been	  done	  to	  correct	  a	  patient	  mutation	  for	  the	  type	  VII	  collagen	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(COL7AI)	  gene	  in	  patient-­‐derived	  primary	  fibroblasts181,	  and	  mutations	  in	  the	  β-­‐globin	  gene	  (HBB),	  which	  causes	  β-­‐thalassemia,	  in	  induced	  pluripotent	  stem	  cells	  (iPSCs)182.	  	  
	   Design,	  construction,	  and	  testing	  of	  a	  custom	  TALEN	  pair	  targeting	  SAP	  in	  Jurkat	  cells	  led	  to	  the	  generation	  of	  a	  SAP-­‐null	  cell	  line	  in	  which	  the	  effects	  of	  SAP-­‐defects	  in	  a	  CD4+	  	  cell	  lineage	  could	  be	  tested.	  	  Gene	  editing	  attempted	  to	  target	  a	  nucleotide,	  cytosine	  163	  with	  SAP169,	  and	  generate	  a	  mutation	  observed	  in	  several	  XLP1	  patients183–185	  using	  a	  single	  strand	  donor	  oligonucleotide.	  Studies	  have	  shown	  that	  ~50	  homologous	  nucleotides	  flanking	  the	  site	  of	  correction	  are	  sufficient	  for	  use	  during	  gene	  editing	  to	  induce	  homologous	  recombination186	  and	  this	  was	  used	  as	  a	  guideline	  to	  design	  the	  SAP	  specific	  oligonucleotide.	  It	  was	  possible	  that	  the	  TALEN	  pair	  did	  not	  efficiently	  create	  a	  DSB	  to	  activate	  the	  HR	  machinery	  to	  incorporate	  the	  template	  or	  that	  the	  sequence	  homology	  was	  insufficient	  for	  recognition.	  Also,	  it	  is	  plausible	  that	  the	  correction	  was	  made	  but	  the	  population	  was	  unable	  to	  be	  recovered	  during	  clonal	  isolation.	  Screening	  for	  the	  correction	  was	  particularly	  challenging,	  as	  there	  was	  no	  difference	  in	  the	  size	  of	  the	  gene	  and	  the	  edits	  could	  not	  be	  resolved	  by	  CE	  screening.	  
	   Although	  the	  specific	  patient	  mutation	  was	  not	  generated,	  the	  SAP	  gene	  was	  effectively	  disrupted	  by	  NHEJ	  after	  the	  TALEN	  induced	  a	  DSB,	  which	  allowed	  the	  clonal	  isolation	  of	  a	  SAP-­‐null	  cell	  line.	  While	  the	  TALEN	  plasmid	  utilized	  contained	  no	  selection	  markers,	  current	  generation	  plasmids	  contain	  fluorescent	  proteins	  which	  would	  facilitate	  separation	  and	  enrichment	  of	  transfected	  cells	  by	  fluorescence-­‐activated	  cell	  sorting	  (FACS)187.	  This	  enriched	  population	  could	  then	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be	  clonally	  isolated	  and	  analyzed	  by	  sequencing	  reactions	  to	  identify	  corrected	  cells.	  Gene	  editing	  also	  introduces	  the	  potential	  for	  random	  incorporation	  within	  the	  genome.	  While	  there	  was	  no	  evidence	  of	  the	  expression	  of	  a	  FLAG	  fusion	  protein	  in	  the	  SAP-­‐null	  cells,	  a	  Southern	  blot	  would	  be	  required	  to	  formally	  exclude	  the	  presence	  of	  an	  integration	  event.	  	  
	   The	  TALEN	  was	  constructed	  using	  nested	  PCR	  followed	  by	  multiple	  restriction	  digests	  and	  ligations.	  	  Diagnostic	  restriction	  digests	  and	  sequencing	  of	  the	  assembled	  TALEN	  plasmids	  confirmed	  their	  nucleotide	  content	  prior	  to	  their	  use.	  The	  efficiency	  of	  TALEN	  editing	  was	  systematically	  analyzed	  using	  capillary	  electrophoresis	  to	  identify	  insertions	  and	  deletions	  with	  high	  resolution,	  and	  confirmed	  by	  sequence	  analysis.	  	  Analysis	  of	  single	  cell	  clones	  confirmed	  the	  acquisition	  of	  mutations	  within	  the	  SAP-­‐null	  Jurkat	  cell	  line,	  which	  possessed	  both	  an	  insertion	  and	  deletion,	  thereby	  eliminating	  SAP	  expression.	  These	  cells	  provided	  an	  experimental	  system	  to	  analyze	  T	  cell	  signaling	  defects	  attributable	  to	  SAP.	  The	  validated	  SAP-­‐null	  cells	  were	  functionally	  examined,	  as	  described	  in	  chapters	  3	  and	  4,	  to	  characterize	  SAP-­‐dependent	  defects	  in	  a	  T	  cell	  lineage	  and	  add	  insights	  into	  the	  biology	  of	  XLP1.	  	  	  
2.5	  Materials	  &	  Methods	  	  
TAL	  primers.	  The	  following	  primers	  were	  used	  to	  construct	  the	  TAL	  unit	  modules	  during	  nested	  PCR	  reactions.	  	  The	  primers	  are	  listed	  in	  5’-­‐3’	  orientation.	  	  (11)	   AGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGA	  (12)	   AGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGA	  (14)	   AGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGA	  (15)	   AGCAAGTCGTGGCCATTGCAAGCAATGGGGGTGGCAAACAGGCTCTTGAGACGGTTCAGA	  (16)	   ATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCCAAC	  (17)	   ATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTCCAAC	  (19)	   ATCAAGTTGTAGCGATTGCGAATAACAATGGAGGGAAACAAGCATTGGAGACTGTCCAAC	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(20)	   ATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTCCAAC	  (21)	   CACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTAAGCAGGCGCTGGAAACAGTACAGC	  (22)	   CACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTAAGCAGGCGCTGGAAACAGTACAGC	  (24)	   CACAAGTGGTCGCCATCGCCAACAACAACGGCGGTAAGCAGGCGCTGGAAACAGTACAGC	  (25)	   CACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTAAGCAGGCGCTGGAAACAGTACAGC	  (26)	   ACCAGGTAGTCGCAATCGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAA	  (27)	   ACCAGGTAGTCGCAATCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAA	  (29)	   ACCAGGTAGTCGCAATCGCGAACAATAATGGGGGAAAGCAAGCCCTGGAAACCGTGCAAA	  (30)	   ACCAGGTAGTCGCAATCGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAA	  (Extension	  2)	  TGCAATGGCCACGACTTGCTCCGGTGTAAGGCCGTGGTCTTGACAAAGGACCGGCAACAACCTTTGCACGGTTTCCAGGGCT	  (Extension	  3)	  CGCAATCGCTACAACTTGATCGGGAGTCAGCCCGTGGGCTTGACAGAGAACTGGGAGAAGTCTCTGAACCGTCTCAAGAGCC	  (Extension	  4)	  GGCGATGGCGACCACTTGTGCAGGCGTCAAACCGTGGGCTTGACACAACACGGGAAGGAGCCGTTGGACAGTCTCCAATGCT	  (Extension	  5)	  	  TCCATGATCCTGGCACAGTACAGGCAGCAGGCGCTGTACTGTTTCCAGCGCC	  (Scaffold	  345)	  GTACCTCGCGAATGCATCTAGAGAAGACAAGAACCTGACCCCAGACCAGGTAGTCGCAATCGCG	  (Scaffold	  346)	  	  GTACCTCGCGAATGCATCTAGAGAAGACAACTGACCCCAGACCAGGTAGTCGCAATCGCG	  (Scaffold	  347)	  ATGCAGGCCTCTGCAGTCGACGGGCCCGGGATCCGGTCTCTTCAGTCCATGATCCTGGCACAGTA	  (Scaffold	  384)	  	  GTACCTCGCGAATGCATCTAGAGAAGACAATTGACCCCAGACCAGGTAGTCGCAATCGCG	  (Scaffold	  385)	  ATGCAGGCCTCTGCAGTCGACGGGCCCGGGATCCGGTCTCTTCAATCCATGATCCTGGCACAGTA	  
	  
PCR	  amplification	  and	  sequencing	  primers.	  The	  following	  primers	  were	  used	  for	  PCR	  amplification	  or	  sequencing	  reactions,	  as	  indicated.	  Sequencing	  reactions	  were	  performed	  by	  the	  University	  of	  Michigan	  DNA	  Sequencing	  Core.	  	  SAPEX2F	  	  	   5’-­‐GGA	  AAC	  TGT	  GGT	  TGG	  GCA	  GAT	  ACA	  ATA	  TGG-­‐3’	   (PCR)	  SAPEX2R	  	   5’-­‐GGC	  TAA	  ACA	  GGA	  CTG	  GGA	  CCA	  AAA	  TTC	  TC-­‐3’	   (PCR)	  MEL2R	  	  	   5’-­‐ACC	  CCC	  AGA	  AGC	  AAA	  AAT	  AAA-­‐3’	   	   (sequencing	  &	  PCR)	  BGHRev	  	   5’-­‐TAG	  AAG	  GCA	  CAG	  TCG	  AGG-­‐3’	  	   	   (sequencing)	  NK49	  	   	   5’-­‐GGC	  CTG	  GAC	  AAT	  TGG	  GCT-­‐3’	   	   	   (sequencing)	  MES1F	  	   	   5’-­‐CAC	  CAT	  ATA	  CGT	  GTG	  TCC-­‐3’	   	   	   (sequencing)	  	   	  	  
	  
Nested	  PCR	  reactions	  for	  module	  construction.	  Four	  separate	  PCR	  reactions,	  one	  for	  each	  module	  were	  prepared	  as	  shown	  in	  table	  2.2.	  	  PCR	  reaction	  conditions	  were:	  initial	  denaturation	  at	  98°C	  for	  3	  minutes;	  followed	  by	  35	  cycles	  of	  98°	  for	  1	  minute,	  63°	  for	  30	  seconds,	  and	  72°	  for	  1	  minute;	  and	  ending	  with	  72°	  for	  3	  minutes.	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The	  entire	  400	  base	  pair	  product	  from	  each	  module	  PCR	  reaction	  was	  visualized	  on	  a	  1%	  agarose	  gel.	  These	  fragments	  were	  excised	  and	  purified	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  according	  to	  manufacturer’s	  instructions	  and	  eluted	  in	  50uL	  of	  water.	  
	  
Component           Module 1          Module 2            Module 3           Module 4 
5X Phusion Buffer 40uL  40uL   40uL   40uL 
Phusion Polymerase 2uL  2uL    2uL    2uL 
dNTP Mix (10 µM) 6uL  6uL    6uL    6uL 
Extension 2-5 (0.5µM) 2uL  2uL    2uL    2uL 
TAL Unit #X (0.5 µM)   2uL    2uL    2uL    2uL 
TAL Unit #X (0.5 µM)   2uL    2uL    2uL    2uL 
TAL Unit #X (0.5 µM)   2uL    2uL    2uL    2uL 
TAL Unit #X (0.5 µM)   2uL    2uL    2uL    2uL 
Scaffold (10 µM)  #345-4uL #346-4uL #384-4uL #346-4uL 
Scaffold (10 µM)  #347-4uL #385-4uL #347-4uL #347-4uL 
Ultra pure H2O  134uL  134uL  134uL  134uL 
 
Total volume  200uL 
Table	  2.1	  	  Nested	  PCR	  reaction	  components.	  
	  
Subcloning	  of	  modules	  1	  &	  2	  and	  module	  3	  &	  4.	  PCR	  products	  of	  modules	  1	  and	  3	  were	  prepared	  with	  XbaI	  and	  BsaI,	  while	  modules	  2	  and	  4	  were	  digested	  with	  BbsI	  and	  BamHI	  and	  T-­‐V0	  was	  digested	  with	  XbaI	  and	  BamHI.	  	  Digests	  were	  incubated	  for	  2	  hours	  at	  37°.	  	  The	  entire	  digest	  for	  each	  module	  was	  visualized	  on	  a	  1%	  agarose	  gel	  ran	  at	  100V	  for	  45	  minutes.	  The	  400	  base	  pair	  module	  fragments	  for	  each	  module	  and	  the	  2.7kb	  fragment	  for	  T-­‐V0	  were	  excised	  and	  purified	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  according	  to	  manufacturer’s	  instructions.	  	  Modules	  were	  eluted	  in	  30uL	  and	  T-­‐V0	  eluted	  in	  50	  μL	  of	  water.	  	  Ligation	  reactions	  were	  prepared	  using	  150ng	  of	  each	  module	  and	  vector	  DNA.	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Component             Module 1            Module 2            Module 3           Module 4                  T-V0 
Module/Vector DNA 50uL  50uL   50uL   50uL  2.5uL 
10X Digest Buffer #4-10uL  #2-10uL  #4-10uL  #2-10uL  #4-10uL 
10X BSA  10uL  10uL  10uL  10uL  10uL 
Enzyme #1 (2uL)  XbaI  BbsI  XbaI  BbsI  BbsI 
Enzyme #2 (2uL)  BsaI  BamHI  BsaI  BamHI  BamHI 
Ultra pure H2O  26uL  26uL  26uL  26uL  23.5uL 
   
Total volume  100uL        50uL 
 
Table	  2.2	  	  Digest	  in	  preparation	  for	  ligation	  of	  modules	  1	  &	  2	  and	  modules	  3	  &	  4.	  Ligation	  reactions	  were	  transformed	  into	  XL-­‐1	  Blue	  cells	  and	  plated	  on	  agar	  plates.	  	  These	  colonies	  were	  further	  screened	  using	  in	  well	  DNA	  preparations	  and	  PCR	  reactions.	  Initially,	  colonies	  were	  selected	  and	  cultured	  on	  96-­‐well	  plates	  containing	  150	  μL	  of	  LB	  broth	  +	  carb	  (1:1000)	  with	  incubation	  at	  37°	  overnight.	  A	  PCR	  reaction	  was	  prepared	  using	  2	  μL	  of	  the	  culture	  DNA,	  5	  μL	  of	  5X	  Go-­‐Taq	  buffer,	  0.5	  μL	  of	  (10	  μM)	  dNTP	  mix,	  1	  μL	  (10	  μM)	  of	  M13F,	  1uL	  (10	  μM)	  of	  M13R,	  0.1	  μL	  Go-­‐Taq	  polymerase,	  and	  15.4	  μL	  ultra-­‐pure	  water.	  	  PCR	  reaction	  conditions	  were:	  98°	  for	  3	  minutes;	  35	  cyles	  of	  98°	  for	  1	  minute,	  63°	  for	  30	  seconds	  and	  72°	  for	  1	  minutes;	  and	  72°	  for	  3	  minutes.	  	  The	  colony	  PCR	  products	  were	  visualized	  on	  a	  1%	  agarose	  gel	  ran	  at	  100V	  for	  30	  minutes.	  	  Approximately	  10-­‐20%	  of	  colonies	  were	  expected	  to	  contain	  the	  correct	  size	  of	  1kb	  band.	  Colonies	  were	  expanded	  to	  5	  mL	  LB	  +	  carbicillin	  (1:1000)	  in	  a	  37°	  shaker	  incubator	  overnight.	  	  The	  following	  day	  cultures	  were	  prepared	  using	  the	  Qiagen	  Spin	  Mini	  Prep	  Kit	  according	  to	  manufacturer’s	  instructions.	  	  Plasmids	  were	  sequenced	  by	  the	  University	  of	  Michigan	  Sequencing	  Core	  using	  M13	  forward	  and	  M13	  reverse	  primers	  and	  compared	  to	  the	  ZiFiT	  sequence.	  	  Homology	  for	  module	  1/2	  alignment	  began	  at	  5’-­‐GAAC	  and	  stopped	  at	  5’-­‐TTGA	  while	  homology	  for	  module	  3/4	  began	  at	  5’-­‐CTGA	  and	  stopped	  at	  5’-­‐C/TTGA.	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TALE	  clones	  with	  precise	  alignments	  were	  then	  used	  for	  the	  final	  three-­‐part	  ligation	  into	  the	  TALEN	  (JDS)	  vector	  backbone.	  	  	  
	  
Final	  ligation	  into	  TALEN	  vector.	  	  The	  purified	  800	  base	  pair	  modules	  were	  prepared	  for	  cloning	  into	  the	  final	  TALEN	  vector	  (JDS70).	  Modules	  1/2	  and	  modules	  3/4	  were	  double	  digested	  with	  BbsI	  and	  BsaI	  while	  the	  TALEN	  JDS	  vector	  was	  digested	  with	  BsmBI.	  	  After	  two	  hours	  incubation	  at	  37°,	  the	  entire	  volume	  was	  visualized	  on	  a	  1%	  agarose	  gel	  at	  100V	  for	  45	  minutes.	  	  The	  800	  base	  pair	  modules	  and	  the	  JDS	  fragment	  were	  excised	  and	  gel	  purified	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  according	  to	  manufacturer’s	  instructions.	  	  Modules	  and	  vector	  were	  eluted	  to	  30uL	  in	  water.	  Purified	  digests	  were	  prepared	  for	  ligation	  using	  150ng	  of	  each	  module	  and	  150ng	  of	  JDS	  vector.	  	  	  
	  
Screen	  of	  final	  ligation	  into	  TALEN	  (JDS)	  vector.	  	  The	  overnight	  ligation	  of	  modules	  1/2/3/4/JDS	  vector	  were	  transformed	  using	  40	  μL	  of	  XL1	  Blue	  cells	  and	  one-­‐half	  (10	  μL)	  of	  the	  ligation	  reaction.	  	  After	  gentle	  mixing	  and	  incubation	  on	  ice	  for	  15	  minutes,	  the	  cells	  were	  heat	  shocked	  for	  45	  seconds	  at	  42°.	  	  The	  transformation	  was	  transferred	  to	  250	  μL	  of	  SOC	  media	  in	  a	  15	  mL	  BD	  Falcon	  tube	  and	  placed	  in	  a	  shaking	  incubator	  at	  37	  degrees	  for	  one	  hour.	  	  	  Cells	  were	  plated	  on	  carbicillin-­‐	  (1:1000)	  containing	  agar	  plates	  and	  incubated	  at	  37°	  overnight.	  	  Colonies	  from	  plates	  grown	  overnight	  were	  selected	  and	  cultured	  on	  96-­‐well	  plates	  containing	  150	  μL	  of	  LB	  broth	  +	  carb	  (1:1000)	  with	  incubation	  at	  37°	  overnight.	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Eight	  to	  ten	  colonies	  were	  selected	  from	  the	  96-­‐well	  plate	  for	  preliminary	  screening	  and	  transferred	  to	  overnight	  5	  mL	  starter	  cultures	  +	  antibiotic	  in	  a	  15	  mL	  BD	  Falcon	  tube.	  	  Cultures	  were	  prepared	  using	  the	  Qiagen	  Spin	  Mini	  Prep	  Kit	  according	  to	  manufacturer’s	  instructions.	  A	  diagnostic	  restriction	  digest	  was	  used	  to	  examine	  selected	  cultures	  after	  plasmid	  preparation	  using	  ClaI	  and	  BamHI.	  Digest	  reactions	  contained:	  10	  μL	  of	  plasmid	  preparation;	  2.5	  μL	  NEB	  Buffer	  4;	  2.5	  μL	  10X	  BSA;	  1	  μL	  BamHI;	  1	  μL	  ClaI;	  and	  8	  μL	  H2O	  and	  were	  incubated	  at	  37°	  for	  one	  hour,	  followed	  by	  visualization	  on	  a	  1%	  agarose	  gel	  ran	  at	  100V	  for	  30	  minutes.	  	  The	  fragment	  sizes	  indicate	  whether	  the	  modules	  were	  correctly	  incorporated	  into	  the	  JDS	  backbone.	  	  The	  desired	  fragment	  size	  was	  2400	  base	  pairs	  (module	  1/2	  +	  module	  3/4	  	  +	  500	  base	  pairs	  to	  ClaI	  +	  300	  base	  pairs	  to	  BamHI).	  The	  plasmid	  preparations	  exhibiting	  the	  correct	  2400	  base	  pair	  fragment	  sizes	  were	  sequenced	  using	  T7	  and	  specific	  reverse	  (NK49)	  primers	  and	  compared	  to	  the	  ZiFiT	  assembly	  sequence.	  Sequencing	  reactions	  were	  performed	  by	  the	  University	  of	  Michigan	  Sequencing	  Core.	  
	  
Capillary	  Electrophoresis	  (CE).	  Genomic	  DNA	  extracts	  were	  prepared,	  followed	  by	  PCR	  using	  5’-­‐6	  -­‐FAM	  labeled	  primer	  (10 µM)	  forward	  with	  the	  corresponding	  anti-­‐sense	  primer	  for	  SAP	  exon	  2	  (5’-­‐	  /6-­‐FAM/AAACTGTGGTTGGGCAGATACAATATGG	  -­‐3’	  and	  5’-­‐GGCTAAACAGGACTGGGACCAAAATTCTC-­‐3’).	  	  A	  25	  μL	  reaction	  was	  prepared	  using	  2.5	  μL	  of	  each	  primer,	  0.25	  μL	  dNTP	  (10mM	  mix),	  5	  μL	  of	  5X	  colorless	  Go-­‐Taq	  buffer,	  0.125	  μL	  of	  Taq	  polymerase,	  12.6	  μL	  of	  H2O,	  and	  2.0	  μL	  of	  gDNA.	  	  Reaction	  conditions	  were:	  95°	  for	  5	  minutes;	  35	  cycles	  of	  95°	  for	  30	  seconds,	  56°	  for	  30	  seconds	  and	  72°	  for	  30	  seconds;	  followed	  by	  72°	  for	  10	  minutes.	  	  A	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compatible	  96-­‐well	  plate	  containing	  GS500Rox	  standard	  dye	  for	  capillary	  electrophoresis	  was	  prepared	  by	  the	  University	  of	  Michigan	  Sequencing	  Core	  and	  PCR	  reactions	  were	  diluted	  to	  1:150	  with	  1	  μL	  of	  this	  dilution	  added	  to	  the	  CE	  plate.	  CE	  analysis	  was	  performed	  by	  the	  University	  of	  Michigan	  Sequencing	  Core	  with	  resulting	  data	  files	  interpreted	  using	  the	  GeneMaker	  Software	  program.	  	  	  
	  
STR	  Analysis.	  Genomic	  DNA	  extracted	  from	  the	  cell,	  0.1	  ng/uL,	  was	  processed	  by	  the	  University	  of	  Michigan	  Sequencing	  Core	  using	  the	  Identifiler	  Plus	  PCR	  amplification	  kit,	  (Life	  Technologies	  ABI	  catalog	  number	  4427368).	  	  Information	  on	  loci	  markers	  was	  analyzed	  by	  the	  GeneMapper	  ID-­‐X	  Software	  (Applied	  Biosystems)	  program,	  and	  the	  profiles	  were	  compared	  to	  reference	  databases.	  
	  
Media.	  Jurkat	  cells	  were	  cultured	  in	  RPMI	  1640	  (Corning	  15-­‐041-­‐CV)	  supplemented	  with	  1%	  GlutaMax	  (Gibco	  35050-­‐061)	  and	  10%	  FBS	  (Atlas)	  with	  incubation	  conditions	  at	  37°	  and	  5%	  CO2.	  
	  
Transfection	  of	  Jurkat	  Cells.	  Jurkat	  cells	  were	  transfected	  using	  a	  BioRad	  Gene	  Pulser	  II	  (250	  V	  and	  975	  uF)	  using	  0.4	  cm	  gap	  cuvettes	  (BioRad	  1652088).	  10^7	  cells	  were	  transfected	  with	  30	  μg	  of	  each	  TALEN.	  	  Otherwise,	  10	  μg	  of	  expression	  plasmids	  were	  used	  for	  each	  transfection.	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DNA	  extraction.	  Genomic	  DNA	  was	  extracted	  using	  the	  HotShot	  lysis	  method.	  	  Cells	  were	  centrifuged	  at	  300	  rpm	  for	  5	  minutes	  and	  resuspended	  in	  50	  μL	  of	  lysis	  buffer	  (14	  μL	  of	  50%	  NaOH,	  14	  μL	  of	  AccuGene	  0.5M	  EDTA,	  10mL	  H2O)	  and	  placed	  on	  a	  95°	  heating	  block	  for	  30	  minutes.	  	  Samples	  were	  incubated	  on	  ice	  for	  5	  minutes	  followed	  by	  50	  μL	  of	  neutralization	  solution	  (40mM	  Tris-­‐HCl).	  	  Samples	  were	  briefly	  vortexed	  and	  pelleted.	  	  Supernatant	  was	  stored	  at	  -­‐20°.	  	  	  
	  
Whole	  cell	  lysate	  preparation.	  Cells	  were	  harvested	  by	  centrifugation	  at	  300	  rpm	  for	  5	  minutes	  and	  resuspended	  in	  100	  μL	  of	  prepared	  radioimmunoprecipitation	  assay	  (RIPA)	  lysis	  solution	  per	  10^6	  cells.	  	  RIPA	  buffer	  consists	  of	  PBS	  containing	  1%	  NP-­‐40,	  0.5%	  Na-­‐deoxycholate,	  and	  0.1%	  sodium	  dodecyl	  sulfate	  (SDS).	  	  To	  prepare	  lysis	  solution,	  10mL	  of	  RIPA	  buffer	  was	  supplemented	  with	  1	  protease	  inhibitor	  tablet	  (complete	  Mini	  EDTA-­‐free	  Roche	  11836170001),	  100	  μL	  Na3VO4	  (BioLab	  P0758S	  100mM),	  of	  1mM	  DTT,	  and	  10	  μM	  PMSF,	  and	  20	  μL	  NaF	  (BioLab	  P0759S	  500mM).	  Suspension	  was	  incubated	  on	  ice	  for	  10	  minutes,	  followed	  by	  a	  10	  minute	  centrifugation	  at	  13000	  rpm	  at	  4°.	  	  Supernatants	  were	  stored	  at	  -­‐80°.	  	  
Western	  blotting.	  Protein	  concentration	  was	  determined	  by	  using	  the	  Pierce	  BCA	  kit.	  	  Cytoplasmic	  extracts	  (25	  μg)	  were	  prepared	  in	  LDS	  sample	  buffer	  (Invitrogen)	  and	  loaded	  on	  a	  4-­‐12%	  NuPage	  gel	  in	  MES	  running	  buffer.	  	  Following	  transfer,	  nitrocellulose	  membranes	  were	  blocked	  in	  5%	  milk	  with	  TBS	  0.1%	  Tween,	  followed	  by	  overnight	  incubation	  at	  4°	  with	  the	  appropriate	  antibody.	  	  After	  washing,	  membranes	  were	  incubated	  with	  horseradish	  peroxidase-­‐conjugated	  antibody	  for	  1	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hour	  at	  room	  temperature	  followed	  by	  visualization	  on	  chemiluminescence	  film.	  	  The	  following	  antibodies	  were	  used	  for	  Western	  blotting:	  rat	  anti-­‐SAP	  (Cell	  Signaling	  #2805);	  goat-­‐anti	  rat	  IgG-­‐HRP	  (sc-­‐2006);	  mouse	  anti-­‐FLAG	  M2	  (Sigma	  088K6018);	  anti-­‐mouse	  IgG-­‐HRP	  (Cell	  Signaling	  #7076S);	  HRP-­‐conjugated	  actin	  (Abcam	  20272);	  and	  mouse	  anti-­‐XIAP	  (BD	  610717).	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Chapter	  3	  Analysis	  of	  T	  Cell	  Signaling	  in	  SAP-­‐null	  Jurkat	  Cells	  
	  
3.1	  Introduction	  	  	   While	  previous	  studies	  have	  examined	  the	  role	  of	  SAP	  in	  signaling,	  there	  is	  much	  to	  be	  learned,	  and	  SAP’s	  influence	  on	  T	  cell	  signaling	  remains	  unclear.	  To	  further	  understand	  these	  roles,	  the	  gene	  edited	  cell	  line,	  discussed	  in	  chapter	  2,	  was	  used	  to	  identify	  specific	  SAP-­‐dependent	  effects	  in	  T	  cell	  signaling.	  More	  specifically,	  we	  examined	  the	  influences	  of	  SAP	  on	  cytokine	  production,	  transcription	  factor	  activation,	  and	  calcium	  mobilization	  following	  stimulation	  of	  the	  T	  cell	  receptor.	  	   SAP-­‐dependent	  T	  cell	  activation	  is	  influenced	  by	  protein	  interactions	  with	  the	  cytoplasmic	  tail	  of	  the	  SLAM-­‐family	  of	  receptors91.	  For	  example,	  SAP	  binds	  the	  adaptor	  protein	  FYN,	  a	  protein	  tyrosine	  kinase	  (PTK)	  that	  contains	  a	  SH3,	  SH2,	  and	  kinase	  domains,	  which	  allows	  FYN	  to	  phosphorylate	  the	  SLAM	  receptor31,94,95.	  The	  interaction	  of	  SAP	  and	  FYN	  with	  the	  SLAM	  receptor	  has	  been	  associated	  with	  Th2	  differentiation	  and	  NKT	  cell	  development	  101,188.	  Conversely,	  in	  the	  absence	  of	  SAP,	  SLAM	  is	  bound	  to	  the	  inhibitory	  Src-­‐homolgy-­‐2-­‐containing	  inositol	  phosphatase	  1	  (SHIP-­‐1)	  at	  the	  switch	  motif54,89,	  which	  inactivates	  other	  T	  cell	  signaling	  proteins	  such	  as	  ZAP-­‐70	  and	  LCK109,189.	  Notably,	  SAP	  binding	  to	  SLAM	  can	  displace	  SHIP-­‐1,	  allowing	  for	  TCR	  activation54,89.	  	  	   SAP	  binds	  numerous	  members	  of	  the	  SLAM	  family	  of	  receptors	  through	  their	  immunoreceptor	  tyrosine	  switch	  motif	  (ITSM),	  including	  SLAM	  (CD150),	  CD84,	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NTB-­‐A	  (Ly108),	  and	  Ly9	  (CD229)1,94,95,	  all	  of	  which	  have	  important	  immunological	  functions.	  For	  example,	  SAP	  interaction	  with	  CD84,	  expressed	  on	  CD4+	  T	  cells,	  stabilizes	  T	  and	  B	  cell	  interactions	  and	  promotes	  germinal	  center	  development,	  B	  cell	  differentiation,	  and	  antibody	  production139,190.	  	  Additionally,	  while	  the	  impact	  of	  SAP	  engaging	  Ly9,	  a	  receptor	  constitutively	  expressed	  on	  CD4+	  T	  cells,	  is	  unclear191,	  SAP	  interacting	  with	  the	  NK,	  T	  and	  B	  cell	  antigen	  (NTB-­‐A)	  receptor	  stimulates	  Th1-­‐type	  cytokine	  production192	  and	  is	  reportedly	  involved	  in	  the	  death	  of	  activated	  T	  cells159.	  	  Thus,	  SAP/SLAM	  interactions	  in	  CD4+	  T	  cells	  regulate	  T	  cell	  activation,	  cross-­‐talk	  between	  other	  immune	  cells,	  and	  apoptosis.	   	  
	   Defective	  SAP	  in	  T	  cells	  is	  best	  characterized	  by	  the	  clinical	  manifestations	  observed	  in	  XLP1	  patients,	  who	  harbor	  mutation	  in	  the	  SAP	  gene.	  As	  mentioned	  above,	  together	  with	  TCR	  stimulation,	  SAP	  binding	  to	  SLAM	  modulates	  T	  cell	  signaling,	  which	  results	  in	  the	  production	  of	  various	  cytokine.	  Notably,	  XLP1	  patients	  have	  abnormal	  amounts	  of	  cytokines	  that	  induce	  immune	  cell	  proliferation	  and	  differentiation,	  such	  as	  IL-­‐2193,	  suggesting	  that	  SAP	  regulates	  cytokine	  production.	  One	  proposed	  mechanism	  for	  decreased	  IL-­‐2	  production	  in	  XLP1	  patients	  has	  been	  described,	  resulting	  in	  elevated	  levels	  of	  diacylglycerol	  kinase	  α	  (DGKα)194,	  which	  phosphorylates	  diacylglycerol	  (DAG)	  to	  form	  phosphatidic	  acid	  (PA)	  and	  prevents	  the	  activation	  of	  PKC-­‐θ	  and	  NF-­‐κB	  (figure	  3.1).	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Figure	  3.1	  Activation	  and	  co-­‐stimulation	  of	  the	  T	  cell	  receptor.	  	  Stimulation	  of	  the	  T	  cell	  receptor	  and	  SLAM,	  a	  co-­‐stimulatory	  receptor,	  results	  in	  the	  activation	  of	  PLCγ−1 which	  activates	  DAG	  and	  PKC-­‐θ	  to	  cause	  the	  CBM	  complex	  to	  phosphorylate	  IκBα	  which	  marks	  it	  for	  degradation,	  allowing	  for	  the	  nuclear	  translocation	  of	  NF-­‐κB.	  Similarly,	  PLCγ−1 stimulates	  the	  release	  of	  calcium,	  activating	  the	  phosphatase	  calciuneurin	  to	  activate	  NFAT	  and	  allowing	  for	  its	  nuclear	  translocation.	  In	  addition,	  TCR	  stimulation	  activates	  the	  MAPK	  (mitogen-­‐activated	  protein	  kinase)	  pathway	  resulting	  in	  the	  formation	  of	  the	  AP-­‐1	  transcription	  factor,	  which	  also	  converges	  on	  the	  IL-­‐2	  promoter	  with	  the	  constitutively	  active	  Oct1.	  	  	   Through	  an	  unknown	  mechanism,	  SAP	  decreases	  the	  activity	  of	  DGKα,	  allowing	  for	  NF-­‐κB	  activation	  following	  TCR	  stimulation	  and	  production	  of	  cytokines	  like	  IL-­‐2.	  	  In	  vitro	  studies	  demonstrated	  that	  inhibition	  of	  DGKα	  in	  SAP-­‐deficient	  cells	  partially	  restored	  PKC-­‐θ	  activity	  and	  IL-­‐2	  production,	  suggesting	  that	  a	  potential	  role	  for	  SAP	  is	  to	  inhibit	  DGKα	  during	  T	  cell	  activation190.	  	  	  	   In	  addition	  to	  IL-­‐2,	  another	  cytokine	  that	  influences	  immune	  cell	  activation	  is	  IFN-­‐γ.	  IFN-­‐γ	  has	  pleiotropic	  effects	  and	  is	  produced	  by	  various	  cells,	  including	  T	  and	  NK	  cells195.	  Elevated	  IFN-­‐γ	  production	  leads	  to	  increased	  macrophage	  activation,	  a	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characteristic	  of	  HLH	  patients196	  and	  there	  are	  cases	  of	  elevated	  IFN-­‐γ	  levels	  in	  XLP1	  patients197.	  Additionally,	  previous	  reports	  demonstrated	  that	  splenocytes	  from	  Sap-­‐deficient	  mice	  produced	  elevated	  levels	  of	  IFN-­‐γ following	  TCR	  stimulation152	  and	  this	  has	  directed	  naïve	  CD4+	  T	  cells	  to	  develop	  towards	  a	  Th1	  cell	  phenotype198,	  which	  suggests	  that	  elevated	  IFN-­‐γ	  expression	  disturbs	  the	  balance	  of	  the	  other	  T	  helper	  and	  regulatory	  cells.	  	  
	   A	  key	  clinical	  observation	  is	  that	  patients	  with	  XLP1	  frequently	  present	  to	  the	  emergency	  room	  with	  infections.	  Previous	  studies	  have	  explored	  the	  relationship	  between	  SAP	  expression	  and	  cytokine	  production	  upon	  exposure	  to	  several	  infectious	  agents.	  	  More	  specifically,	  SAP	  expression	  in	  human	  CD4+	  T	  cells	  inversely	  correlates	  to	  IFN-­‐γ	  levels	  after	  tuberculosis	  infection,	  suggesting	  that	  the	  presence	  of	  SAP	  disrupts	  IFN-­‐γ	  production199. Furthermore, these results suggest that SAP 
deregulation has implications in T cell signaling and subsequent effects in T cell 
activation, and cytokine production.   
3.2	  Results	  	  	  
 XLP1	  patients	  are	  diagnosed	  by	  measuring	  SAP	  expression	  by	  flow	  cytometry	  and	  sequencing	  the	  SAP	  gene.	  To	  assist	  future	  efforts	  in	  primary	  T	  cells	  and	  provide	  a	  rapid	  mechanism	  to	  assess	  SAP	  expression,	  an	  intracellular	  staining	  protocol	  was	  developed	  to	  analyze	  SAP	  expression.	  The	  wild	  type	  and	  SAP-­‐null	  cells	  were	  analyzed	  by	  flow	  cytometry,	  as	  shown	  in	  figure	  3.2,	  to	  compare	  SAP	  expression.	  .	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Figure	  3.2	  Development	  of	  a	  flow	  cytometric	  assay	  for	  intracellular	  SAP	  expression.	  The	  wild	  type	  and	  SAP-­‐null	  Jurkats	  were	  analyzed	  by	  flow	  cytometry	  for	  SAP	  expression.	  The	  isotope	  control	  for	  both	  the	  WT	  and	  SAP-­‐null	  cells	  are	  shown	  in	  black	  along	  with	  the	  corresponding	  peaks	  for	  SAP.	  	  
	  	   These	  Jurkat	  cells	  were	  used	  as	  a	  representative	  model	  of	  CD4+	  T	  cells,	  to	  evaluate	  the	  influences	  of	  SAP	  in	  T	  cell	  signaling.	  TCR	  stimulation	  results	  in	  the	  downstream	  production	  of	  cytokines	  and	  activates	  various	  transcription	  factors,	  which	  together	  regulate	  T	  cell	  proliferation	  and	  differentiation	  programs.	  Two	  cytokines	  that	  have	  been	  examined	  in	  XLP1	  patients	  are	  IL-­‐2	  and	  IFN-­‐γ and	  studies	  have	  shown	  that	  IL-­‐2	  mRNA	  production	  is	  decreased	  in	  XLP1	  patient	  T	  cells122,	  while	  IFN-­‐γ production	  varies152.	  To	  assess	  whether	  IL-­‐2	  and	  IFN-­‐γ mRNA	  production	  differed	  in	  a	  SAP-­‐deficient	  cell,	  the	  Jurkat	  cells	  were	  stimulated	  for	  6	  hours	  with	  activating	  CD3	  and	  CD28	  antibodies,	  a	  biological	  approximation	  of	  TCR	  stimulation.	  RNA	  from	  unstimulated	  and	  stimulated	  cells	  was	  collected	  and	  prepared	  for	  qRT-­‐PCR	  analysis	  for	  IL-­‐2	  and	  IFN-­‐γ.	  IL-­‐2	  transcription	  was	  decreased	  in	  SAP-­‐null	  Jurkats	  upon	  stimulation	  with	  CD3	  and	  CD28	  compared	  to	  the	  wild	  type	  cells	  (figure	  3.3).	  	  Conversely,	  IFN-­‐γ	  transcription	  was	  increased	  upon	  TCR	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stimulation	  in	  SAP-­‐null	  cells,	  suggesting	  that	  SAP	  modulates	  IFN-­‐γ	  production.	  While	  IL-­‐2	  production	  was	  extremely	  low	  and	  sometimes	  below	  the	  threshold	  of	  detection	  in	  unstimulated	  Jurkat	  cells,	  there	  was	  measurable	  production	  of	  IFN-­‐γ	  in	  unstimulated	  wild	  type	  and	  SAP-­‐null	  cells.	  To	  assess	  the	  extent	  of	  IFN-­‐γ production	  in	  the	  SAP-­‐null	  cells	  with	  and	  without	  TCR	  stimulation,	  the	  SAP-­‐null	  samples	  were	  also	  normalized	  to	  the	  wild	  type	  unstimulated	  samples,	  as	  described	  in	  figure	  3.3B.	  This	  illustrated	  that	  the	  fold	  changes	  in	  expression	  were	  measurable	  with	  or	  without	  stimulation,	  indicating	  that	  these	  were	  basal	  differences	  in	  IFN-­‐
γ expression,	  and	  that	  the	  fold	  change	  was	  even	  more	  pronounced	  in	  the	  SAP-­‐deficient	  cells	  when	  comparing	  the	  transcription	  levels	  to	  the	  wild	  type	  cells	  after	  TCR	  stimulation.	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Figure	  3.3	  Altered	  cytokine	  production	  in	  SAP-­‐null	  Jurkats.	  	  Jurkat	  cells	  were	  stimulated	  for	  6	  hours	  with	  activating	  CD3	  and	  CD28	  antibodies	  (4	  μg/mL;	  4	  μg/mL).	  RNA	  was	  harvested	  and	  analyzed	  by	  qRT-­‐PCR	  and	  Ct	  values	  were	  normalized	  to	  GAPDH.	  	  Fold	  change	  was	  calculated	  by	  normalizing	  to	  unstimulated	  of	  same	  cell	  type	  A)	  or	  to	  wild	  type	  B),	  as	  indicated.	  	  Statistical	  significance	  was	  calculated	  using	  a	  one-­‐sided	  t-­‐test	  and	  values	  are	  indicated.	  Data	  represent	  three	  independent	  experiments	  performed	  in	  triplicate.	  
	  	   NFAT	  is	  a	  key	  transcription	  factor	  that	  is	  required	  for	  IL-­‐2	  production.	  To	  assess	  the	  activity	  of	  NFAT	  in	  SAP-­‐deficient	  cells,	  a	  luciferase	  reporter	  plasmid	  was	  transfected	  into	  the	  cells,	  which	  were	  subsequently	  treated	  with	  CD3	  and	  CD28	  for	  18	  hours	  and	  analyzed,	  as	  shown	  in	  figure	  3.4.	  The	  wild	  type	  cells	  exhibited	  elevated	  levels	  of	  NFAT	  reporter	  activity	  following	  stimulation,	  while	  the	  SAP-­‐null	  cells	  had	  negligible	  activity	  above	  the	  unstimulated	  levels,	  suggesting	  that	  SAP	  defects	  impair	  NFAT	  activity	  resulting	  in	  decreased	  IL-­‐2	  production.	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Figure	  3.5	  Transfection	  efficiency	  in	  Jurkat	  cells.	  A)	  Wild	  type	  and	  SAP-­‐null	  Jurkat	  cells	  were	  co-­‐transfected	  with	  a	  reporter	  plasmid	  and	  pEBB-­‐cherry.	  	  Images	  represent	  untransfected	  and	  transfected	  cells	  at	  48	  hours	  with	  representative	  quantification	  by	  flow	  cytometry	  shown	  B).	  	  	  
	  
	  
	  	   The	  evidence	  of	  both	  decreased	  NFAT	  reporter	  activity	  and	  IL-­‐2	  mRNA	  production	  in	  the	  SAP-­‐null	  cells	  suggested	  that	  a	  SAP-­‐dependent	  defect	  occurred	  upstream	  of	  NFAT	  activation.	  	  NFAT	  activity	  is	  dependent	  on	  calcium	  mobilization	  from	  the	  ER	  to	  the	  cytoplasm	  to	  stimulate	  the	  phosphatase	  calcineurin200.	  	  It	  was	  possible	  that	  SAP-­‐deficiencies	  alter	  calcium	  mobilization	  within	  the	  cell,	  and	  this	  has	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Figure	  3.6	  Intracellular	  calcium	  mobilization	  in	  Jurkat	  cells.	  	  Cells	  were	  stained	  with	  fluor-­‐4-­‐direct	  dye,	  followed	  by	  stimulation	  with	  CD3	  and	  CD28	  (4	  μg/mL;	  4	  μg/mL)	  and	  measurement	  of	  intracellular	  calcium.	  	  Representative	  data	  are	  shown	  from	  two	  independent	  experiments	  with	  bars	  indicating	  standard	  deviation.	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   The	  results	  described	  above	  suggested	  that	  TCR	  stimulation	  in	  SAP-­‐deficient	  cells	  impaired	  the	  transcription	  of	  IL-­‐2	  activity	  by	  altering	  the	  activity	  of	  NFAT	  and	  maintaining	  excess	  free	  calcium	  within	  the	  cells.	  	  However,	  to	  attribute	  these	  defects	  to	  SAP,	  it	  was	  necessary	  to	  restore	  SAP	  expression	  in	  the	  SAP-­‐null	  cells	  by	  co-­‐transfecting	  a	  FLAG-­‐SAP	  plasmid	  (SAP-­‐null	  +	  pSAP)	  and	  an	  antibiotic	  resistance	  plasmid	  into	  the	  SAP-­‐null	  cells	  followed	  by	  continual	  growth	  in	  selection	  media.	  	  These	  cells,	  with	  restored	  SAP	  expression,	  were	  analyzed	  by	  flow	  cytometry	  (figure	  3.7A)	  and	  Western	  blot	  analysis	  (figure	  3.7B)	  to	  verify	  the	  reconstitution	  of	  SAP	  expression	  within	  the	  cell	  population.	  	  The	  flow	  cytometry	  results	  illustrated	  that	  the	  FLAG-­‐SAP	  population	  had	  two	  peaks,	  indicated	  by	  the	  red	  lines,	  and	  one	  of	  these	  peaks	  overlaid	  the	  isotype	  control,	  similar	  to	  the	  SAP-­‐null	  cells.	  	  This	  suggested	  that	  the	  SAP-­‐null	  +	  pSAP	  population	  is	  a	  combination	  of	  the	  SAP-­‐null	  cells	  and	  cells	  ectopically	  expressing	  SAP.	  	  Additionally,	  the	  Western	  blot	  demonstrated	  that	  SAP	  expression	  is	  restored	  in	  the	  SAP-­‐null	  cells,	  as	  shown	  by	  the	  FLAG-­‐SAP	  fusion	  protein.	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Figure	  3.7	  Reconstitution	  of	  SAP	  expression	  in	  SAP-­‐null	  Jurkats.	  	  A)	  SAP-­‐null	  Jurkats	  were	  co-­‐transfected	  with	  pEBB-­‐FLAG-­‐SAP	  (10	  μg)	  and	  1	  μg	  of	  pBABE-­‐puromycin	  followed	  by	  antibiotic	  selection	  with	  0.5	  μg/mL	  puromycin.	  Intracellular	  SAP	  staining	  was	  analyzed	  by	  flow	  cytometry	  for	  the	  wild	  type,	  SAP-­‐null,	  and	  reconstituted	  SAP	  expressing	  cells,	  with	  black	  lines	  indicating	  respective	  isotype	  controls.	  B)	  The	  restoration	  of	  SAP	  expression	  was	  further	  confirmed	  by	  Western	  blotting	  as	  illustrated	  by	  the	  presence	  of	  the	  FLAG-­‐SAP	  fusion	  protein	  in	  lane	  3.	  Jurkat-­‐derived	  cells	  were	  analyzed	  by	  Western	  blot	  using	  anti-­‐SAP	  antibody.	  	  	  
	  	   Reconstituting	  SAP	  expression	  in	  the	  SAP-­‐null	  cell	  line	  allowed	  us	  to	  determine	  if	  the	  measured	  cytokine	  defects	  upon	  TCR	  stimulation	  were	  SAP-­‐dependent.	  The	  wild	  type,	  SAP-­‐null,	  and	  SAP-­‐null	  +	  pSAP	  cells	  were	  stimulated	  with	  CD3	  and	  CD28	  for	  six	  hours	  prior	  to	  RNA	  harvest,	  followed	  by	  qRT-­‐PCR	  to	  measure	  IL-­‐2	  and	  IFN-­‐γ production.	  Reconstitution	  of	  SAP	  in	  the	  SAP-­‐deficient	  cells	  partially	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Figure	  3.8	  SAP	  reconstitution	  partially	  restored	  cytokine	  production.	  	  Wild	  type,	  SAP-­‐null,	  and	  
SAP-­‐null	  +	  pSAP	  cells	  were	  stimulated	  for	  six	  hours	  with	  CD3/CD28	  (4	  μg/mL;	  4	  μg/mL).	  RNA	  was	  harvested	  and	  analyzed	  by	  qRT-­‐PCR	  and	  Ct	  values	  normalized	  to	  GAPDH.	  	  Fold	  change	  was	  calculated	  by	  normalizing	  to	  the	  unstimulated	  sample	  of	  the	  same	  cell	  type.	  Data	  represents	  two	  independent	  experiments	  performed	  in	  triplicate.	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3.3	  Discussion	  	  	   The	  gene	  editing	  derived	  SAP-­‐deficient	  T	  cells,	  when	  stimulated	  by	  CD3	  and	  CD28,	  led	  to	  altered	  cytokine	  production,	  impaired	  NFAT	  transcription	  factor	  activity,	  and	  increased	  free	  intracellular	  calcium	  compared	  to	  the	  wild	  type.	  The	  wild	  type	  and	  SAP-­‐deficient	  cells	  were	  examined	  for	  cytokine	  deficiencies	  and	  the	  
SAP-­‐null	  cells	  had	  impaired	  IL-­‐2	  mRNA	  production	  and	  increased	  IFN-­‐γ	  mRNA	  levels	  compared	  to	  the	  wild	  type	  cells	  following	  TCR	  stimulation.	  Restoration	  of	  SAP	  expression	  in	  the	  SAP-­‐null	  cell	  line	  demonstrated	  that	  IL-­‐2	  transcription	  after	  TCR	  stimulation	  was	  partially	  restored,	  as	  shown	  by	  increased	  IL-­‐2	  levels	  compared	  to	  the	  SAP-­‐null	  cells.	  Similarly,	  the	  cells	  with	  ectopic	  SAP	  expression	  had	  reduced	  levels	  of	  IFN-­‐γ,	  compared	  to	  the	  SAP-­‐null	  cells,	  to	  approximate	  the	  same	  levels	  as	  expressed	  by	  the	  control	  cells.	  The	  activity	  of	  NFAT	  was	  also	  examined,	  finding	  that	  the	  SAP-­‐null	  cells	  did	  not	  exhibit	  measurable	  NFAT	  reporter	  activity	  following	  TCR	  stimulation,	  suggesting	  an	  NFAT	  defect.	  Additionally,	  an	  intracellular	  SAP	  staining	  protocol	  was	  developed	  to	  confirm	  the	  loss	  of	  SAP	  expression	  in	  the	  SAP-­‐null	  Jurkat	  cells	  and	  is	  available	  for	  future	  lines	  of	  inquiry	  using	  primary	  cell	  lines.	  Finally,	  the	  decreased	  NFAT	  activity	  supported	  the	  idea	  that	  calcium	  mobilization	  is	  altered	  in	  
SAP-­‐null	  cells	  as	  indicated	  by	  increased	  free	  intracellular	  calcium	  levels	  after	  TCR	  stimulation.	  	  These	  results	  may	  be	  clinically	  relevant	  since	  XLP1	  patients	  have	  been	  shown	  to	  exhibit	  similar	  characteristics	  with	  decreased	  IL-­‐2	  production	  and	  excess	  calcium	  mobilization	  within	  the	  cell193.	  Together,	  these	  results	  provided	  additional	  insights	  to	  the	  SAP-­‐dependent	  effects	  in	  T	  cell	  signaling,	  and	  may	  have	  important	  clinical	  implications	  in	  the	  diagnosis	  of	  XLP1.	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   A	  key	  consequence	  of	  T	  cell	  activation	  is	  IL-­‐2	  production,	  and	  prior	  studies	  have	  demonstrated	  that	  T	  cells	  from	  XLP1	  patient	  have	  impaired	  IL-­‐2	  production	  following	  TCR	  stimulation122,129,	  although	  the	  mechanism	  was	  unclear.	  Consistent	  with	  these	  studies,	  (figure	  3.3)	  illustrated	  that	  IL-­‐2	  production	  was	  decreased	  in	  the	  
SAP-­‐null	  Jurkat	  cells,	  compared	  to	  the	  wild	  type	  control	  cells.	  	  IL-­‐2	  expression	  was	  measured	  at	  the	  transcriptional	  level	  by	  assessing	  mRNA	  production.	  While	  it	  was	  assumed	  that	  transcriptional	  differences	  equate	  to	  expression	  differences,	  it	  was	  not	  conclusively	  proven	  to	  be	  the	  case.	  Two	  approaches	  would	  confirm	  the	  expression	  of	  cytokines:	  measuring	  the	  secretion	  by	  an	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  and	  intracellular	  staining	  and	  quantification	  by	  flow	  cytometry.	  	  
	   It	  is	  also	  possible	  that	  the	  IL-­‐2	  mRNA	  is	  transcribed	  in	  the	  wild	  type	  Jurkat	  cells	  but	  there	  is	  a	  difference	  in	  the	  stability	  of	  the	  transcripts,	  potentially	  equalizing	  the	  amounts	  of	  IL-­‐2	  expressed	  or	  secreted.	  Cytokines	  have	  been	  observed	  to	  have	  short	  mRNA	  half	  lives	  in	  response	  to	  stimuli201.	  Although	  there	  is	  increased	  transcription	  of	  IL-­‐2	  in	  the	  wild	  type	  Jurkat	  cells,	  the	  mRNA	  could	  be	  unstable	  due	  to	  deadenylation,	  removal	  of	  the	  3’-­‐poly(A)	  tail,	  or	  directed	  by	  AU-­‐rich	  sequences	  within	  the	  3’-­‐untranslated	  region202.	  Genes	  with	  AU-­‐rich	  sequences	  are	  targeted,	  through	  unknown	  mechanisms,	  for	  decay	  upon	  recruitment	  of	  AU-­‐binding	  proteins203	  and	  analysis	  of	  the	  adenylate-­‐uridylate-­‐rich	  elements	  (AREs)	  within	  the	  3’-­‐untranslated	  region	  of	  the	  mRNA	  would	  determine	  stability	  of	  the	  IL-­‐2	  message.	  An	  experimental	  approach	  to	  examine	  this	  would	  be	  accomplished	  by	  a	  nuclear	  run-­‐on	  experiment.	  The	  IL-­‐2	  transcript	  would	  be	  in	  vitro	  labeled	  by	  the	  incorporation	  of	  radionucleotides,	  which	  can	  then	  be	  isolated	  and	  hybridized	  to	  a	  complementary	  
	   66	  
probe	  and	  quantified	  by	  radiography.	  	  Should	  the	  IL-­‐2	  mRNA	  be	  stable,	  this	  would	  support	  that	  SAP	  defects	  impair	  IL-­‐2	  transcription	  and	  expression.	  	  
	   The	  decreased	  IL-­‐2	  transcription	  in	  the	  SAP-­‐deficient	  cells	  is	  partially	  due	  to	  impaired	  NFAT	  activation	  and	  calcium	  mobilization.	  NFAT	  is	  a	  family	  of	  transcription	  factors	  that	  regulate	  not	  only	  T	  cell	  activation	  but	  also	  influence	  thymocyte	  development	  and	  T	  cell	  differentiation204.	  The	  functional	  contributions	  of	  each	  NFAT	  isoform	  are	  not	  well	  understood205	  and	  isoform	  reduction	  using	  RNAi	  in	  conjunction	  with	  SAP	  expressing	  and	  SAP-­‐deficient	  cells	  would	  identify	  what	  characteristics,	  such	  as	  cytokine	  production	  and	  the	  regulation	  of	  other	  genes,	  are	  ascribed	  to	  each	  variant.	  	  An	  intriguing	  possibility	  that	  might	  account	  for	  impaired	  NFAT	  activation	  and	  the	  calcium	  processing	  defects	  observed	  in	  the	  SAP-­‐deficient	  cells	  is	  abnormal	  expression	  of	  carabin,	  the	  negative	  regulator	  of	  calcineurin’s	  phosphatase	  activity206.	  While	  little	  is	  known	  about	  its	  regulation,	  carabin	  binds	  with	  and	  inhibits	  the	  activation	  of	  calcineurin206.	  Carabin-­‐null	  mice	  were	  shown	  to	  exhibit	  normal	  T	  cell	  development,	  however,	  upon	  TCR	  stimulation	  demonstrated	  increased	  proliferation	  and	  NFAT	  activation,	  implicating	  carabin	  as	  a	  negative	  regulator	  of	  TCR	  signaling207.	  Although	  analysis	  of	  the	  mechanism	  of	  calcium	  mobilization	  defects	  are	  beyond	  the	  scope	  of	  this	  study,	  it	  is	  possible	  that	  SAP	  regulates	  carabin	  expression,	  and	  when	  SAP	  is	  deficient	  carabin	  levels	  may	  increase,	  impeding	  calcineurin’s	  activity	  and	  accounting	  for	  the	  decreased	  NFAT	  activation	  and	  calcium	  mobilization	  observed	  in	  the	  SAP-­‐null	  cells.	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   Aside	  from	  IL-­‐2,	  SAP-­‐null	  Jurkats	  exhibited	  increased	  IFN-­‐γ	  expression	  following	  TCR	  stimulation.	  IFN-­‐γ	  has	  pleiotropic	  effects	  and	  is	  produced	  by	  various	  cells,	  including	  T	  and	  NK	  cells195.	  Additionally,	  the	  influence	  of	  elevated	  IFN-­‐γ	  levels	  on	  macrophage	  production	  is	  of	  clinical	  interest	  for	  potential	  therapeutic	  intervention	  in	  XLP1	  patients,	  because	  they	  exhibit	  excessive	  macrophage	  activation196.	  A	  phase	  II	  clinical	  trial	  has	  been	  initiated	  to	  investigate	  the	  efficacy	  of	  using	  neutralizing	  IFN-­‐γ	  antibodies	  to	  decrease	  macrophage	  activation	  in	  HLH	  patients208.	  	  Characterizing	  the	  extent	  of	  macrophage	  activation	  by	  T	  cells	  with	  SAP	  defects	  would	  be	  of	  interest	  to	  determine	  whether	  XLP1	  patients	  are	  likely	  to	  benefit	  from	  this	  treatment.	  	  	   The	  impact	  of	  excess	  IFN-­‐γ	  production	  has	  been	  observed	  in	  splenocytes	  from	  Sap-­‐deficient	  mice,	  preferentially	  differentiating	  into	  Th1	  cells	  after	  TCR	  stimulation152,	  and	  previous	  work	  suggested	  that	  SAP’s	  interaction	  with	  FYN	  is	  necessary	  for	  Th2	  differentiation101,188,209.	  It	  is	  reasonable	  to	  speculate	  that	  disruption	  of	  the	  SAP/FYN	  interaction	  may	  result	  in	  the	  observed	  increase	  in	  IFN-­‐γ	  production	  and	  that	  this	  preferentially	  differentiates	  T	  helper	  cells	  toward	  a	  Th1	  fate	  in	  human	  cells.	  Importantly,	  the	  implications	  of	  elevated	  IFN-­‐γ	  levels	  and	  decreased	  Th2	  cell	  development	  would	  be	  impaired	  release	  of	  IL-­‐4	  by	  Th2	  cells,	  which	  could	  impede	  B	  cell	  proliferation	  and	  antibody	  production	  during	  humoral	  immunity209.	  	  	   Previous	  work	  has	  shown	  that	  IFN-­‐γ production	  by	  CD4	  cells	  is	  modulated	  by	  T-­‐bet210	  (T-­‐box	  family	  of	  transcription	  factor)	  and	  Bcl-­‐6211.	  T-­‐bet	  and	  Bcl-­‐6	  associate	  on	  the	  IFN-­‐γ	  promoter	  and	  when	  Bcl-­‐6	  expression	  is	  high	  there	  is	  less	  IFN-­‐γ	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expression212.	  T	  helper	  cells	  express	  Bcl-­‐6,	  which	  is	  expressed	  at	  high	  levels	  in	  germinal	  center	  B	  cells	  213.	  Since	  SAP	  defects	  impair	  the	  development	  of	  GCs,	  it	  is	  plausible	  that	  this	  contributes	  to	  decreased	  Bcl-­‐6	  expression	  and	  the	  elevated	  IFN-­‐γ	  transcription	  identified	  in	  the	  SAP-­‐null	  Jurkat	  cells.	  To	  further	  test	  this,	  measurement	  of	  the	  levels	  of	  T-­‐bet	  and	  Bcl-­‐6	  expression	  followed	  by	  selective	  targeting	  of	  each	  gene	  would	  confirm	  which	  components	  are	  modulated	  by	  SAP.	  	   An	  area	  relatively	  unexplored	  in	  SAP-­‐deficiencies	  is	  the	  activation	  of	  T	  regulatory	  cells,	  which	  modulate	  the	  proliferation	  of	  other	  T	  cells.	  NFAT	  is	  required,	  in	  addition	  to	  the	  transcription	  factor	  FOXP3,	  to	  affect	  Treg	  differentiation214.	  As	  SAP-­‐null	  cells	  exhibit	  impaired	  TCR-­‐mediated	  NFAT	  activity	  (figure	  3.4),	  this	  may	  suggest	  that	  naïve	  T	  cells	  are	  insufficiently	  differentiated	  into	  Treg	  cells,	  potentially	  contributing	  to	  the	  lymphoproliferative	  phenotype	  observed	  in	  XLP1	  patients.	  	  To	  test	  this	  hypothesis,	  future	  studies	  may	  include	  siRNA	  mediated	  silencing	  of	  SAP	  in	  naïve	  primary	  T	  cells	  from	  healthy	  donors,	  followed	  by	  TCR	  stimulation	  to	  determine	  whether	  the	  differentiation	  of	  Treg	  cells	  differs	  based	  on	  reduced	  SAP	  expression.	  Moreover,	  cytokine	  production	  may	  not	  only	  impact	  T	  cell	  differentiation,	  but	  also	  influence	  the	  premature	  death	  of	  immune	  cells,	  which	  could	  impair	  the	  ability	  of	  XLP1	  patients	  to	  clear	  infections.	  	  
3.4	  Materials	  &	  Methods	  	  
Media.	  Cells	  were	  cultured	  in	  RPMI	  1640	  (Corning	  15-­‐041-­‐CV)	  supplemented	  with	  1%	  GlutaMax	  (Gibco	  35050-­‐061)	  and	  10%	  FBS	  (Atlas)	  with	  incubation	  conditions	  at	  37°	  and	  5%	  CO2.	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SAP	  Reconstitution.	  The	  SAP-­‐null	  Jurkat	  cells	  were	  transfected	  using	  a	  BioRad	  Gene	  Pulser	  II	  (250	  V	  and	  975	  uF)	  using	  0.4	  cm	  gap	  cuvettes	  (BioRad	  1652088).	  10^7	  cells	  were	  transfected	  with	  10	  μg	  of	  pEBB-­‐SAP-­‐FLAG	  and	  1	  μg	  of	  pBABE-­‐puro	  selection	  plasmid	  and	  48	  hours	  after	  transfection,	  cells	  were	  continually	  maintained	  in	  0.5	  μg/mL	  of	  puromycin	  containing	  selection	  media.	  	  	  
	  
Whole	  cell	  lysate	  preparation.	  Cells	  were	  harvested	  by	  centrifugation	  at	  300	  rpm	  for	  5	  minutes	  and	  resuspended	  in	  100	  μL	  of	  prepared	  radioimmunoprecipitation	  assay	  (RIPA)	  lysis	  solution	  per	  10^6	  cells.	  	  RIPA	  buffer	  consists	  of	  PBS	  containing	  1%	  NP-­‐40,	  0.5%	  sodium-­‐deoxycholate,	  and	  0.1%	  sodium	  dodecyl	  sulfate	  (SDS).	  	  To	  prepare	  lysis	  solution,	  10mL	  of	  RIPA	  buffer	  was	  supplemented	  with	  1	  protease	  inhibitor	  tablet	  (complete	  Mini	  EDTA-­‐free	  Roche	  11836170001),	  100	  μL	  Na3VO4	  (BioLab	  P0758S	  100mM),	  10	  mM	  DTT,	  and	  20	  μL	  NaF	  (BioLab	  P0759S	  500mM).	  Suspension	  was	  iced	  for	  10	  minutes	  followed	  by	  a	  10	  minute	  centrifugation	  at	  13000	  rpm	  at	  4°.	  	  Supernatants	  were	  stored	  at	  -­‐80°.	  
	  
Western	  blotting.	  Protein	  concentration	  was	  determined	  by	  using	  Pierce	  BCA	  kit	  against	  a	  known	  standard.	  	  Cytoplasmic	  extracts	  (25	  μg)	  were	  prepared	  in	  LDS	  sample	  buffer	  (Invitrogen)	  and	  loaded	  on	  a	  4-­‐12%	  NuPage	  gel	  in	  a	  1:20	  MES	  running	  buffer.	  	  Following	  transfer,	  nitrocellulose	  membranes	  were	  blocked	  in	  5%	  milk	  with	  TBS	  0.1%	  Tween,	  followed	  by	  overnight	  incubation	  at	  4°	  with	  the	  appropriate	  antibody.	  	  After	  washing,	  membranes	  were	  incubated	  with	  horseradish	  peroxidase-­‐conjugated	  antibody	  for	  1	  hour	  at	  room	  temperature	  followed	  by	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visualization	  on	  chemiluminescence	  film.	  	  The	  following	  antibodies	  were	  used	  for	  Western	  blotting:	  rat	  anti-­‐SAP	  (Cell	  Signaling	  #2805);	  goat-­‐anti	  rat	  IgG-­‐HRP	  (sc-­‐2006);	  mouse	  anti-­‐FLAG	  M2	  (Sigma	  088K6018);	  anti-­‐mouse	  IgG-­‐HRP	  (Cell	  Signaling	  #7076S);	  HRP-­‐conjugated	  actin	  (Abcam	  20272);	  and	  mouse	  anti-­‐XIAP	  (BD	  610717).	  
	  
qRT-­‐PCR.	  RNA	  was	  extracted	  using	  the	  RNeasy	  Mini	  Kit	  (Qiagen	  74104)	  according	  to	  manufacturer’s	  instructions.	  High-­‐capacity	  cDNA	  reverse	  transcription	  kit	  (Applied	  Biosystems	  4368814)	  was	  used	  to	  prepare	  cDNA	  from	  1	  μg	  of	  isolated	  RNA.	  The	  following	  Taq-­‐Man	  primers	  were	  used	  for	  qRT-­‐PCR	  on	  Applied	  Biosystems	  platform	  ABViiA7:	  IFN-­‐γ	  Life	  Technologies	  ABI	  Hx00174143_m1	  and	  IL-­‐2	  Life	  Technologies	  ABI	  hs00174114_m1.	  	  Samples	  were	  standardized	  to	  GAPDH	  and	  normalized	  to	  the	  unstimulated	  samples	  using	  the	  ΔΔCt	  method.	  
	  
Reporter	  Assays.	  Jurkat	  cells	  (10^7)	  were	  transfected	  using	  a	  BioRad	  Gene	  Pulser	  II	  (250	  V	  and	  975	  uF)	  with	  0.4	  cm	  gap	  cuvettes	  (BioRad	  1652088).	  10^7	  cells	  were	  transfected	  with	  10	  μg	  of	  NFAT-­‐Luc	  reporter	  or	  2kB-­‐Luc	  reporter	  plasmids	  and	  1	  μg	  of	  pEBB-­‐cherry.	  	  After	  44	  hours,	  cells	  were	  stimulated	  as	  indicated	  for	  6	  hours.	  	  Luciferase	  was	  measured	  with	  the	  dual-­‐luciferase	  reporter	  assay	  system	  (Promega	  E1910).	  	  Briefly,	  10^6	  cells	  were	  harvested	  and	  washed	  in	  1x	  PBS	  prior	  to	  adding	  100	  μL	  of	  1x	  Passive	  Lysis	  buffer	  (PLB#E1941)	  with	  a	  brief	  vortex.	  	  Twenty	  microliters	  of	  this	  was	  transferred	  per	  well	  of	  a	  96-­‐well	  Costar	  white	  bottom	  plate.	  	  Just	  prior	  to	  measurement,	  100	  μL	  of	  prepared	  Luciferase	  Assay	  Reagent	  (LAR)	  was	  added	  per	  well.	  	  Luciferase	  readings	  were	  performed	  on	  a	  Biotek	  Plate	  Reader	  for	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luminescence	  using	  the	  AutoGain	  option.	  Fold	  changes,	  where	  indicated,	  are	  normalized	  against	  unstimulated	  readings	  by	  cell	  type.	  
	  
Intracellular	  SAP	  staining	  with	  flow	  cytometry	  analysis.	  Cells	  were	  fixed	  and	  permeabilized	  using	  eBioscience	  Intracellular	  Fixation	  &	  Permeabilization	  Buffer	  Set	  (88-­‐8824).	  	  Approximately	  750,000	  cells	  were	  centrifuged	  at	  300g	  for	  10	  minutes.	  	  Cells	  were	  fixed	  in	  100	  μL	  of	  IC	  fixation	  buffer	  and	  pulse	  vortexed.	  	  After	  incubation	  in	  the	  dark	  at	  room	  temperature	  for	  30	  minutes,	  cells	  were	  washed	  twice	  by	  resuspending	  in	  2mL	  of	  1X	  permeabilization	  buffer	  and	  centrifuged	  at	  300g	  for	  5	  minutes	  at	  room	  temperature.	  	  Cells	  were	  resuspended	  in	  100	  μL	  of	  1X	  permeabilization	  buffer,	  and	  1	  μg	  of	  SAP	  antibody	  or	  isotype	  control	  was	  added	  with	  incubation	  in	  the	  dark	  at	  room	  temperature	  for	  15	  minutes	  (Mouse	  Anti-­‐SH2D1A	  Abnova	  H00004068-­‐M01	  or	  Purified	  Mouse	  IgG2a	  BioLegend	  41502).	  	  Cells	  were	  washed	  in	  1X	  permeabilization	  buffer	  followed	  by	  centrifuge	  300g	  for	  5	  minutes.	  	  Cells	  were	  resuspended	  in	  100	  μL	  of	  1X	  permeabilization	  buffer	  and	  1	  μg	  of	  secondary	  fluorochrome-­‐labeled	  antibody	  was	  added	  with	  incubation	  in	  the	  dark	  at	  room	  temperature	  for	  15	  minutes	  (Goat	  Anti-­‐Mouse	  IgG2a-­‐FITC	  Southern	  Biotech	  108-­‐02).	  	  Cells	  were	  washed	  in	  1X	  permeabilization	  buffer	  followed	  by	  centrifuge	  300g	  for	  5	  minutes.	  	  	  Cells	  were	  resuspended	  in	  500	  μL	  of	  FACS	  buffer	  and	  processed	  on	  an	  Accuri	  C6	  flow	  cytometer	  with	  a	  500,000	  threshold	  collecting	  10,000	  events.	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Calcium	  mobilization	  assay.	  The	  fluo-­‐4	  direct	  calcium	  assay	  kit	  (Life	  Technologies	  F10471)	  was	  used	  to	  measure	  free	  intracellular	  calcium	  levels	  according	  to	  manufacturer’s	  instructions.	  Briefly,	  loading	  solution	  was	  prepared	  with	  250nM	  probenecid	  stock	  in	  the	  fluo-­‐4	  direct	  calcium	  assay	  buffer.	  	  125,000	  cells	  were	  plated	  in	  50	  μL	  of	  media	  on	  a	  black-­‐sided,	  clear	  bottom,	  96-­‐well	  plate	  followed	  by	  50	  μL	  of	  the	  prepared	  loading	  solution,	  with	  incubation	  at	  37°	  for	  30	  minutes	  followed	  by	  30	  minutes	  at	  room	  temperature.	  Stimulation	  was	  added	  just	  prior	  to	  fluorescence	  measurement	  on	  a	  Biotek	  plate	  reader	  using	  494	  nm	  excitation	  and	  516	  nm	  emission.	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Chapter	  4	  Characterization	  of	  Apoptosis	  in	  SAP-­‐null	  Jurkat	  Cells	  	  
4.1	  Introduction	  	  	   X-­‐linked	  Lymphoproliferative	  disease	  (XLP)	  is	  caused	  by	  mutations	  in	  SAP	  (XLP1)	  or	  XIAP	  (XLP2)5.	  SAP	  and	  XIAP	  are	  structurally	  unrelated	  and	  the	  expression	  of	  SAP	  is	  restricted	  to	  T	  and	  natural	  killer	  (NK)	  cells	  while	  XIAP	  is	  ubiquitously	  expressed1,31,32.	  SAP	  is	  a	  small	  128	  amino	  acid	  protein	  largely	  comprised	  of	  a	  SH2	  domain1,	  while	  XIAP	  is	  a	  497	  amino	  acid	  residue	  with	  three	  baculovirus	  inhibitor	  of	  apoptosis	  protein	  repeat	  (BIR)	  domains,	  capable	  of	  binding	  and	  inhibiting	  caspase	  activity,	  and	  a	  RING	  E3	  ubiquitin	  ligase	  domain5.	  
	  
	  
Figure	  4.1	  Structure	  and	  mutations	  of	  SAP	  and	  XIAP.	  SAP	  is	  a	  small	  SH2	  domain	  containing	  protein	  while	  XIAP	   has	   three	   caspase	   binding	   domains	   and	   enzymatic	   activity.	   	  Mutations	   associated	  with	  XLP	  span	  the	  entire	  regions	  of	  SAP	  and	  XIAP34.	  	  Each	  line	  indicates	  an	  annotated	  patient	  mutation	  and	  the	  star	  denotes	  nonsense	  mutations.	  (Adapted	  from	  Blood	  (2010)	  116:18.)	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   Previous	  studies	  examining	  Sap	  and	  Xiap	  expression	  in	  mouse	  models	  determined	  that	  Sap-­‐deficient	  cells	  have	  normal	  levels	  of	  Xiap	  expression	  and	  vice	  versa6.	  At	  first	  glance,	  SAP	  and	  XIAP	  appear	  to	  be	  functionally	  unrelated	  as	  SAP	  binds	  the	  SLAM	  family	  of	  receptors,	  while	  XIAP	  binds	  and	  inhibits	  caspase	  activity.	  Patients	  with	  XLP1	  and	  XLP2	  have	  similar,	  but	  not	  identical,	  clinical	  presentations,	  as	  shown	  in	  table	  4.1.	  	  	  
XLP1	  (SAP)	   	   	   	   	   	   	   	   XLP2	  (XIAP)	  	  	  	  	  n=33	   	   	   	   	   	   	   	  	  	  	  	  	   	  	  	  	  	  	  n=30	  %	  of	  patients	   	   	   	   	   	   	   	   %	  of	  patients	  	   55	   Hemophagocytic	  Lymphohistiocytosis	  (HLH)	   	  	  	  	  	  	  	  	  76	  	  	   92	   EBV	  triggered	  HLH	   	   	   	   	   	  	  	  	  	  	  	  	  83	  	   61	   HLH	  associated	  lethality	  (HLH	  patients)	   	   	  	  	  	  	  	  	  	  23	  	   67	   Hypogammaglobulinemia	   	   	   	   	  	  	  	  	  	  	  	  33	  	   	  	  7	   Splenomegaly	  (w/o	  HLH)	   	   	   	   	  	  	  	  	  	  	  	  87	  	   30	   Lymphoma	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  0	  	   	  	  0	   Colitis	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  17	  	  
Table	  4.1	  The	  clinical	  picture	  of	  XLP.	  XLP	  patients	  have	  a	  range	  of	  phenotypes	  associated	  with	  XLP1	  and	  XLP234.	  	  However,	  a	  unique	  feature	  of	  XLP1	  (SAP-­‐deficient)	  patients	  is	  lymphoma	  development,	  while	  only	  XLP2	  (XIAP-­‐deficient)	  patients	  exhibit	  colitis.	  (Adapted	  from	  Blood	  (2011)	  117(5).)	  	  
	   As	  described	  in	  chapter	  3,	  there	  is	  strong	  evidence	  to	  suggest	  that	  SAP	  is	  involved	  in	  TCR	  signaling.	  	  T	  cell	  activation	  involves	  the	  proliferation	  and	  clonal	  expansion	  of	  immune	  cells	  and	  is	  followed	  by	  cell	  death.	  	  Studies	  from	  Katz	  et.al,	  (2014)	  provided	  evidence	  that	  SAP	  is	  involved	  in	  apoptosis	  but	  the	  mechanism	  is	  not	  well	  characterized.	  To	  further	  understand	  the	  influences	  of	  SAP	  on	  apoptosis,	  SAP-­‐null	  Jurkat	  cells	  were	  examined	  for	  their	  sensitivity	  to	  cell	  death.	  Furthermore,	  a	  comparative	  approach	  to	  analyze	  sensitivity	  to	  apoptotic	  stimuli	  in	  cells	  with	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decreased	  SAP	  and	  XIAP	  expression	  was	  investigated	  to	  understand	  immune	  cell	  death	  in	  XLP.	  	   Apoptosis	  is	  an	  orchestrated	  cellular	  process	  where	  dying	  cells	  are	  consumed	  by	  neighboring	  cells.	  In	  contrast,	  other	  cell	  death	  programs	  such	  as	  necrosis	  result	  in	  enlarged	  cells	  that	  release	  their	  cellular	  contents	  into	  the	  microenvironment	  causing	  inflammation	  and	  the	  recruitment	  of	  other	  immune	  cells	  to	  the	  necrotic	  sites215,216.	  Thus,	  tumors	  with	  a	  component	  of	  necrotic	  tissue	  have	  been	  shown	  to	  release	  cytokines	  that	  further	  stimulate	  immune	  cell	  proliferation	  69.	  Necrotic	  cells	  appear	  to	  foster	  an	  inflammatory	  environment	  whereas	  apoptosis	  does	  not	  appear	  to	  introduce	  additional	  inflammation	  within	  the	  microenvironment.	  	  	   Apoptosis,	  as	  shown	  in	  figure	  4.2,	  can	  be	  initiated	  by	  cell	  surface	  receptors	  or	  by	  the	  sensing	  of	  a	  plethora	  of	  cellular	  stresses	  that	  result	  in	  the	  activation	  of	  effector	  proteins	  called	  caspases	  (cysteine	  aspartate-­‐specific	  proteinases),	  in	  particular,	  Caspase-­‐3217,218.	  In	  receptor-­‐induced	  apoptosis,	  cell	  death	  can	  be	  initiated	  by	  members	  of	  the	  TNF	  (tumor	  necrosis	  factor)	  receptor	  superfamily,	  which	  contain	  a	  cysteine-­‐rich	  extracellular	  domain,	  a	  transmembrane	  region,	  and	  variable	  cytoplasmic	  tails	  that	  govern	  the	  specific	  functions	  of	  the	  receptor219.	  Certain	  TNF	  receptors	  contain	  death	  domains	  (DDs)	  in	  their	  cytoplasmic	  tails,	  which	  help	  trigger	  apoptotic	  signaling	  pathways	  following	  ligand	  activation.	  A	  well	  characterized	  death	  receptor	  is	  Fas	  (CD95/APO-­‐1)219,	  which	  is	  activated	  by	  binding	  of	  Fas	  ligand	  (FasL).	  Ligation	  recruits	  the	  Fas-­‐associated	  death	  domain	  (FADD)	  protein	  to	  the	  death	  domain	  (DD)	  in	  the	  cytoplasmic	  tail	  of	  Fas220.	  Additionally,	  pro-­‐Caspase-­‐8221	  is	  recruited	  to	  the	  receptor	  complex,	  forming	  the	  death-­‐inducing	  signaling	  complex	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(DISC)222.	  Once	  formed,	  the	  complex	  induces	  the	  cleavage	  and	  activation	  of	  pro-­‐Caspase-­‐8	  which,	  in	  turn,	  activates	  Bid223,224.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
Figure	  4.2	  The	  apoptotic	  cascade.	  Apoptosis	  is	  initiated	  by	  extrinsic	  stimuli,	  involving	  death	  receptors,	  or	  by	  internal	  cellular	  stress,	  such	  as	  DNA	  damage.	  For	  receptor-­‐mediated	  apoptosis	  FasL,	  for	  example,	  is	  produced	  by	  immune	  cells	  and	  ligates	  with	  the	  Fas	  receptor,	  recruiting	  FADD	  and	  pro-­‐Caspase-­‐8	  to	  the	  death	  domain	  (DD)	  to	  form	  the	  DISC.	  Activated	  Caspase-­‐8	  stimulates	  Bid	  to	  induce	  the	  mitochondria,	  via	  Bax	  and	  Bak,	  to	  release	  Cytochrome	  c.	  Cytochrome	  c	  forms	  the	  apoptosome	  with	  Apaf1	  and	  Caspase-­‐9	  affecting	  Caspase-­‐3	  activity,	  which	  leads	  to	  cells	  death.	  Similarly,	  intracellular	  stress,	  such	  as	  DNA	  damage,	  increases	  the	  activity	  of	  p53	  to	  affect	  Bad	  and	  Bax	  to	  induce	  the	  mitochondria	  to	  release	  Cytochrome	  c.	  The	  XLP2	  disease	  related	  protein	  XIAP	  has	  functional	  roles	  in	  apoptosis	  as	  it	  binds	  with	  and	  inhibit	  caspase	  activation225,226.	  	  Intracellular	  stress	  or	  the	  activation	  of	  Bid	  by	  Caspase-­‐8,	  can	  increase	  the	  level	  of	  Bax	  and	  Bak	  oligomerization	  on	  the	  mitochondrial	  surface,	  creating	  pores	  that	  allow	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Cytochrome	  c	  release227,228.	  Once	  released,	  Cytochrome	  c	  then	  binds	  to	  the	  apoptotic	  protease	  activating	  factor	  1	  (Apaf1)	  to	  form	  the	  apoptosome,	  which	  recruits	  Caspase-­‐9229	  and	  activates	  downstream	  Caspase-­‐3	  to	  affect	  cell	  death.	  Caspase-­‐3	  activation,	  as	  an	  indicator	  of	  apoptosis,	  was	  measured	  in	  the	  SAP-­‐null	  cells	  to	  determine	  the	  impact	  of	  SAP-­‐defects	  on	  T	  cell	  apoptosis.	  	  	  
4.2	  Results	  	  	  	   Since	  XIAP	  and	  SAP	  contribute	  to	  the	  development	  of	  XLP,	  and	  XIAP	  has	  a	  recognized	  role	  in	  apoptosis,	  through	  its	  binding	  and	  inhibition	  of	  caspases230,	  the	  initial	  question	  was	  whether	  cells	  deficient	  for	  SAP	  or	  XIAP	  had	  similar	  responses	  to	  apoptotic	  stimuli.	  To	  address	  this	  question	  in	  a	  comparative	  manner,	  Caspase-­‐3	  activity	  was	  measured	  after	  death	  receptor	  stimulation	  in	  RNAi	  silenced	  cells.	  	  Jurkat	  cells	  were	  transfected	  with	  siRNA	  targeting	  SAP,	  XIAP,	  or	  GFP	  as	  a	  negative	  control,	  and	  the	  samples	  were	  subsequently	  stimulated	  with	  activating	  anti-­‐Fas	  antibody.	  Caspase-­‐3	  activity	  was	  assessed	  by	  measuring	  caspase-­‐mediated	  cleavage	  of	  a	  fluorescently	  labeled	  target	  substrate.	  The	  results	  shown	  in	  figure	  4.3	  indicate	  that	  the	  suppression	  of	  both	  SAP	  and	  XIAP	  expression	  increased	  Caspase-­‐3	  activity	  following	  Fas	  stimulation	  compared	  to	  the	  control.	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cleavage	  expression,	  a	  marker	  of	  caspase	  activation	  (figure	  4.4B).	  These	  data	  demonstrated	  that	  there	  was	  no	  measurable	  Caspase-­‐3	  activity	  prior	  to	  stimulation	  in	  either	  cell	  type	  but,	  after	  treatment,	  the	  SAP-­‐null	  cells	  exhibited	  higher	  levels	  of	  cleaved	  Caspase-­‐3	  activity,	  compared	  to	  wild	  type.	  This	  also	  suggested	  that	  SAP-­‐deficiencies	  increase	  the	  amount	  of	  active	  Caspase-­‐3	  within	  the	  cell	  upon	  stimulation	  of	  Fas.	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B)	   Figure	  4.4	  Increased	  Caspase-­‐3	  
activity	  in	  SAP-­‐null	  Jurkats.	  A)	  Cells	  were	  treated	  for	  6	  hours	  with	  activating	  anti-­‐Fas	  antibody	  (250	  ng/mL)	  prior	  to	  measuring	  caspase	  activity.	  	  Data	  are	  representative	  of	  three	  independent	  experiments	  with	  error	  bars	  indicating	  standard	  deviation.	  	  (p<0.002	  at	  all	  time	  points	  between	  WT	  and	  SAP-­‐null	  with	  Fas	  treatment.	  	  Lines	  at	  bottom	  of	  graph	  represent	  unstimulated	  SAP-­‐null	  in	  green	  and	  WT	  in	  blue.)	  B)	  Cells	  were	  treated	  for	  18	  hours	  with	  anti-­‐Fas	  antibody	  (250	  ng/mL)	  prior	  to	  protein	  extraction	  and	  Western	  blotting	  using	  anti-­‐SAP	  and	  anti-­‐Caspase-­‐3	  antibodies.	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   The	  observation	  that	  Caspase-­‐3	  expression	  was	  elevated	  in	  SAP-­‐deficient	  cells	  after	  Fas	  activation	  suggested	  that	  apoptosis	  might	  be	  higher	  in	  cells	  with	  SAP	  defects.	  To	  detect	  changes	  in	  cell	  viability	  upon	  Fas	  stimulation	  wild	  type	  and	  SAP-­‐null	  cells	  were	  stimulated	  with	  activating	  anti-­‐Fas	  antibody	  and	  viability	  was	  assessed	  by	  propidium	  iodide	  exclusion	  assay	  followed	  by	  flow	  cytometry.	  Indeed,	  
SAP-­‐deficient	  cells	  were	  less	  viable	  following	  Fas	  treatment	  as	  compared	  to	  wild	  type	  cells	  (figure	  4.5A),	  suggesting	  that	  the	  SAP-­‐null	  cells	  were	  more	  sensitive	  to	  Fas-­‐mediated	  death.	  Although	  the	  results	  illustrated	  that	  the	  SAP-­‐null	  cells	  have	  increased	  Caspase-­‐3	  activity	  (figure	  4.4)	  and	  are	  less	  viable	  after	  Fas	  treatment	  (figure	  4.5),	  it	  is	  possible	  that	  the	  observed	  decrease	  in	  viability	  was	  caspase-­‐independent.	  	  T	  cell	  death	  independent	  of	  caspase	  activation	  or	  Cytochrome	  c	  release	  has	  previously	  been	  reported231.	  To	  confirm	  that	  the	  Fas-­‐mediated	  sensitivity	  was	  caspase-­‐dependent,	  cells	  were	  pre-­‐treated	  with	  the	  pan-­‐caspase	  inhibitor	  zVAD-­‐fmk.	  Pre-­‐treatment	  with	  zVAD-­‐fmk	  blocked	  Fas-­‐mediated	  cell	  death	  in	  the	  SAP-­‐null	  cells	  (figure	  4.5B),	  supporting	  the	  notion	  that	  the	  decreased	  viability	  in	  the	  SAP-­‐deficient	  cells	  following	  Fas	  treatment	  resulted	  from	  a	  caspase-­‐dependent	  mechanism.	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Figure	  4.7	  SAP	  reconstitution	  and	  Caspase-­‐3.	  	  A)	  Cells	  were	  treated	  for	  6	  hours	  with	  activating	  anti-­‐Fas	  antibody	  (250	  ng/mL)	  prior	  to	  measuring	  caspase	  activity.	  (p<0.04	  between	  WT	  and	  SAP-­‐null	  with	  Fas	  treatment	  and	  between	  SAP-­‐null	  cells	  and	  cells	  with	  SAP	  reconstitution.)	  B)	  Cells	  were	  analyzed	  by	  Western	  blot	  using	  anti-­‐Caspase-­‐3	  (full-­‐length)	  and	  anti-­‐SAP	  antibodies.	  	  
B)	  
A)	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more	  universal	  susceptibility	  to	  death	  stimuli,	  wild	  type	  and	  SAP-­‐null	  cells	  were	  treated	  with	  various	  death	  inducing	  agents.	  	  Cells	  were	  incubated	  with	  the	  indicated	  concentrations	  of	  Fas,	  TNF	  and	  cycloheximide	  (CHX),	  or	  etoposide	  prior	  to	  measuring	  viability	  by	  PI	  exclusion	  and	  flow	  cytometry.	  TNF	  is	  a	  member	  of	  the	  TNF	  superfamily232	  that	  requires	  the	  addition	  of	  cycloheximide	  (CHX)	  to	  induce	  apoptosis233,	  while	  etoposide	  is	  a	  topoisomerase	  II	  inhibitor	  that,	  as	  a	  consequence	  of	  inducing	  DNA	  damage,	  leads	  to	  the	  release	  of	  Cytochrome	  c	  	  from	  the	  mitochondria234.	  	  As	  shown	  in	  figure	  4.8,	  the	  SAP-­‐null	  cells	  exhibited	  increased	  sensitivity	  to	  Fas,	  TNF/CHX	  and	  etoposide	  treatment	  when	  compared	  to	  wild	  type	  cells,	  indicating	  that	  a	  deficiency	  in	  SAP	  confers	  a	  heightened,	  non-­‐specific,	  sensitivity	  to	  cell	  death.	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4.3	  Discussion	  	  	   The	  analysis	  of	  SAP’s	  role	  in	  T	  cell	  apoptosis	  demonstrated	  that	  SAP	  deficient	  Jurkat	  cells	  were	  more	  sensitive	  to	  apoptotic	  stimuli,	  as	  measured	  by	  cell	  viability	  and	  analysis	  of	  Caspase-­‐3	  activity.	  Initial	  results	  demonstrated	  that	  Fas	  stimulation	  in	  Jurkat	  cells	  with	  reduced	  XIAP	  and	  SAP	  expression	  led	  to	  increased	  Caspase-­‐3	  activity.	  These	  results	  were	  further	  supported	  by	  analyzing	  Caspase-­‐3	  activity	  and	  cleaved	  Caspase-­‐3	  levels,	  both	  of	  which	  were	  elevated	  in	  the	  SAP-­‐null	  Jurkats	  compared	  to	  the	  wild	  type	  following	  Fas	  stimulation.	  Similarly,	  the	  SAP-­‐null	  cells	  have	  heightened	  sensitivity	  to	  Fas-­‐mediated	  apoptosis	  as	  shown	  by	  viability,	  and	  this	  cell	  death	  was	  caspase-­‐dependent,	  demonstrated	  by	  the	  addition	  of	  a	  pan-­‐caspase	  inhibitor.	  Restoration	  of	  SAP	  expression	  in	  the	  SAP-­‐deficient	  cells	  rescued	  viability	  and	  provided	  resistance	  to	  Fas-­‐mediated	  cell	  death.	  	  	   The	  restoration	  of	  SAP	  expression	  in	  the	  SAP-­‐null	  Jurkat	  cells	  decreased	  the	  activity	  of	  Caspase-­‐3	  following	  Fas	  stimulation	  (figure	  4.7),	  but	  not	  to	  the	  level	  of	  the	  wild	  type.	  This	  could	  be	  explained	  by	  the	  partial	  rescue	  of	  SAP	  expression	  and	  that	  the	  population	  contains	  a	  mixture	  of	  cells	  with	  ectopic	  SAP	  expression	  and	  the	  SAP-­‐null	  cells	  (figure	  3.7).	  To	  determine	  which	  cells	  are	  responsible	  for	  the	  decrease	  in	  Caspase-­‐3	  activity,	  the	  bulk	  population	  would	  be	  stimulated	  with	  Fas	  followed	  by	  intracellular	  staining	  and	  flow	  cytometry	  analysis	  for	  SAP	  and	  Caspase-­‐3	  expression.	  This	  double	  staining	  approach	  would	  determine	  whether	  the	  SAP	  expressing	  cells	  are	  responsible	  for	  the	  decrease	  in	  Caspase-­‐3	  activity	  observed	  during	  the	  rescue	  experiment.	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   The	  increased	  sensitivity	  to	  other	  apoptotic	  stimuli	  observed	  in	  the	  SAP-­‐deficient	  cells	  suggests	  a	  novel	  role	  of	  SAP	  in	  CD4+	  T	  cells.	  Sensitivity	  to	  apoptotic	  stimuli	  is	  a	  concern	  to	  maintain	  the	  proper	  balance	  of	  immune	  cells	  to	  respond	  to	  infections.	  A	  generalized	  sensitivity	  to	  apoptosis	  suggests	  involvement	  of	  the	  mitochondrial	  organelles.	  The	  elevated	  production	  of	  IFN-­‐γ	  observed	  in	  the	  SAP-­‐null	  cells	  (chapter	  3)	  is	  a	  potential	  contributor	  to	  apoptosis	  as	  previous	  work	  has	  shown	  that	  overexpression	  of	  IFN-­‐γ	  increased	  destabilization	  of	  the	  mitochondria	  by	  increased	  Bax	  levels235	  and,	  in	  stem	  cells,	  increased	  Caspase-­‐3	  mediated	  apoptosis236.	  While	  measuring	  Caspase-­‐3	  activity	  is	  an	  indicator	  of	  apoptosis,	  it	  does	  not	  specifically	  address	  changes	  in	  mitochondrial	  membrane	  potential.	  To	  address	  this,	  experiments	  were	  performed	  to	  assess	  the	  outer	  mitochondrial	  membrane	  potential	  and	  these	  results	  indicated	  that	  the	  membrane	  potential	  in	  the	  SAP-­‐null	  Jurkat	  cells	  was	  lower	  than	  the	  wild	  type	  prior	  to	  Fas	  stimulation,	  but	  this	  difference	  was	  not	  observed	  following	  Fas	  treatment	  (data	  not	  shown).	  It	  was	  possible	  that	  unstimulated	  SAP-­‐deficient	  cells	  had	  fewer	  mitochondria,	  accounting	  for	  the	  decreased	  mitochondrial	  membrane	  potential.	  However,	  subsequent	  analysis	  of	  the	  mitochondrial	  mass	  indicated	  that	  there	  was	  no	  difference	  in	  the	  total	  number	  of	  mitochondria	  among	  the	  cell	  types	  (Chang	  and	  Kim	  2015,	  data	  not	  shown).	  These	  data	  suggest	  that	  the	  apoptotic	  sensitivity	  is	  not	  due	  to	  inherent	  mitochondrial	  defects	  due	  to	  SAP-­‐deficiencies,	  but	  rather	  result	  from	  defects	  within	  the	  signaling	  cascades.	  Alternatively,	  it	  is	  possible	  that	  elevated	  calcium	  levels	  induce	  apoptosis237	  as	  high	  levels	  of	  calcium	  ions	  can	  disrupt	  the	  outer	  mitochondrial	  membrane	  potential	  to	  affect	  the	  release	  of	  Cytochrome	  c	  238.	  Selectively	  inhibiting	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calcium	  mobilization	  followed	  by	  death	  receptor	  stimulation	  may	  indicate	  whether	  calcium	  mobilization	  is	  dispensable	  for	  SAP-­‐mediated	  apoptotic	  sensitivity.	  	   Suppression	  of	  SAP	  or	  XIAP	  demonstrated	  increased	  Caspase-­‐3	  activity	  upon	  Fas	  stimulation	  (figure	  4.3).	  Considering	  that	  XLP	  results	  from	  mutations	  in	  either	  
SAP	  or	  XIAP,	  two	  genes	  with	  no	  structural	  similarities,	  this	  suggests	  that	  these	  genes	  share	  a	  commonly	  deregulated	  pathway.	  	  While	  further	  studies	  are	  needed	  to	  fully	  appreciate	  this	  relationship,	  it	  is	  possible	  that	  the	  shared	  apoptotic	  sensitivity	  is	  responsible	  for	  the	  overlapping	  HLH	  phenotype.	  	  	   Since	  the	  primary	  clinical	  presentation	  of	  XLP1	  patients	  is	  often	  associated	  with	  infections,	  the	  relationship	  between	  SAP	  expression	  and	  response	  to	  various	  infections	  has	  been	  explored.	  More	  specifically,	  SAP	  expression	  in	  human	  CD4+	  T	  cells	  inversely	  correlated	  to	  IFN-­‐γ levels	  after	  tuberculosis	  infection,	  again	  suggested	  that	  the	  presence	  of	  SAP	  disrupts	  IFN-­‐γ	  production199.	  Although	  not	  directly	  tested	  by	  infecting	  the	  SAP-­‐null	  Jurkat	  cells,	  an	  interesting	  study190	  monitored	  two	  brothers	  diagnosed	  with	  XLP1	  for	  two	  years,	  and	  one	  brother	  had	  an	  acute	  EBV	  infection	  during	  the	  study	  while	  the	  other	  had	  previous	  exposure	  to	  the	  virus.	  	  Both	  brothers	  exhibited	  elevated	  IFN-­‐γ	  levels	  throughout	  the	  study	  and	  not	  only	  did	  their	  CD4+	  T	  cells	  favor	  a	  Th1	  phenotype	  but	  they	  had	  reduced	  numbers	  of	  CD4+	  T	  cells	  throughout	  the	  study190,	  compared	  to	  EBV	  infected	  cells	  with	  normal	  SAP	  expression.	  Combining	  the	  observations	  in	  the	  SAP-­‐null	  Jurkats	  with	  evidence	  in	  the	  literature,	  it	  is	  possible	  that	  SAP	  defects	  predispose	  CD4+	  cells	  to	  apoptosis	  and	  that	  the	  remaining	  T	  cells	  exhibit	  increased	  IFN-­‐γ	  production.	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   Enhanced	  sensitivity	  to	  apoptosis	  is	  an	  intriguing	  observation,	  and	  clinical	  evidence	  has	  been	  shown	  in	  XLP1	  patients.	  For	  example,	  a	  case	  report239	  quantifying	  lymphocytes	  of	  an	  EBV+	  infected	  XLP1	  patient	  demonstrated	  a	  reduction	  of	  the	  total	  percentage	  of	  CD4+	  T	  cells	  compared	  to	  the	  SAP	  expressing	  EBV	  infected	  ranges239.	  These	  findings	  could	  also	  be	  explained	  by	  the	  increased	  sensitivity	  to	  cell	  death	  observed	  in	  the	  SAP-­‐null	  cells	  (figure	  4.5),	  suggesting	  that	  either	  fewer	  CD4+	  cells	  are	  produced	  or	  the	  cells	  are	  more	  sensitive	  to	  apoptosis,	  which	  may	  lead	  to	  fewer	  measurable	  cells.	  	  	   The	  question	  was	  raised	  if	  the	  SAP-­‐null	  cells	  were	  producing	  factors	  that	  influence	  cell	  viability	  that	  differ	  from	  SAP-­‐expressing	  cells.	  To	  address	  this,	  conditioned	  media	  was	  prepared	  from	  the	  SAP-­‐null	  and	  wild	  type	  Jurkat	  cells	  and	  was	  placed	  on	  the	  wild	  type	  Jurkat	  cells	  followed	  by	  measurement	  of	  cell	  viability	  (data	  not	  shown).	  	  This	  experiment	  showed	  that	  exposure	  to	  conditioned	  media	  from	  the	  SAP-­‐null	  cells	  decreased	  the	  viability	  of	  the	  wild	  type	  cells,	  compared	  to	  cells	  exposed	  to	  the	  wild	  type	  conditioned	  media.	  This	  suggested	  that	  factors	  are	  being	  released	  by	  the	  SAP-­‐deficient	  cells	  that	  affect	  cell	  viability.	  Future	  experiments	  using	  mass	  spectrometry	  could	  analyze	  the	  conditioned	  media	  to	  identify	  these	  death	  sensitizing	  factors.	  	  
	   Immune	  cells	  with	  increased	  sensitivity	  to	  death	  can	  have	  impaired	  abilities	  to	  respond	  to	  infection.	  Although	  EBV	  primarily	  infects	  B	  cells,	  CD4+	  T	  cells	  influence	  the	  control	  of	  the	  infected	  cells240.	  The	  in	  vivo	  presence	  of	  CD4+	  T	  cells	  during	  early	  EBV	  infection	  has	  been	  shown	  to	  decrease	  the	  appearance	  of	  rapidly	  proliferating	  transformed	  B	  cells	  that	  express	  CD23+	  on	  their	  surface241.	  	  In	  cultures	  depleted	  of	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CD4+	  T	  cells	  there	  was	  a	  marked	  increased	  in	  the	  presence	  of	  CD23+	  B	  cells242.	  This	  suggests	  that	  CD4+	  cells	  modulates	  the	  proliferation	  of	  EBV-­‐infected	  B	  cells	  and	  when	  they	  are	  absent	  or	  in	  decreased	  quantities	  this	  contributes	  to	  B	  cell	  lymphoproliferation.	  This	  supports	  the	  hypothesis	  that	  SAP-­‐deficient	  CD4+	  T	  cells	  are	  more	  sensitive	  to	  apoptotic	  stimuli,	  particularly	  after	  an	  infection,	  and	  therefore	  fewer	  Th	  cells	  are	  able	  to	  provide	  support	  to	  B	  cells.	  	  Moreover,	  in	  vitro	  studies	  of	  XLP1	  patient	  T	  cells	  have	  shown	  that	  SAP-­‐deficient	  cells	  fail	  to	  induce	  B	  cells	  to	  efficiently	  produce	  antibodies243,	  implying	  a	  decrease	  in	  the	  ability	  of	  B	  cells	  to	  clear	  EBV	  infection.	  	  	  	   Interestingly,	  EBV	  infection	  itself	  has	  been	  shown	  to	  result	  in	  a	  decrease	  in	  
SAP	  transcription	  presumably	  through	  a	  NF-­‐κB	  dependent	  mechanism	  in	  cells	  with	  normal	  SAP	  expression244,	  suggesting	  that	  EBV	  infection	  may	  decrease	  T	  cell	  signals	  by	  modulating	  SAP	  levels.	  This	  raises	  the	  question	  as	  to	  whether	  EBV	  infection	  would	  affect	  SAP	  expression	  and	  thus	  impair	  cytokine	  production	  and	  augment	  cell	  death.	  To	  assess	  the	  influence	  of	  EBV	  on	  SAP	  expression	  in	  T	  cells,	  the	  Jurkat	  cells	  can	  be	  transfected	  with	  the	  EBV-­‐associated	  latent	  membrane	  protein	  1	  (LMP1)245,246	  followed	  by	  measurement	  of	  SAP	  expression	  and	  cytokine	  production	  following	  TCR	  stimulation.	  Also,	  it	  would	  be	  clinically	  relevant	  to	  determine	  whether	  EBV	  infections	  in	  XLP1	  patients	  lead	  to	  a	  decreased	  total	  number	  of	  CD4+	  T	  cells	  or	  if	  the	  
SAP	  defects	  impair	  T	  cell	  signaling	  resulting	  in	  a	  decreased	  ability	  to	  kill	  infected	  cells.	  This	  may	  add	  insights	  as	  to	  EBV-­‐dependent	  modulation	  of	  SAP	  expression	  and	  result	  in	  increased	  monitoring	  of	  CD4+	  T	  cells	  in	  the	  clinic	  due	  to	  their	  sensitivity	  to	  cell	  death.	  Together,	  these	  studies	  reinforce	  the	  idea	  that	  SAP	  influences	  the	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presence	  of	  CD4+	  T	  cells,	  as	  demonstrated	  in	  the	  reduction	  in	  viable	  SAP-­‐null	  Jurkat	  cells	  following	  stimuli,	  and	  in	  patients	  following	  infection.	  These	  findings	  also	  underscore	  the	  importance	  of	  CD4+	  T	  cells	  in	  controlling	  the	  proliferation	  of	  EBV	  infected	  B	  cells.	  	  
4.4	  Materials	  &	  Methods	  	  
 
Media.	  Jurkat	  cells	  were	  cultured	  in	  RPMI	  1640	  (Corning	  15-­‐041-­‐CV)	  supplemented	  with	  1%	  GlutaMax	  (Gibco	  35050-­‐061)	  and	  10%	  FBS	  (Atlas)	  with	  incubation	  conditions	  at	  37°	  and	  5%	  CO2.	  
	  
Transfection	  of	  Jurkat	  Cells.	  Jurkat	  cells	  were	  electroporated	  using	  a	  BioRad	  Gene	  Pulser	  II	  (250	  V	  and	  975	  μF)	  using	  0.4	  cm	  gap	  cuvettes	  (BioRad	  1652088).	  10^7	  cells	  were	  transfected	  with	  20	  nM	  of	  each	  siRNA	  targeting	  SAP,	  XIAP	  or	  GFP	  control.	  	  For	  SAP	  reconstitution	  experiments,	  10^7	  SAP-­‐null	  Jurkat	  cells	  were	  transfected	  with	  10	  μg	  of	  pEBB-­‐SAP-­‐FLAG	  and	  1	  μg	  of	  pBABE-­‐puro	  selection	  plasmid.	  Forty-­‐eight	  hours	  after	  transfection	  cells	  were	  maintained	  in	  0.5	  μg/mL	  of	  puromycin	  containing	  selection	  media.	  	  	  	  
Whole	  cell	  lysate	  preparation.	  Cells	  were	  harvested	  by	  centrifugation	  at	  300	  rpm	  for	  5	  minutes	  and	  resuspended	  in	  100	  μL	  of	  prepared	  radioimmunoprecipitation	  assay	  (RIPA)	  lysis	  solution	  per	  10^6	  cells.	  	  RIPA	  buffer	  consists	  of	  PBS	  containing	  1%	  NP-­‐40,	  0.5%	  sodium-­‐deoxycholate,	  and	  0.1%	  sodium	  dodecyl	  sulfate	  (SDS).	  	  To	  prepare	  lysis	  solution,	  10	  mL	  of	  RIPA	  buffer	  was	  supplemented	  with	  1	  protease	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inhibitor	  tablet	  (cOmplete	  Mini	  EDTA-­‐free	  Roche	  11836170001),	  100	  μL	  Na3VO4	  (BioLab	  P0758S	  100	  mM),	  10	  μL	  of	  1mM	  DTT,	  and	  20	  μL	  NaF	  (BioLab	  P0759S	  500	  mM).	  Cell	  lysates	  were	  incubated	  on	  ice	  for	  10	  minutes	  followed	  by	  a	  10	  minute	  centrifugation	  at	  13000	  rpm	  at	  4°.	  Supernatants	  were	  stored	  at	  -­‐80°.	  
	  
Western	  blotting.	  Protein	  concentration	  was	  determined	  by	  using	  Pierce	  BCA	  kit	  against	  a	  known	  standard.	  	  Cytoplasmic	  extracts	  (25	  μg)	  were	  prepared	  in	  LDS	  sample	  buffer	  (Invitrogen)	  and	  loaded	  on	  a	  4-­‐12%	  NuPage	  gel	  in	  a	  1:20	  MES	  running	  buffer.	  	  Following	  transfer,	  nitrocellulose	  membranes	  were	  blocked	  in	  5%	  milk	  with	  TBS	  0.1%	  Tween,	  followed	  by	  overnight	  incubation	  at	  4°	  with	  the	  appropriate	  antibody.	  	  After	  washing,	  membranes	  were	  incubated	  with	  horseradish	  peroxidase-­‐conjugated	  antibody	  for	  1	  hour	  at	  room	  temperature	  followed	  by	  visualization	  on	  chemiluminescence	  film.	  	  The	  following	  antibodies	  were	  used	  for	  Western	  blotting:	  rat	  anti-­‐SAP	  (Cell	  Signaling	  #2805);	  goat-­‐anti	  rat	  IgG-­‐HRP	  (Santa	  Cruz-­‐2006);	  mouse	  anti-­‐FLAG	  M2	  (Sigma	  088K6018);	  anti-­‐mouse	  IgG-­‐HRP	  (Cell	  Signaling	  #7076S);	  HRP-­‐conjugated	  actin	  (Abcam	  20272);	  anti-­‐rabbit	  full	  length	  Caspase-­‐3	  (Cell	  Signaling	  9665);	  anti-­‐rabbit	  cleaved	  Caspase-­‐3	  (Cell	  Signaling	  9661);	  and	  mouse	  anti-­‐XIAP	  (BD	  610717).	  	  
Caspase-­‐3	  assay.	  Cells	  were	  synchronized	  on	  the	  day	  prior	  to	  the	  experiment	  by	  centrifugation	  and	  resuspension	  in	  fresh	  media.	  	  2x10^5	  cells	  per	  condition	  were	  unstimulated	  or	  stimulated	  with	  250	  ng/mL	  of	  activating	  anti-­‐Fas	  (CD95	  CH11	  clone)	  for	  six	  hours	  with	  incubation	  at	  37°.	  	  Cells	  were	  collected	  by	  centrifugation	  at	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3000	  rpm	  for	  5	  minutes	  and	  50	  μL	  of	  Biosource	  Caspase	  Assay	  Kit	  cell	  lysis	  buffer	  (BY01)	  was	  added,	  followed	  by	  a	  brief	  vortex	  and	  incubated	  on	  ice	  for	  10	  minutes.	  	  A	  2X	  reaction	  buffer	  consisting	  of	  800	  μL	  of	  the	  BY01	  buffer,	  8	  μL	  of	  1M	  DTT,	  and	  4	  μL	  of	  DEVD-­‐AFC	  was	  prepared.	  Fifty	  microliters	  of	  the	  reaction	  buffer	  was	  added	  to	  each	  well	  on	  a	  Costar	  96-­‐well	  black-­‐sided	  clear	  bottom	  plate	  followed	  by	  50	  μL	  of	  the	  cell	  in	  lysis	  buffer.	  	  Assay	  was	  measured	  on	  a	  BioTek	  plate	  reader	  using	  an	  AutoAdjust	  Gain	  fluorescence	  program	  with	  bottom	  read	  set	  for	  excitation	  at	  400	  nm	  and	  emission	  at	  505	  nm.	  	  A	  kinetics	  program	  read	  every	  5	  minutes	  for	  the	  indicated	  time	  frames.	  	  Data	  was	  graphed	  using	  average	  fluorescence	  units.	  
	  
Viability	  assay.	  Cells	  were	  untreated	  or	  incubated	  in	  the	  presence	  of	  250	  ng/mL.	  of	  activating	  anti-­‐Fas	  (CD95	  Clone	  CH11	  Millipore	  05-­‐201)	  for	  18	  hours	  at	  37°.	  	  Where	  indicated,	  cells	  were	  treated	  with	  z-­‐VAD-­‐fmk	  (Cayman	  14463)	  at	  specified	  concentrations.	  Cells	  were	  harvested	  by	  centrifugation	  and	  resuspended	  in	  PBS	  plus	  1%	  bovine	  serum	  albumin.	  	  Propidium	  iodide	  (PI),	  2	  μg/mL,	  was	  added	  just	  prior	  to	  analysis	  by	  flow	  cytometry	  using	  Accuri	  C6	  machine	  at	  500,000	  threshold	  for	  10,000	  events.	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Chapter	  5	  Discussion	  	  	  
5.1	  Introduction	  	  	   Although	  XLP	  is	  a	  disease	  that	  was	  first	  described	  in	  young	  males	  in	  the	  mid-­‐1970s27,	  there	  remain	  unknown	  aspects	  of	  how	  the	  disease	  develops	  into	  a	  spectrum	  of	  hematological	  deficiencies.	  Several	  previous	  studies	  have	  addressed	  the	  role	  of	  SAP	  in	  the	  disease	  using	  patient	  derived	  material,	  mouse	  models,	  or	  cell-­‐based	  studies.	  However,	  there	  are	  many	  unanswered	  questions	  as	  to	  how	  SAP-­‐defects	  impair	  T	  cell	  activation.	  There	  were	  several	  ways	  to	  address	  this	  question.	  	  Ideally,	  patient	  derived	  T	  cells	  would	  have	  provided	  an	  optimal	  way	  to	  examine	  signaling	  defects.	  However,	  the	  patient	  population	  is	  small	  and	  access	  to	  the	  materials	  extremely	  limits	  this	  approach.	  Several	  studies	  have	  used	  Sap-­‐deficient	  mouse	  models	  to	  provide	  valuable	  insights	  into	  T	  cell	  differentiation	  and	  signaling	  defects.	  	  This	  approach	  has	  limitations	  in	  that	  mice	  have	  genetic	  differences	  from	  humans	  and,	  importantly,	  cannot	  be	  infected	  by	  EBV.	  Previous	  studies	  have	  used	  established	  cell	  lines	  to	  identify	  SAP-­‐dependent	  effects	  using	  RNAi	  to	  disrupt	  SAP	  expression	  and	  elucidate	  signaling	  defects	  and	  protein	  interactions.	  However,	  this	  also	  has	  limitations	  by	  the	  transient	  nature	  of	  the	  SAP	  disruption	  and	  the	  incomplete	  effects	  of	  silencing	  the	  gene.	  The	  utilization	  of	  a	  TALEN-­‐based	  gene	  editing	  approach	  presented	  the	  opportunity	  to	  create	  a	  SAP-­‐null	  Jurkat	  cell	  line	  with	  a	  total	  disruption	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of	  SAP	  expression	  and	  allowed	  the	  comparative	  analysis	  of	  the	  SAP-­‐dependent	  effects	  on	  T	  cell	  signaling.	  	  	   The	  work	  presented	  in	  this	  dissertation	  exclusively	  examined	  signaling	  in	  the	  Jurkat	  T	  leukemia	  line.	  Jurkat	  cells	  have	  been	  extensively	  used	  to	  characterize	  T	  cell	  signaling247,	  but	  all	  established	  cell	  lines	  have	  limitations,	  so	  it	  is	  important	  to	  bear	  this	  in	  mind	  when	  interpreting	  observations.	  Jurkat	  cells	  have	  defects	  in	  the	  lipid	  phosphatases	  PTEN	  (phosphatase	  tensin	  homolog)	  and	  SHIP-­‐1	  (SH2-­‐domain-­‐containing	  inositol	  phosphatase)248.	  PTEN	  defects	  contribute	  to	  these	  cells	  being	  in	  a	  partially	  activated	  state,	  which	  may	  affect	  the	  basal	  activity	  of	  target	  genes	  that	  would	  not	  be	  observed	  in	  a	  naïve	  T	  cell.	  	  When	  SHIP-­‐1	  is	  bound	  to	  the	  SLAM	  receptor	  this	  inhibits	  T	  cell	  activation249	  and	  it	  is	  possible	  that	  the	  absence	  of	  this	  inhibitor	  abnormally	  activates	  Jurkat	  cells.	  However,	  Jurkat	  cells	  have	  been	  very	  useful	  to	  characterize	  T	  cell	  signaling	  in	  the	  past	  and	  provided	  a	  mechanism	  to	  assess	  the	  SAP-­‐dependent	  signaling	  defects	  following	  TCR	  stimulation107.	  	  	   To	  more	  fully	  understand	  how	  SAP	  influences	  T	  cell	  signaling,	  future	  studies	  should	  be	  performed	  in	  primary	  T	  cells	  or	  patient	  derived	  material.	  However,	  Jurkat	  cells	  are	  useful	  for	  hypothesis	  generation	  and	  the	  identification	  of	  cellular	  characteristics	  that	  differ	  based	  on	  the	  presence	  or	  absence	  of	  SAP.	  As	  described	  in	  chapter	  2,	  we	  used	  a	  TALEN-­‐based	  gene	  editing	  approach	  to	  edit	  the	  SAP	  gene	  and	  eliminate	  SAP	  expression.	  These	  SAP-­‐null	  Jurkat	  cells	  were	  used	  to	  interrogate	  T	  cell	  signaling	  alterations	  in	  cytokine	  production,	  transcription	  factor	  activity,	  and	  calcium	  mobilization,	  illustrated	  in	  chapter	  3.	  In	  chapter	  4	  the	  sensitivity	  to	  death	  stimuli	  was	  examined	  in	  the	  SAP-­‐null	  Jurkat	  cells,	  which	  further	  identified	  a	  SAP-­‐
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dependent	  increase	  in	  sensitivity	  to	  apoptosis.	  	  Together,	  our	  results	  signify	  specific	  
SAP-­‐dependent	  defects	  in	  T	  cell	  signaling,	  in	  Jurkat	  cells,	  which	  uncovered	  contributing	  factors	  to	  immune	  deregulation	  that	  apply	  to	  XLP1	  patients.	  It	  is	  thought	  provoking	  to	  discuss	  how	  SAP	  regulates	  immune	  cell	  signaling	  in	  the	  context	  of	  the	  development	  of	  cancer.	  Further	  exploration	  of	  immune	  surveillance	  of	  pre-­‐neoplastic	  cells	  in	  primary	  cells	  or	  other	  transformed	  cell	  lines	  would	  add	  powerful	  reinforcement	  to	  the	  findings	  within	  this	  dissertation	  and	  how	  they	  relate	  to	  the	  development	  of	  XLP.	  	  	  
5.2	  Remaining	  questions	  regarding	  SAP-­‐dependent	  effects	  on	  immune	  
surveillance	  	  	  
	  Does	  SAP	  participate	  in	  T	  cell	  activation	  in	  the	  apparent	  absence	  of	  signaling	  by	  
the	  SLAM	  family	  of	  co-­‐receptors?	  	   The	  observation	  that	  NFAT	  activity	  and	  IL-­‐2	  production	  was	  impaired	  in	  the	  
SAP-­‐null	  Jurkat	  cells	  following	  TCR	  stimulation	  was	  surprising.	  If	  SAP	  simply	  interacts	  with	  the	  SLAM	  receptor	  family	  and	  provides	  co-­‐stimulation,	  the	  addition	  of	  CD3	  and	  CD28	  would	  have	  bypassed	  SAP	  defects	  and	  not	  altered	  the	  production	  of	  IL-­‐2,	  as	  shown	  in	  figure	  1.4.	  	  
	   The	  observed	  decreased	  in	  IL-­‐2	  production	  and	  transcription	  factor	  activity	  suggests	  that	  SAP	  is	  modulating	  other	  components	  of	  T	  cells	  signaling	  that	  are	  required	  during	  T	  cell	  activation	  that	  are	  independent	  of	  CD3/CD28	  stimulation.	  	  One	  explanation	  is	  that	  SAP	  has	  SLAM	  independent	  roles	  by	  uncharacterized	  interactions	  with	  other	  PTKs	  within	  the	  signaling	  cascades,	  such	  as	  potential	  direct	  
	   96	  
engagement	  with	  ZAP-­‐70	  or	  LCK	  (figure	  1.3).	  Alternately,	  the	  SLAM	  family	  of	  receptors	  are	  self-­‐ligands,	  and	  direct	  cell-­‐to-­‐cell	  contact	  by	  immune	  cells	  may	  provide	  a	  background	  level	  of	  T	  cell	  stimulation	  in	  the	  absence	  of	  TCR	  activation	  through	  CD3.	  	  In	  this	  case,	  SLAM	  on	  the	  surface	  of	  Jurkat	  cells	  may	  be	  responding	  to	  interaction	  with	  other	  Jurkat	  cells	  leading	  to	  a	  basal	  level	  of	  SLAM	  activity.	  This	  may	  be	  an	  artifact	  of	  the	  cell	  model	  and	  would	  require	  further	  examination	  in	  patient	  derived	  material	  or	  primary	  T	  cells.	  	   Another	  potential	  explanation	  for	  impaired	  T	  cell	  activation	  in	  cells	  with	  SAP	  defects	  is	  that	  SAP	  modulates	  the	  activity	  of	  other	  proteins	  with	  characterized	  roles	  in	  immune	  cells	  activation	  and	  development.	  Following	  TCR	  stimulation,	  integrin	  mediated	  actin	  mobilization	  leads	  to	  cytoskeletal	  shifts	  at	  the	  immune	  synapse18.	  The	  nucleotide	  exchange	  factor	  VAV-­‐1	  activates	  the	  Rho	  family	  GTPases	  that	  regulate	  the	  cytoskeletal	  reorganization	  following	  TCR	  stimulation250.	  During	  reorganization,	  PKC-­‐θ	  moves	  to	  the	  lipid	  raft	  where	  it	  can	  activate	  NF-­‐κB251.	  	  When	  VAV-­‐1	  is	  defective,	  this	  decreases	  NF-­‐κB	  activation	  by	  impairing	  the	  recruitment	  of	  PKC-­‐θ252.	  Notably,	  impaired	  NF-­‐κB	  activation	  has	  been	  shown	  in	  Sap-­‐deficient	  mice111	  and	  SAP	  has	  been	  shown	  to	  regulate	  VAV-­‐1	  activity	  in	  NK	  cells,	  in	  a	  FYN	  dependent	  manner253.	  Therefore,	  SAP-­‐deficiencies	  may	  modulate	  VAV-­‐1	  activity	  and	  decrease	  the	  recruitment	  of	  PKC-­‐θ	  leading	  to	  impaired	  NF-­‐κB	  activation.	  	  	   Studies	  engineering	  VAV-­‐1	  defects	  in	  Jurkat	  cells	  demonstrated	  that	  VAV-­‐1	  is	  required	  for	  NFAT	  activity	  and	  IL-­‐2	  production254,255,	  both	  of	  which	  were	  deficient	  in	  the	  SAP-­‐null	  Jurkats.	  VAV-­‐1	  deficient	  Jurkat	  cells	  exhibited	  elevated	  calcium	  influx,	  potentially	  due	  to	  opening	  of	  the	  calcium	  channels	  during	  TCR	  stimulation256.	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Although	  not	  directly	  tested,	  it	  is	  possible	  that	  the	  SAP-­‐null	  Jurkat	  cells	  have	  VAV-­‐1	  impairments	  that	  are	  responsible	  for	  the	  observed	  cytokine,	  transcription	  factor,	  and	  calcium	  defects.	  This	  could	  explain	  the	  role	  of	  SAP	  in	  T	  cell	  activation	  that	  is	  independent	  of	  CD3/CD28	  stimulation	  in	  both	  SLAM-­‐dependent	  and	  –independent	  mechanisms.	  Additionally,	  the	  activity	  of	  the	  MAPK	  pathway	  was	  outside	  the	  scope	  of	  this	  study	  and	  defects	  in	  AP-­‐1	  formation	  cannot	  be	  excluded	  as	  contributing	  to	  the	  impaired	  defects	  observed	  in	  the	  SAP-­‐null	  Jurkat	  cells.	  	  	  	  
Is	  XLP-­‐1	  associated	  lymphoma	  due	  to	  impaired	  immune	  surveillance?	  	  
	   Pre-­‐cancerous	  cells	  develop	  characteristics	  that,	  when	  grown	  in	  absence	  of	  immune	  surveillance,	  can	  develop	  neoplastic	  phenotypes.	  Transformed	  cells	  activate	  intracellular	  signaling	  through	  tyrosine	  kinase	  domains	  and	  these	  activated	  cells	  avoid	  apoptosis.	  It	  is	  challenging	  to	  determine	  if	  growth	  signals	  are	  transmitted	  by	  autonomous	  signals	  within	  the	  cancer	  cell	  or	  from	  neighboring	  cells	  in	  a	  paracrine	  manner.	  Mutations	  in	  PTEN257,	  which	  lead	  to	  the	  constitutive	  activation	  of	  PI3K	  are	  observed	  in	  several	  cancers258.	  Cancer	  cells	  also	  avoid	  apoptotic	  signaling	  by	  impairing	  extrinsic	  signaling	  through	  the	  modification	  of	  death	  receptors	  (i.e.,	  Fas)	  or	  through	  intrinsic	  programs,	  which	  normally	  affect	  the	  mitochondrial	  membrane.	  One	  of	  the	  most	  commonly	  mutated	  gene	  is	  in	  the	  DNA	  damage	  sensor	  p53259.	  A	  subset	  of	  mutations	  in	  p53	  are	  unable	  to	  up-­‐regulate	  the	  BH3-­‐containing	  proteins	  that	  inhibit	  the	  Bcl-­‐2	  family	  members260,261.	  The	  balancing	  of	  Bcl-­‐2	  (anti-­‐apoptotic	  family)	  with	  pro-­‐apoptotic	  signaling,	  such	  as	  Bax	  and	  Bak,	  regulate	  the	  overall	  apoptotic	  threshold260.	  However,	  since	  the	  SAP-­‐null	  cells	  are	  more	  sensitive	  
	   98	  
to	  apoptosis,	  it	  is	  likely	  that	  the	  pre-­‐cancerous	  non-­‐SAP	  expressing	  B	  cells	  are	  the	  ones	  that	  must	  obtain	  additional	  capabilities	  to	  allow	  them	  to	  evade	  cell	  death.	  While	  it	  is	  likely	  that	  the	  cancer	  cells	  in	  XLP1-­‐associated	  lymphoma	  also	  have	  developed	  the	  ability	  to	  evade	  apoptosis,	  the	  inherent	  SAP-­‐dependent	  defects	  in	  T	  cell	  signaling	  could	  impair	  the	  surveillance	  abilities	  of	  immune	  cells	  themselves	  and	  these	  malfunctioning	  cells	  support	  conditions	  for	  pre-­‐cancerous	  outgrowth.	  In	  this	  case,	  patients	  with	  XLP	  initiate	  the	  development	  of	  cancer	  due	  to	  malfunctioning	  immune	  cells	  rather	  than	  genetically	  predisposing	  B	  cells	  to	  neoplasia.	  	   SAP-­‐deficiencies	  increase	  the	  levels	  of	  IFN-­‐γ production	  (figure	  3.3)	  and	  this	  may	  contribute	  to	  an	  environment	  with	  persistent	  inflammation	  that	  is	  conducive	  to	  metastasis.	  Elevated	  IFN-­‐γ 	  production	  is	  thought	  to	  increase	  the	  relative	  numbers	  of	  macrophages	  and	  these	  cells	  secrete	  metalloproteinases	  that	  degrade	  the	  cellular	  matrix262.	  This	  facilitates	  invasion	  into	  the	  surrounding	  tissue	  and	  dissemination	  to	  distant	  sites,	  another	  characteristic	  in	  the	  formation	  of	  cancer.	  However,	  prior	  to	  invasion	  and	  metastasis,	  the	  pre-­‐cancerous	  cell	  must	  actively	  evade	  immune	  surveillance.	  	  	   It	  is	  not	  well	  understood	  how	  cancer	  cells	  evade	  a	  fully	  functional	  immune	  system	  and	  several	  studies	  have	  addressed	  how	  a	  pre-­‐malignant	  cell	  avoids	  immune	  surveillance	  in	  immune	  deficiencies.	  The	  majority	  of	  viral-­‐induced	  cancers	  are	  within	  immunocompromised	  individuals65	  and	  this	  suggests	  that	  mechanisms	  that	  control	  viral	  infection	  must	  become	  deregulated	  in	  order	  for	  cancer	  to	  develop	  or	  that	  persistent	  infection	  can	  lead	  to	  cancer	  development.	  Alternately,	  defective	  immune	  cells	  can	  become	  activated	  but	  they	  are	  ineffective	  at	  killing.	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Histopathological	  examination	  of	  tumors	  have	  demonstrated	  that	  immune	  cells	  are	  present66	  yet	  they	  are	  ineffective	  at	  preventing	  tumor	  formation.	  XLP1	  patients	  with	  EBV	  infection	  have	  been	  shown	  to	  have	  increased	  percentage	  and	  absolute	  quantities	  of	  CD8+	  T	  cells	  and	  whether	  these	  cells	  are	  defective	  at	  killing	  target	  cells	  or	  whether	  the	  lack	  of	  SAP	  disturbs	  the	  ratios	  of	  CD4+	  T	  cells	  available	  to	  assist	  B	  cell	  surveillance	  is	  unknown239.	  However,	  several	  murine	  studies	  have	  revealed	  an	  increased	  tumor	  burden	  when	  the	  CD8+,	  CD4+,	  or	  natural	  killer	  cells	  are	  perturbed70,71.	  	  
	  
	  
Figure	  5.1	  Immune	  surveillance	  defects	  contribute	  to	  cancer.	  It	  is	  possible	  that	  XLP-­‐1	  associated	  lymphoma	  results	  from	  a	  combination	  of	  events	  that	  allow	  the	  pre-­‐cancerous	  non-­‐SAP	  expressing	  B	  cell	   to	   avoid	   immune	   surveillance	   and	   the	   inability	   of	   SAP-­‐deficient	   immune	   cells	   to	   detect	   or	   kill	  mutant	  cells.	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   Innate	  immune	  cells	  in	  particular	  are	  thought	  to	  secrete	  tumor	  promoting	  growth	  factors	  and	  activation	  inducing	  signals67,68	  or	  secrete	  reactive	  oxygen	  species	  that	  promote	  genetic	  mutations69.	  As	  previously	  discussed	  (chapter	  1),	  tumor	  cells	  can	  secrete	  the	  pleiotropic	  transforming	  growth	  factor-­‐β	  (TGF-­‐β)263,	  which	  can	  lead	  to	  abnormally	  high	  quantities	  of	  Treg	  cells264,265	  limiting	  the	  expansion	  of	  CD4	  and	  CD8	  cells265	  and	  disrupt	  CTL	  activity	  by	  impairing	  perforin	  production266,267.	  Together,	  expression	  of	  TGF-­‐β	  is	  another	  mechanism	  that	  cells	  can	  avoid	  immune	  surveillance	  as	  well	  as	  modulates	  the	  quantity,	  type,	  and	  functional	  capabilities	  of	  immune	  cells	  in	  the	  vicinity	  of	  the	  tumor.	  	   Evidence	  presented	  in	  the	  SAP-­‐null	  cells	  suggests	  that	  SAP	  defects	  contribute	  to	  defective	  immune	  responses	  (figure	  5.1).	  Jurkat	  cells	  are	  a	  representative	  CD4+	  T	  cell	  lineage	  which,	  when	  SAP	  is	  defective,	  exhibit	  impaired	  cytokine	  production,	  transcription	  factor	  activity,	  and	  apoptotic	  sensitivity.	  The	  possibility	  exists	  that	  there	  are	  fewer	  total	  CD4+cells	  compared	  to	  CD8+	  and	  NK	  cells.	  The	  impact	  of	  fewer	  CD4+	  T	  cells	  would	  be	  decreased	  Th1	  cell	  production	  and	  a	  relative	  increase	  in	  the	  presence	  of	  CTLs.	  Elevated	  proportions	  of	  CTLs	  could	  be	  recruited	  to	  the	  virally	  infected	  T	  cells,	  generating	  the	  release	  of	  cytokines	  that	  promote	  the	  production	  of	  tumor	  growth	  factors	  (ie.,	  EGF	  and	  VEGF)	  and	  matrix	  degrading	  enzymes68,	  but	  the	  CTLs	  are	  unable	  to	  kill	  the	  infected	  immune	  cells.	  Thus,	  it	  is	  plausible	  that	  XLP1-­‐associated	  lymphoma	  arises	  by	  impaired	  surveillance	  of	  EBV-­‐infected	  B	  cells	  and	  the	  recruitment	  of	  CTLs	  that	  are	  ineffective	  at	  killing	  target	  promoting	  a	  tumor	  permissive	  environment.	  Together,	  data	  presented	  in	  this	  dissertation	  suggest	  that	  lack	  of	  SAP	  contributes	  to	  decreased	  activation	  of	  CD4+	  T	  cells	  through	  impaired	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activation	  of	  NFAT.	  These	  T	  cells	  are	  more	  sensitive	  to	  cell	  death	  and	  are	  potentially	  unable	  to	  response	  to	  antigen.	  This	  contributes	  to	  persistent	  infection	  and	  a	  continually	  inflamed	  microenvironment	  that	  is	  conducive	  to	  the	  formation	  of	  cancer.	  	  	   Three	  potential	  influences	  of	  SAP	  during	  the	  immune	  response	  can	  be	  envisioned,	  as	  illustrated	  in	  figure	  5.2.	  In	  cells	  with	  normal	  SAP	  expression,	  pathogens	  stimulate	  the	  proliferation	  of	  immune	  cells	  (i.e.,	  T	  and	  NK	  cells)	  followed	  by	  apoptosis	  of	  the	  target	  cell.	  First,	  the	  immune	  cells	  could	  be	  initially	  activated	  in	  response	  to	  the	  pathogen	  but	  they	  prematurely	  die	  due	  to	  increased	  sensitivity	  to	  apoptotic	  stimuli.	  The	  SAP-­‐null	  Jurkat	  cells	  have	  increased	  sensitivity	  to	  cell	  death	  compared	  to	  the	  wild	  type	  cells	  and	  following	  exposure	  to	  pathogens	  activated	  T	  cells	  could	  be	  viable	  for	  a	  shorter	  time	  and	  unable	  to	  clear	  the	  infection	  resulting	  in	  persistent	  inflammation.	  Second,	  it	  is	  possible	  that	  SAP-­‐deficient	  immune	  cells	  are	  not	  activated	  to	  affect	  killing	  of	  target	  cells.	  The	  lack	  of	  IL-­‐2	  production	  observed	  in	  the	  SAP-­‐null	  cells	  suggests	  that	  there	  would	  be	  reduced	  proliferation	  of	  T	  cells	  and	  fewer	  immune	  cells	  would	  be	  available.	  Third,	  key	  immune	  cells	  may	  never	  be	  present	  within	  the	  organism	  due	  to	  SAP	  defects.	  Immune	  cells	  that	  do	  not	  develop	  cannot	  respond	  to	  antigen	  and	  this	  is	  best	  illustrated	  in	  XLP1	  patients’	  inability	  to	  develop	  NKT	  cells34.	  Taken	  together,	  the	  role	  of	  SAP	  in	  the	  clearance	  of	  virally	  infected	  cells	  and	  how	  this	  contributes	  to	  the	  development	  of	  lymphoma	  is	  an	  area	  to	  further	  explore.	  	  	  
	   102	  
Figure	   5.2	   Proposed	   influence	   of	   SAP	   defects	   on	   immune	   cells.	   Immune	   cells	   proliferate	   in	  response	   to	   pathogens	   and	   this	   expansion	   is	   followed	   by	   death	   of	   the	   expanded	   immune	   cells	   to	  maintain	  immune	  homeostasis.	  Three	  potential	  defects,	  listed	  above,	  result	  from	  SAP	  defects	  and	  this	  could	   contribute	   to	   the	   abnormal	   numbers	   of	   immune	   cells	   and	   ineffective	   response	   to	   antigens	  leading	  to	  persistent	  inflammation.	  	  	  
	  
Why	  do	  XLP2	  patients	  not	  develop	  lymphoma?	  	   XLP2	  is	  caused	  by	  mutations	  in	  XIAP	  and	  results	  in	  similar	  clinical	  presentations	  to	  XLP128,41.	  However,	  it	  remains	  unclear	  why	  XIAP-­‐deficient	  patients	  do	  not	  develop	  lymphoma.	  XIAP	  expression	  is	  elevated	  in	  many	  types	  of	  cancers,	  including	  B	  cell	  lymphoma268.	  Tumors	  that	  upregulate	  the	  expression	  of	  XIAP269	  promote	  cell	  survival	  by	  inhibiting	  caspase	  activation.	  However,	  XIAP	  has	  an	  ascribed	  function270	  in	  the	  upregulation	  of	  cyclin	  D1	  expression	  by	  the	  E3	  ligase	  within	  the	  RING	  domain.	  One	  explanation	  of	  why	  XLP2	  patients	  do	  not	  develop	  lymphoma	  could	  be	  that	  XIAP	  defects	  impair	  the	  expression	  of	  cyclin	  D1	  and	  B	  cells	  are	  unable	  to	  proceed	  in	  the	  cell	  cycle	  and	  extensively	  proliferate.	  Whether	  the	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absence	  of	  lymphoma	  in	  XLP2	  patients	  is	  due	  to	  increased	  death	  of	  B	  cells	  or	  impaired	  cell	  cycling	  remains	  to	  be	  determined.	  The	  observation	  of	  increased	  sensitivity	  to	  Fas	  mediated	  apoptosis	  in	  Jurkat	  cells	  with	  reduced	  XIAP	  expression	  (figure	  4.3)	  supports	  that	  T	  cells	  are	  more	  sensitive	  to	  death	  and	  further	  studies	  are	  required	  to	  determine	  if	  this	  is	  also	  the	  case	  in	  B	  cells.	  	  	   The	  examination	  of	  XIAP’s	  role	  in	  T	  cell	  activation	  has	  not	  been	  explored	  in-­‐depth.	  It	  is	  possible	  that	  XIAP,	  with	  ubiquitous	  expression,	  does	  not	  play	  a	  role	  in	  T	  cell	  signaling	  and	  immune	  cells	  from	  XIAP	  patients	  are	  competent	  to	  detect	  virally	  infected	  cells	  during	  immune	  surveillance	  and	  this	  prevents	  pre-­‐neoplastic	  cells	  from	  accumulating.	  Xiap-­‐deficient	  mice	  are	  able	  to	  form	  germinal	  centers	  while	  Sap-­‐deficient	  mice	  cannot6	  and	  this	  suggests	  that	  XLP2	  patients	  would	  be	  able	  to	  appropriately	  respond	  to	  EBV	  infection,	  which	  is	  not	  the	  case28.	  Further	  studies	  directly	  comparing	  the	  effects	  of	  TCR	  stimulation	  in	  a	  XIAP-­‐null	  Jurkat	  cell	  would	  clarify	  whether	  defects	  in	  TCR	  activation	  are	  SAP	  specific	  or	  whether	  there	  are	  shared	  functional	  roles	  between	  XIAP	  and	  SAP.	  	  	   EBV	  induces	  B-­‐cell	  lymphoproliferation	  and	  the	  development	  of	  lymphoma	  in	  immunocompromised	  individuals242.	  Nikiforow,	  et	  al	  (2001)	  demonstrated	  that	  while	  CD8+	  T	  cells	  kill	  EBV	  infected	  cells,	  it	  is	  the	  CD4+	  T	  cells	  that	  limit	  the	  expansion	  of	  EBV-­‐infected	  B	  cells	  and	  prevent	  their	  lymphoproliferation.	  	  While	  the	  mechanism	  is	  unclear,	  this	  is	  particularly	  relevant	  to	  the	  findings	  within	  this	  dissertation	  as	  the	  SAP-­‐null	  cells	  have	  fewer	  proliferative	  (IL-­‐2)	  cytokines	  and	  the	  CD4+	  cells	  are	  more	  sensitive	  to	  apoptosis.	  These	  potentially	  short-­‐lived	  CD4+	  T	  cells	  with	  SAP	  defects	  are	  unable	  to	  control	  the	  proliferation	  of	  EBV-­‐infected	  B	  cells.	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Coupled	  with	  ineffective	  killing	  by	  CTLs,	  this	  could	  explain	  why	  XLP1	  patients	  progress	  to	  lymphoma	  through	  a	  combination	  of	  early	  events	  of	  CD4+	  T	  cell	  surveillance	  and	  ineffective	  killing	  of	  B	  cells	  following	  infection.	  This	  could	  also	  explain	  why	  XLP2	  patients	  do	  not	  present	  with	  lymphoma	  as	  there	  is	  no	  evidence	  to	  support	  that	  their	  T	  cell	  compartment	  is	  altered.	  However,	  the	  preliminary	  data	  demonstrating	  that	  decreased	  XIAP	  expression	  also	  increased	  apoptotic	  sensitivity	  in	  Jurkat	  cells	  requires	  further	  analysis	  to	  explore	  whether	  there	  are	  compensatory	  mechanisms	  for	  control	  of	  EBV	  infection	  due	  to	  the	  presence	  of	  functional	  SAP	  in	  their	  T	  cell	  populations.	  	  
	  
Is	  apoptosis	  the	  shared	  pathway	  in	  XLP1	  &	  XLP2	  that	  contributes	  to	  HLH	  
development?	  	  
	   SAP	  and	  XIAP	  appear	  to	  have	  similar	  cytoprotective	  properties	  in	  Jurkat	  cells.	  Results	  indicated	  that	  cells	  with	  either	  suppression	  of	  SAP	  or	  XIAP	  demonstrated	  increased	  Caspase-­‐3	  activity	  upon	  Fas	  stimulation	  (figure	  4.3).	  XLP1	  and	  XLP2	  patients	  both	  develop	  HLH	  and	  it	  is	  possible	  that	  the	  increased	  apoptotic	  sensitivity	  observed	  in	  T	  cells	  contributes	  to	  this	  phenotype.	  As	  previously	  discussed	  (chapter	  1)	  familial	  HLH	  patients	  have	  defects	  in	  CTL	  or	  NK	  cell	  killing	  of	  virally	  infected	  cells	  due	  to	  defects	  in	  genes	  related	  to	  the	  movement	  or	  release	  of	  cytotoxic	  granules.	  SAP	  defects	  are	  associated	  with	  defective	  cytotoxic	  activity	  of	  NK	  cells	  but	  it	  is	  unclear	  why	  XIAP	  patients	  develop	  HLH.	  It	  is	  plausible	  that	  XIAP	  defects	  increase	  the	  sensitivity	  of	  immune	  cells	  to	  undergo	  apoptosis	  and,	  in	  a	  manner	  similar	  to	  SAP	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defects,	  result	  in	  fewer	  or	  short-­‐lived	  CLTs	  or	  NK	  cells	  available	  to	  kill	  virally	  infected	  target	  cells.	  	  	   Considering	  that	  XLP	  results	  from	  mutations	  in	  either	  of	  two	  genes,	  with	  no	  structural	  similarities,	  yet	  co-­‐located	  at	  the	  same	  Xq25	  locus,	  this	  suggests	  that	  these	  genes	  share	  a	  commonly	  deregulated	  pathway.	  This	  is	  an	  area	  that	  has	  not	  been	  explored,	  particularly	  in	  a	  comparative	  nature.	  Thus,	  two	  apparently	  functionally	  unrelated	  genes	  may	  contribute	  to	  the	  shared	  phenotype	  by	  deregulating	  the	  process	  of	  apoptosis.	  	  
5.3	  Potential	  XLP1	  therapy	  using	  engineered	  T	  cells	  	  	   Within	  the	  XLP	  patient	  population,	  it	  is	  particularly	  challenging	  to	  find	  a	  matched	  donor	  for	  a	  curative	  bone	  marrow	  transplant	  and	  there	  are	  few	  treatment	  options	  available.	  There	  are	  several	  emergent	  techniques	  to	  encourage	  immune	  surveillance	  and	  the	  clearance	  of	  both	  infected	  or	  pre-­‐neoplastic	  cells.	  For	  example,	  the	  use	  of	  chimeric	  antigen	  receptor	  T	  cells	  (CAR	  Ts)271–273	  in	  immunotherapy	  presents	  the	  opportunity	  to	  modify	  patient	  T	  cells	  with	  receptors	  that	  can	  recognize	  and	  target	  specific	  cells	  that	  would	  otherwise	  evade	  immune	  surveillance.	  An	  added	  benefit	  is	  the	  use	  of	  patient	  derived	  material	  to	  minimize	  rejection.	  	  CAR	  Ts	  contain	  the	  variable	  domains	  of	  the	  TCR271–273	  fused	  with	  T	  cell	  activation	  domains272,273	  and	  recognize,	  in	  the	  case	  of	  a	  B	  cell	  targeting	  CAR	  T,	  the	  CD19	  receptor	  expressed	  by	  mature	  B	  cells274.	  Notably,	  this	  recognition	  is	  independent	  of	  the	  T	  cell	  receptor	  and	  does	  not	  require	  MHC	  presentation	  or	  recognition	  of	  a	  specific	  peptide	  by	  the	  T	  cell	  but,	  rather	  recognizes	  proteins	  expressed	  on	  the	  surface	  of	  B	  cells275.	  This	  is	  particularly	  important	  when	  using	  CAR	  Ts	  on	  patients	  that	  have	  acquired	  the	  ability	  
	   106	  
to	  downregulate	  MHC	  class	  I	  expression	  to	  escape	  T	  cell-­‐mediated	  immune	  surveillance58.	  Low	  MHC-­‐I	  expression	  levels	  rely	  on	  NK	  cells	  to	  target	  virally	  infected	  cells	  while	  high	  MHC-­‐I	  expression	  supports	  recognition	  by	  TCR	  containing	  CTLs59.	  Should	  the	  patient’s	  tumor	  cells	  have	  decreased	  MHC-­‐I	  expression,	  the	  CAR	  Ts	  would	  be	  able	  to	  recognize	  the	  aberrant	  B	  cells	  and	  kill	  the	  target.	  	  	   CAR	  T	  cells	  have	  shown	  promise	  in	  children	  and	  adults	  in	  promoting	  clinical	  remission	  and	  survivability276,	  suggesting	  that	  CAR	  T	  cells	  could	  replace	  BMTs	  or	  offer	  a	  viable	  alternative	  to	  transplantation	  when	  a	  donor	  is	  unavailable.	  Specifically,	  the	  use	  of	  CAR	  T	  cells	  in	  B-­‐cell	  lymphoma	  showed	  that	  22/27	  patients	  entered	  remission	  and	  half	  of	  these	  patients	  remained	  disease	  free	  during	  three	  years	  of	  follow-­‐up277.	  Modulating	  the	  numbers	  of	  CAR	  T	  cells	  and	  using	  them	  in	  conjunction	  with	  chemotherapy	  seem	  to	  be	  effective	  against	  B	  cell	  lymphomas278,	  but	  the	  therapy	  is	  not	  without	  risk.	  	  	   Mortality	  has	  been	  documented279	  during	  CAR	  T	  therapy	  due	  to	  excessive	  cytokine	  production,	  particularly	  IFN-­‐γ	  and	  TNF279.	  This	  is	  of	  particular	  concern	  in	  the	  context	  of	  increased	  IFN-­‐γ	  production	  observed	  in	  the	  SAP-­‐deficient	  Jurkat	  cells.	  XLP1	  patients	  develop	  HLH	  during	  cytokine	  storms39	  and	  since	  this	  is	  a	  potential	  side	  effect	  of	  CAR	  T	  therapy,	  this	  raises	  questions	  as	  to	  its	  suitability	  for	  use	  in	  XLP	  patients.	  It	  is	  possible	  that	  CD19	  CAR	  T	  cell	  treatment	  in	  XLP-­‐associated	  lymphoma	  patients	  would	  exhibit	  further	  increased	  IFN-­‐γ	  production	  and	  patients	  would	  require	  close	  monitoring	  and	  potential	  intervention	  with	  neutralizing	  IFN-­‐γ	  antibodies.	  To	  combat	  the	  potential	  cytokine	  storm	  during	  CAR	  T	  therapy,	  it	  would	  be	  necessary	  to	  reintroduce	  SAP	  expression	  at	  the	  same	  time	  modifications	  are	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made	  to	  the	  patient	  T	  cells.	  This	  could	  be	  done	  by	  several	  gene	  editing	  techniques,	  such	  as	  TALENs	  or	  CRISPR/Cas9.	  In	  theory,	  XLP1	  patient	  CAR	  T	  cells	  with	  the	  reconstitution	  of	  SAP	  expression	  would	  not	  only	  correct	  the	  patient	  mutation	  but	  also	  target	  the	  aberrant	  B	  cell	  proliferation.	  	  	   Particularly	  relevant	  to	  XLP1	  patients,	  CAR	  T	  cells	  for	  EBV+	  malignancies	  have	  been	  tested280,281	  as	  the	  CAR	  T	  cells	  recognize	  CD19	  B	  cells	  with	  EBV	  peptides	  on	  their	  surface282,283.	  Again,	  without	  the	  restoration	  of	  SAP	  expression,	  these	  CAR	  T	  cells	  would	  be	  potentially	  ineffective	  at	  killing	  EBV	  infected	  B	  cells	  due	  to	  SAP	  dependent	  cytotoxic	  defects.	  However,	  tailoring	  a	  CAR	  T	  cell	  to	  recognize	  only	  EBV	  infected	  B	  cells	  would,	  in	  theory,	  have	  minimal	  effects	  on	  uninfected	  B	  cells	  and	  avoid	  the	  continual	  targeting	  of	  the	  entire	  B	  cell	  compartment.	  Targeting	  all	  B	  cells	  could	  result	  in	  decreased	  antibody	  production	  or	  hypogammaglobulinemia284,	  a	  clinical	  characteristic	  observed	  in	  a	  portion	  of	  XLP	  patients.	  	  However,	  it	  is	  feasible	  to	  consider	  using	  modified	  CAR	  T	  cells	  in	  patients	  with	  XLP1-­‐associated	  lymphomas	  to	  improve	  survivability.	  	   	  
5.4	  Future	  studies	  using	  patient-­‐derived	  T	  cells	  	  	  	   Patient-­‐derived	  T	  cells	  would	  be	  the	  ideal	  system	  to	  further	  analyze	  the	  SAP-­‐	  dependent	  influences	  on	  T	  cell	  signaling.	  Initial	  experiments	  would	  focus	  on	  the	  apoptotic	  sensitivity	  as	  well	  as	  confirm	  the	  findings	  regarding	  cytokine	  defects	  and	  NFAT	  impairments	  discovered	  in	  the	  SAP-­‐null	  cells	  using	  the	  developed	  intracellular	  staining	  and	  flow	  cytometry	  protocol	  (chapter	  3)	  compared	  to	  donor	  T	  cells.	  Concurrently,	  the	  examination	  of	  Caspase	  expression	  in	  response	  to	  intrinsic	  and	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extrinsic	  apoptotic	  stimuli	  would	  identify	  whether	  the	  results	  are	  reproducible	  in	  primary	  cells	  or	  whether	  these	  findings	  are	  specific	  to	  the	  SAP-­‐null	  Jurkat	  cell.	  	  	   There	  are	  several	  additional	  options	  to	  examine	  the	  SAP-­‐dependent	  modulation	  of	  apoptosis.	  One	  mechanism	  malignant	  cells	  use	  to	  evade	  apoptosis	  is	  by	  upregulating	  the	  expression	  of	  the	  anti-­‐apoptotic	  protein	  c-­‐FLIP285	  (cellular	  FADD-­‐like	  IL-­‐1β-­‐converting	  enzyme	  inhibitory	  protein).	  Stimulation	  of	  primary	  T	  cells	  normally	  increases	  c-­‐FLIP	  expression,	  which	  blocks	  Caspase-­‐8	  activation	  during	  Fas	  mediated	  apoptosis222.	  Although	  this	  concept	  has	  not	  been	  explored	  in	  the	  context	  of	  SAP	  deficiencies,	  it	  is	  possible	  that	  c-­‐FLIP	  expression	  is	  inhibited,	  though	  unknown	  interactions,	  and	  this	  increases	  the	  sensitivity	  to	  apoptosis	  compared	  to	  the	  wild	  type.	  Moreover,	  mice	  with	  Caspase-­‐8	  impairments	  having	  low	  responses	  to	  viral	  infections16	  and	  impaired	  T	  cell	  activation16	  characterized	  by	  decreased	  IL-­‐2	  production	  in	  response	  to	  CD3	  stimulation286,287.	  It	  is	  unknown	  whether	  SAP	  defects	  influence	  Caspase-­‐8	  expression	  or	  activation,	  by	  modulating	  c-­‐FLIP,	  but	  it	  is	  possible	  based	  on	  the	  characteristics	  observed	  in	  the	  SAP-­‐null	  cells.	  	  	   Activation	  induced	  cell	  death	  (AICD),	  a	  negative	  regulator	  of	  T	  cell	  activation,	  is	  another	  area	  of	  interest	  relevant	  to	  SAP-­‐deficiencies.	  Activated	  T	  cells	  increase	  the	  transcription	  and	  export	  of	  Fas	  ligand	  (FasL)	  which	  can	  then	  kill	  the	  cell	  producing	  FasL	  or	  other	  immune	  cells	  within	  the	  vicinity	  that	  express	  the	  Fas	  receptor288,289.	  Studies	  introducing	  overexpression	  of	  SAP	  into	  B-­‐LCL	  lines	  using	  retroviral	  delivery	  illustrated	  that	  the	  presence	  of	  SAP	  increased	  the	  number	  of	  dead	  cells	  following	  exposure	  to	  DNA	  damage	  inducing	  radiation	  while	  the	  wild	  type,	  non-­‐SAP	  expressing	  cells,	  were	  more	  resistant	  to	  cell	  death290.	  Although	  radiation	  was	  not	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specifically	  tested	  in	  the	  SAP-­‐null	  Jurkat	  cells,	  the	  introduction	  of	  DNA	  damaging	  etoposide	  resulted	  in	  increased	  cell	  death	  compared	  to	  the	  wild	  type.	  This	  contrast	  in	  finding	  could	  be	  attributed	  to	  the	  overexpression	  of	  SAP	  inducing	  an	  effect	  that	  is	  not	  normally	  observed	  in	  the	  B	  cell	  lineage.	  Alternatively,	  this	  could	  mean	  that	  the	  apoptotic	  sensitivity	  is	  restricted	  to	  the	  CD4+	  Jurkat	  cells.	  Preliminary	  experiments	  demonstrated	  that	  the	  SAP-­‐null	  Jurkat	  cells	  are	  less	  viable	  following	  TCR	  stimulation	  compared	  to	  the	  wild	  type	  cells	  (data	  not	  shown),	  but	  further	  analysis	  in	  primary	  T	  cells	  using	  either	  siRNA	  modulation	  of	  SAP	  expression	  or	  patient	  derived	  materials	  would	  elucidate	  the	  specific	  effects	  of	  SAP	  defects	  on	  T	  cell	  viability	  following	  TCR	  activation.	  	  	   XLP1-­‐associated	  lymphomas,	  similar	  to	  endemic	  Burkitt’s	  lymphoma46,	  occur	  in	  childhood	  and	  pediatric	  cancers	  suggest	  that	  defects	  occur	  during	  development.	  Although	  SAP	  is	  not	  known	  to	  regulate	  fetal	  development,	  it	  is	  possible	  that	  certain	  proteins	  that	  are	  expressed	  during	  development	  are	  aberrantly	  reactivated	  during	  childhood	  or	  by	  exposure	  to	  viruses.	  Particularly	  in	  hematopoietic	  malignancies	  these	  developmental	  proteins,	  called	  oncofetal	  antigens,	  have	  been	  shown	  to	  be	  expressed	  in	  cancer	  cells	  and	  not	  in	  normal	  tissues	  making	  them	  an	  attractive	  therapy	  for	  recognition	  by	  CTLs291.	  One	  such	  candidate	  is	  the	  B-­‐cell	  tumor	  associated	  antigen	  ROR1	  (receptor	  tyrosine	  kinase-­‐like	  orphan	  receptor	  1),	  expressed	  in	  embryonic	  stem	  cells	  and	  in	  B-­‐cell	  lymphoma	  but	  absent	  in	  normal	  B	  cells292.	  There	  may	  be	  yet	  uncharacterized	  fetal	  proteins	  that	  are	  expressed	  by	  the	  lymphoma	  cells	  that	  promote	  a	  survival	  advantage	  or	  enhance	  cell	  proliferation	  in	  these	  patients.	  Determining	  whether	  ROR1	  or	  other	  B	  cell	  related	  oncofetal	  antigens	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are	  expressed	  in	  cells	  from	  XLP1-­‐associated	  lymphomas	  would	  provide	  understanding	  of	  factors	  that	  influence	  a	  portion	  of	  SAP-­‐deficient	  patients	  to	  develop	  cancer	  as	  well	  as	  identify	  markers	  that,	  when	  expressed,	  increase	  the	  likelihood	  of	  lymphoma	  development.	  These	  biomarkers	  could	  greatly	  improve	  the	  early	  diagnosis	  and	  potential	  survivability.	  	  
5.5	  Final	  remarks	  	  	  	  	   The	  studies	  presented	  in	  this	  dissertation	  demonstrated	  that	  lack	  of	  SAP	  impairs	  T	  cell	  signaling	  by	  altering	  cytokine	  production,	  NFAT	  transcription	  factor	  activity,	  calcium	  mobilization,	  and	  sensitivity	  to	  apoptosis.	  These	  changes	  potentially	  contribute	  to	  abnormal	  immune	  cell	  activation,	  as	  well	  as	  alter	  the	  number	  and	  type	  of	  cells	  that	  are	  able	  to	  respond	  to	  infectious	  agents.	  Furthermore,	  the	  analysis	  of	  the	  SAP-­‐null	  Jurkat	  cells	  provided	  a	  composite	  analysis	  of	  traits,	  some	  of	  which	  have	  been	  previously	  associated	  with	  various	  XLP1	  studies,	  attributable	  to	  
SAP-­‐dependent	  T	  cell	  signaling	  defects.	  This	  is	  the	  first	  study	  to	  systematically	  compare	  the	  SAP-­‐dependent	  effects	  on	  T	  cell	  signaling	  in	  the	  same	  cell	  line,	  using	  this	  particular	  gene	  editing	  technology,	  and	  identified	  defects,	  which	  can	  be	  tested	  in	  XLP1	  patients.	  Screening	  for	  these	  SAP-­‐dependent	  effects	  in	  the	  clinic	  may	  improve	  survival	  of	  patients	  with	  undiagnosed	  SAP	  defects.	  Additionally,	  recognizing	  how	  SAP	  defects	  impair	  the	  ability	  of	  immune	  cells	  to	  recognize	  and	  eliminate	  pre-­‐neoplastic	  cells	  will	  further	  enhance	  the	  understanding	  of	  how	  XLP1	  patients	  develop	  lymphoma.	  Together	  the	  insights	  provided	  in	  this	  study	  functionally	  characterized	  SAP-­‐dependent	  defects	  in	  T	  cell	  signaling	  with	  implications	  towards	  the	  etiology	  of	  the	  complex	  immunological	  disease	  known	  as	  XLP.	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